<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Oncol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Oncol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Oncology</journal-title>
</journal-title-group>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30542640</article-id>
<article-id pub-id-type="pmc">6277865</article-id>
<article-id pub-id-type="doi">10.3389/fonc.2018.00512</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Human Herpesvirus 6 and Malignancy: A Review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Eliassen</surname>
<given-names>Eva</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/466807/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lum</surname>
<given-names>Emily</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pritchett</surname>
<given-names>Joshua</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ongradi</surname>
<given-names>Joseph</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/61707/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krueger</surname>
<given-names>Gerhard</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/596666/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crawford</surname>
<given-names>John R.</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/129960/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Phan</surname>
<given-names>Tuan L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/591883/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ablashi</surname>
<given-names>Dharam</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/174507/overview" xlink:type="simple"></uri>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hudnall</surname>
<given-names>Stanley David</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/588225/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>HHV-6 Foundation, Santa Barbara</institution>, <addr-line>CA</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>Department of Internal Medicine, Mayo Clinic</institution>, <addr-line>Rochester, MN</addr-line>, <country>United States</country></aff>
<aff id="aff3"><sup>3</sup><institution>Institute of Medical Microbiology, Semmelweis University</institution>, <addr-line>Budapest</addr-line>, <country>Hungary</country></aff>
<aff id="aff4"><sup>4</sup><institution>Department of Pathology and Laboratory Medicine, University of Texas- Houston Medical School</institution>, <addr-line>Houston, TX</addr-line>, <country>United States</country></aff>
<aff id="aff5"><sup>5</sup><institution>Department of Neurosciences and Pediatrics, University of California San Diego and Rady Children's Hospital</institution>, <addr-line>San Diego, CA</addr-line>, <country>United States</country></aff>
<aff id="aff6"><sup>6</sup><institution>Department of Microbiology and Immunology, Tulane University School of Medicine</institution>, <addr-line>New Orleans, LA</addr-line>, <country>United States</country></aff>
<aff id="aff7"><sup>7</sup><institution>Department of Pathology, Yale University</institution>, <addr-line>New Haven, CT</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Daniel Christian Hoessli, University of Karachi, Pakistan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Saraswati Sukumar, Johns Hopkins University School of Medicine, United States; Kwok-Ming Yao, University of Hong Kong, Hong Kong; Deilson Elgui De Oliveira, Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Brazil</p>
</fn>
<corresp id="c001">*Correspondence: Dharam Ablashi <email>dharam_ablashi@hhv-6foundation.org</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>11</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>8</volume>
<elocation-id>512</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>7</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Eliassen, Lum, Pritchett, Ongradi, Krueger, Crawford, Phan, Ablashi and Hudnall.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Eliassen, Lum, Pritchett, Ongradi, Krueger, Crawford, Phan, Ablashi and Hudnall</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>In order to determine the role of human herpesvirus 6 (HHV-6) in human disease, several confounding factors, including methods of detection, types of controls, and the ubiquitous nature of the virus, must be considered. This is particularly problematic in the case of cancer, in which rates of detection vary greatly among studies. To determine what part, if any, HHV-6 plays in oncogenesis, a review of the literature was performed. There is evidence that HHV-6 is present in certain types of cancer; however, detection of the virus within tumor cells is insufficient for assigning a direct role of HHV-6 in tumorigenesis. Findings supportive of a causal role for a virus in cancer include presence of the virus in a large proportion of cases, presence of the virus in most tumor cells, and virus-induced <italic>in-vitro</italic> cell transformation. HHV-6, if not directly oncogenic, may act as a contributory factor that indirectly enhances tumor cell growth, in some cases by cooperation with other viruses. Another possibility is that HHV-6 may merely be an opportunistic virus that thrives in the immunodeficient tumor microenvironment. Although many studies have been carried out, it is still premature to definitively implicate HHV-6 in several human cancers. In some instances, evidence suggests that HHV-6 may cooperate with other viruses, including EBV, HPV, and HHV-8, in the development of cancer, and HHV-6 may have a role in such conditions as nodular sclerosis Hodgkin lymphoma, gastrointestinal cancer, glial tumors, and oral cancers. However, further studies will be required to determine the exact contributions of HHV-6 to tumorigenesis.</p>
</abstract>
<kwd-group>
<kwd>HHV-6</kwd>
<kwd>herpesvirus</kwd>
<kwd>human herpesvirus 6</kwd>
<kwd>HHV6</kwd>
<kwd>oncogenic</kwd>
<kwd>cancer</kwd>
<kwd>malignant</kwd>
<kwd>transformation</kwd>
</kwd-group>
<counts>
<fig-count count="4"></fig-count>
<table-count count="8"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="211"></ref-count>
<page-count count="33"></page-count>
<word-count count="21942"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Background</title>
<p>Human herpesvirus-6A and−6B (HHV-6A and HHV-6B) are linear, double-stranded DNA viruses and members of betaherpesvirinae, along with CMV and HHV-7. HHV-6A and HHV-6B were identified as two distinct herpesviruses as early as 1992 (<xref ref-type="bibr" rid="B1">1</xref>), and in 2014, they were formally classified as two separate species (<xref ref-type="bibr" rid="B2">2</xref>). While less is known about the epidemiology of HHV-6A, HHV-6B is a ubiquitous virus, with over 90% of the human population infected within the first 3 years of life. In 1986, HHV-6 was isolated from the peripheral blood mononuclear cells of AIDS-associated non-Hodgkin lymphomas by Robert Gallo and associates at the National Cancer Institute in their search for undiscovered herpesviruses that might be causing cancer in HIV-infected patients (<xref ref-type="bibr" rid="B3">3</xref>). Soon afterward, it was found that both HHV-6-transfected NIH3T3 fibroblasts (<xref ref-type="bibr" rid="B4">4</xref>) and human primary foreskin epidermal keratinocytes transfected with HHV-6 subgenomic clones PZV714 (<xref ref-type="bibr" rid="B5">5</xref>) and PZVB70 (<xref ref-type="bibr" rid="B6">6</xref>) produced tumors when injected into nude mice (<xref ref-type="bibr" rid="B7">7</xref>). The PZV714 and PZVB70 tumors were cytogenetically abnormal, with loss of chromosomes 12 and 13 and acquisition of extra marker chromosomes. These early results suggested that HHV-6 may be oncogenic in some settings. Decades later, several studies identified HHV-6A and HHV-6B (<xref ref-type="bibr" rid="B2">2</xref>) within a wide variety of tumors, including glioma, oral cancer, cervical cancer, adrenocortical tumors, gastrointestinal cancer, classical Hodgkin lymphoma, and non-Hodgkin lymphoma, as summarized in Tables <xref ref-type="table" rid="T1">1</xref>–<bold>8</bold> (<xref ref-type="bibr" rid="B99">99</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with Hodgkin Lymphoma.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>% Of positive samples belonging to the nodular sclerosis subtype</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Notes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kiani et al. (<xref ref-type="bibr" rid="B8">8</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">12*/22 <bold>(54%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">83%, 0%, (17%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">42%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*5/9 NS, 5/11 MC, and 2/2 LP</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Siddon et al. (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">27/31 <bold>(87%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/6 (83%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">RH</td>
<td align="left" colspan="1" rowspan="1" valign="top">40%, 30%, (30%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lacroix et al. (<xref ref-type="bibr" rid="B10">10</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">68/86 <bold>(79.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">7%, 93%</td>
<td align="left" colspan="1" rowspan="1" valign="top">83.6%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hernández-Losa et al. (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/20 <bold>(40%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">17*/52 (33%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Donor spleen lymphocytes, reactive lymphadenitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">88% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Collot et al. (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">13/37 <bold>(35.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">51/68 (75%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal saliva</td>
<td align="left" colspan="1" rowspan="1" valign="top">8%, 92%</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Shiramizu et al. (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/47 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Schmidt et al. (<xref ref-type="bibr" rid="B14">14</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/88 <bold>(13%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">73%, 27%;<break></break>64% HHV-7+, 64% EBV+, 22% CMV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">45%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*5 NS, 4 MC, 2 untyped</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Valente et al. (<xref ref-type="bibr" rid="B15">15</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">38*/52 <bold>(73%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">13/19 (68.4%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">5%, 95%</td>
<td align="left" colspan="1" rowspan="1" valign="top">79%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*73.1% of NS cases, 50% of interfollicular, 70% of MC, and the single case of LD</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Carbone et al. (<xref ref-type="bibr" rid="B16">16</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Razzaque et al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/1 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dolcetti et al. (<xref ref-type="bibr" rid="B18">18</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/10 <bold>(30%)</bold> HIV+, 13/43 <bold>(30%)</bold> HIV-</td>
<td align="left" colspan="1" rowspan="1" valign="top">15*/30 (50%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV+: 0%, 67%, (33%),<break></break>HIV-: 8%, 92%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*12 HHV-6B, 1 A/B coinfection in HIV+ controls; 2 HHV-6B in HIV- controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Di Luca et al. (<xref ref-type="bibr" rid="B19">19</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">13/45 <bold>(29%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">8/45 (17%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Healthy donor PBLs</td>
<td align="left" colspan="1" rowspan="1" valign="top">8%, 92%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Trovato et al. (<xref ref-type="bibr" rid="B20">20</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/15 <bold>(6.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sumiyoshi et al. (<xref ref-type="bibr" rid="B21">21</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">9/14 <bold>(64.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">55/56 (98.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive lymphadenopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gledhill et al. (<xref ref-type="bibr" rid="B22">22</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/35 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Torelli et al. (<xref ref-type="bibr" rid="B23">23</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/25 <bold>(12%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jarrett et al. (<xref ref-type="bibr" rid="B24">24</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/29 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/35 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nonlymphomatous tissues*</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Reactive LNs, cancers, neoplasms, sarcoidosis, Sjögren's syndrome, and miscellaneous</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Siddon et al. (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">18/21 <bold>(86%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">50%, 33%, (17%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antigen found in RS cells in 48% NSHL cases. Scattered positive RS cells also positive for p41, p98, U94. By FISH, normal tonsil showed rare scattered HHV-6, whereas HL showed numerous scattered cells harboring multiple copies of HHV-6</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lacroix et al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN2"><sup>b</sup></xref>, RS cells<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">28/38 <bold>(73.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">In 17/28 patients (60.7%), DR7B was detected only in RS cells.<break></break>Mummified cells were DR7B+ in 9/28 cases (32.1%). DR7B detected in 9/9 HHV-6+/EBV+ NSHL patients</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lacroix et al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN3"><sup>c</sup></xref>, RS cells<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">15/38 <bold>(39.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lacroix et al. (<xref ref-type="bibr" rid="B25">25</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN3"><sup>c</sup></xref>, infiltrating cells<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">38/38 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN4"><sup>d</sup></xref>, RS cells<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">2/14 <bold>(14.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0*/16 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-neoplastic LNs<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Mummified RS cells were positive. Only rare cells (reactive histiocytes, plasma cells) had cytoplasmic reaction for 101K, gp116.<break></break>*In most controls, only isolated cells stained for p101K, gp106, and gp116</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN5"><sup>e</sup></xref>, RS cells<xref ref-type="table-fn" rid="TN6"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/14*<bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rare cells (reactive histiocytes, plasma cells) had cytoplasmic reaction for 101K, gp116</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Valente et al. (<xref ref-type="bibr" rid="B15">15</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">47/57 <bold>(82.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">70%</td>
<td align="left" colspan="1" rowspan="1" valign="top">No specific localization in neoplastic tissue. No HD or RS cells were positive</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Razzaque et al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/1 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monocytic cells including HD and RS cells most frequently positive, less frequently lymphoid cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Krueger et al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN4"><sup>d</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>(37%)</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Monocytic cells including HD and RS cells most frequently positive, less frequently lymphoid cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Krueger et al. (<xref ref-type="bibr" rid="B27">27</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN3"><sup>c</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">
<bold>(63%)</bold>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rojo et al. (<xref ref-type="bibr" rid="B28">28</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">14/15 <bold>(93.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">13/13 (100%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">LNs from APL and RH</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">21%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymphoid cells, monocytes most often positive, RS cells sometimes positive. Monocytes expressed antigens. Rarely, RS cells also expressed antigens (most markedly HAR3, less frequently p41).<break></break>14/15 cases had increased numbers of HHV-6 DNA containing cells with values between 22 and 590 times over those in RH (median 188)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>APL, atypical polyclonal lymphoproliferation; EBV, Epstein-Barr virus; FISH, fluorescence in situ hybridization; HL/HD, Hodgkin lymphoma/Hodgkin disease; IHC, immunohistochemistry; ISH, in situ hybridization; LD, lymphocyte depleted; LN, lymph node; LP, lymphocytic predominance; MC, mixed cellularity; NA, not available; NS, nodular sclerosis; PBLs, peripheral blood lymphocytes; RH, reactive lymphoid hyperplasia; RS, Reed Sternberg; SB, Southern blot</italic>.</p>
<p><italic><sup>*</sup>For those studies that employed both PCR and Southern Blot or ISH, only PCR results are presented</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><sup>*</sup>IHC was performed using antibodies against</p>
<fn id="TN1">
<label>a</label>
<p><italic>whole virus lysate</italic>,</p>
</fn>
<fn id="TN2">
<label>b</label>
<p><italic>DR7B</italic>,</p>
</fn>
<fn id="TN3">
<label>c</label>
<p><italic>gp116/64/54</italic>,</p>
</fn>
<fn id="TN4">
<label>d</label>
<p>p41, and</p>
</fn>
<fn id="TN5">
<label>e</label>
<p><italic>gp106</italic>.</p>
</fn>
<fn id="TN6">
<label>1</label>
<p><italic>Samples HHV-6 positive by PCR</italic>.</p>
</fn>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Both HHV-6A and HHV-6B share similar replication cycles: immediate-early (IE) proteins are synthesized within a few hours post-infection, which regulate the expression of the early and late genes. It takes ~72 h to complete a replication cycle (i.e., from infection to new virion release). It is now known, however, that these two species utilize distinct receptors for cellular entry: HHV-6A uses CD46, a ubiquitous complement regulatory protein, whereas HHV-6B primarily uses CD134, a molecule expressed only on activated T cells (<xref ref-type="bibr" rid="B100">100</xref>). Like other herpesviruses, HHV-6 displays broad cellular tropism, although it replicates most efficiently in CD4<sup>+</sup> T cells <italic>in vitro</italic>. As is the case for other oncogenic human herpesviruses, including Epstein-Barr virus (EBV) and HHV-8, also known as Kaposi's sarcoma-associated herpesvirus (KSHV), HHV-6 establishes latency in lymphocytes and possesses a strong immunomodulatory capacity that can trigger both immunosuppressive and chronic inflammatory pathways (<xref ref-type="bibr" rid="B101">101</xref>).</p>
<p>HHV-6A/B are unique among human herpesviruses in their ability to integrate into the telomeres of chromosomes as a form of latency. They share significant homology with a neoplastic avian alpha herpesvirus, Marek's disease virus (MDV), which also integrates into the subtelomeric region of the chromosome and causes an aggressive T-cell lymphoma and immunosuppression in domestic chickens (<xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>). Approximately 1% of the world's population carries inherited chromosomally integrated HHV-6 (iciHHV-6), with the full genome integrated into the subtelomeric region of the chromosome in every nucleated cell (<xref ref-type="bibr" rid="B104">104</xref>). These integrated genomes can be activated by drugs (<xref ref-type="bibr" rid="B105">105</xref>), and immunocompromised patients with iciHHV-6 can develop symptomatic infections from the integrated strain (<xref ref-type="bibr" rid="B106">106</xref>). Inherited ciHHV-6 can affect telomeric stability (<xref ref-type="bibr" rid="B107">107</xref>), and telomeric disruption has been associated with hematologic diseases, such as aplastic anemia (<xref ref-type="bibr" rid="B108">108</xref>). Recent studies suggest that iciHHV-6 can be reactivated by HDAC inhibitors and can be horizontally transmitted through liver transplantation (<xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>).</p>
<p>Even if not directly oncogenic, HHV-6 may contribute to oncogenesis in cooperation with other viruses, such as EBV and human papillomavirus (HPV) (<xref ref-type="bibr" rid="B99">99</xref>). The molecular basis of this phenomenon is only partially understood. Herein, we review the wide range of neoplastic conditions associated with HHV-6 infection and the possible mechanisms by which HHV-6 might contribute to tumorigenesis.</p>
</sec>
<sec id="s2">
<title>Methodological limitations</title>
<p>The early use of such methods as serological testing and qualitative PCR represented pioneering steps in elucidating the roles of HHV-6 in a range of diseases, including several types of cancer. Data resulting from these techniques was largely inconclusive, and unfortunately, subsequent studies employing more targeted approaches, such as IHC and ISH, have not been carried out as frequently as would be needed to gain a better understanding of HHV-6 in cancer. Consequently, the progress of research in this field has been slow. As a ubiquitous virus, HHV-6 can often be found at a low viral load in the blood, latent or slightly reactivated without deleterious effects. It also tends to reactivate during periods of immunosuppression and stress. Thus, it is difficult to distinguish background reactivation from pathological reactivation using serological and qualitative PCR approaches that do not provide information on viral load, viral transcription, viral species, and localization of the virus. In tissues, HHV-6 may be found in infiltrating lymphocytes; because of this, staining techniques are preferred over whole-tissue PCR, as infection of tumor cells can thereby be distinguished from infection of infiltrating cells, and active infection can be differentiated from latent virus.</p>
<p>The role of HHV-6 in other illnesses is still under investigation, which can be problematic when choosing controls. For example, HHV-6 has been investigated as a contributing/causative factor in cases of Alzheimer's disease, benign lymphoproliferative disorders, and certain autoimmune conditions. Until the relationships between HHV-6 and these conditions (as well as others) is better understood, it is unclear whether using samples from patients with these disorders as controls is appropriate. Likewise, using samples from immunocompromised individuals may inaccurately represent the HHV-6-status of healthy controls, as patients with compromised immunity are at a much greater risk of HHV-6 reactivation, which can lead to clinical manifestations in some instances. Whenever possible, matched normal tissues from healthy individuals should be used as controls in order to avoid overestimation of the prevalence and activity of HHV-6 in healthy persons.</p>
<p>Since early research into the ability of HHV-6 to induce transformation, little work has been done on this topic. The use of animal models could be especially useful in this area, but to date, few such models exist for the study of HHV-6. In going forward, it will be necessary to standardize reference materials (<xref ref-type="bibr" rid="B111">111</xref>), emphasize collaboration among laboratories, and perform <italic>in vitro</italic> experiments to characterize the transforming potential of HHV-6, including further analysis of the functions of the viral DR-7 gene, as well as any effects the pair of viruses may have on other oncogenic agents.</p>
<p>In light of these limitations, this review will focus on studies and case reports that have employed robust techniques that contribute to our understanding of the correlates of HHV-6 infection. In each section, we will not focus on studies relying on standard serological techniques, instead focusing on studies using PCR, immunohistochemistry (IHC), <italic>in situ</italic> hybridization (ISH), sequencing techniques, and other targeted approaches, and the greatest attention will be paid to those studies that differentiate between active and latent infection, allow localization of viral DNA/mRNA/proteins, and distinguish between HHV-6A and HHV-6B. Likewise, we will include studies of HHV-6 detection in hematological, neurological, gastrointestinal, gynecological, and head and neck cancers in a series of tables, while studies detailing the presence of HHV-6 in other cancers that are, at present, more weakly associated with the virus, are not included. Those cancers that do not fall under these five systems, including skin, lung, and urological cancers, have fewer than five studies published on their association with HHV-6 and are not included in the tables. The tables illustrate the great variation in HHV-6 detection across studies, highlighting the challenges involved in drawing conclusions from many cases, particularly from detection rates alone.</p>
</sec>
<sec id="s3">
<title>HHV-6 as the sole infectious agent in cancers: by system/site</title>
<sec>
<title>Hematological</title>
<sec>
<title>Hodgkin lymphoma (Table <xref ref-type="table" rid="T1">1</xref>, Figure <xref ref-type="fig" rid="F1">1</xref>)</title>
<p>Using PCR, HHV-6 was detected in the lymph nodes of 13/31 (12 HHV-6B, 1 HHV-6A) nodular sclerosis cases but 0/6 tissues from mixed-cellularity and lymphocyte-depleted HL (<xref ref-type="bibr" rid="B12">12</xref>), and the mean copy number was high at 6,711.4 per μg of DNA. Other PCR-based studies also found HHV-6 in a proportion of cases, but those based on ISH/IHC have proven to be more fruitful. In 1994, Krueger et al. reported HHV-6 p41 and gp116/64/54 antigen in Hodgkin Reed-Sternberg (RS) cells (<xref ref-type="bibr" rid="B27">27</xref>). Four years later, Luppi et al. detected HHV-6 p41 early antigen in the so-called “mummified” RS cells in two Hodgkin disease cases (<xref ref-type="bibr" rid="B26">26</xref>). The presence of viral antigen in these HL-associated cells indicated possible viral contribution to HL.</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>HHV-6 in nodular sclerosis Hodgkin lymphoma. <bold>(A)</bold> Presence of HHV-6 p41 by immunohistochemistry. Cytoplasmic staining of numerous large cells using a monoclonal antibody to HHV-6 p41 (3E3 clone). <bold>(B)</bold> HHV-6 U94 detection by immunohistochemistry. Staining with monoclonal antibody to HHV-6 U94 reveals positivity in the cytoplasm of numerous large cells. <bold>(C)</bold> Presence of HHV-6 by colorimetric <italic>in-situ</italic> hybridization with multiplex probe. HHV-6 DNA present in the nuclei of both small and large cells. From Eliassen et al. (<xref ref-type="bibr" rid="B112">112</xref>).</p>
</caption>
<graphic xlink:href="fonc-08-00512-g0001"></graphic>
</fig>
<p>Later, Lacroix et al. analyzed lymph node biopsies from 48 patients, 38 of which were EBV-negative, and all but three of nodular sclerosis (NS) subtype (<xref ref-type="bibr" rid="B25">25</xref>). HHV-6 protein DR7B was detected by IHC in RS cells of 74% of EBV-negative cases, and in most of these cases (61%), DR7B was detected only in RS cells. Among the nine patients with HHV-6/EBV coinfections, the DR7B-positive RS cells were also positive for the EBV oncoprotein LMP-1, a key player in EBV-induced cell transformation. Notably, in 6 of the 9 patients with co-infections, DR7B was detected only in RS cells; all 6 patients had the NS subtype. In the single EBV/HHV-6+ patient with mixed cellularity subtype HL, only LMP-1 was found in RS cells, while DR7B was exclusively detected in infiltrating inflammatory cells. Both DR7A and DR7B have been shown to bind and inactivate the tumor suppressor p53 (<xref ref-type="bibr" rid="B113">113</xref>), suggesting that DR7 might play a role in lymphomagenesis (<xref ref-type="bibr" rid="B2">2</xref>).</p>
<p>The most recent study, conducted by Siddon et al., found HHV-6 by PCR in 27 of 31 (87%) NS subtype HL lymph node specimens. In nearly half of the HHV-6-positive cases (48%), U94 latent antigen, p41 early antigen, and/or p98 (HHV-6B) late antigen was expressed in scattered RS cells and leukocytes, suggesting viral replication within granulocytes and a few RS cells (<xref ref-type="bibr" rid="B9">9</xref>). Collectively, the use of immunohistochemical techniques has provided evidence suggestive of variable HHV-6 activity depending on HL subtype, with involvement of HHV-6 appearing more likely among NS cases. Additionally, greater viral load among NS cases than those of other subtypes supports the notion that there are subtype-specific differences in the role of HHV-6 in HL (<xref ref-type="bibr" rid="B10">10</xref>). Siddon et al. also reported that patients with HHV-6+ RS cells trended toward a younger age than those with EBV+ RS cells (<italic>p</italic> = 0.073).</p>
<p>The reported preferential localization of DR7 in RS cells, and not primarily among infiltrating inflammatory cells as would be expected as a normal distribution of latent virus or in the case of opportunistic reactivation, suggests that HHV-6 may be involved in HL pathogenesis (<xref ref-type="bibr" rid="B25">25</xref>). However, in some cases, HHV-6 was primarily located in infiltrating granulocytes, suggesting that HHV-6 may simply be reactivated within the immunodeficient microenvironment of HL. While greater sample sizes and further investigation is needed, the evidence suggestive of a role for HHV-6 in HL is presently strongest for NS cases.</p>
</sec>
<sec>
<title>Non-hodgkin lymphoma (Table <xref ref-type="table" rid="T2">2</xref>)</title>
<p>In non-Hodgkin lymphoma (NHL), associations are weaker. The heterogeneity of methods, types of NHL, and types of controls included in past studies has compounded the difficulty in assigning a role to HHV-6 in this setting. PCR-based reports have documented an extreme range of HHV-6 positivity with 0–100% of blood/bone marrow/lymph nodes from cases testing positive. For instance, Usui et al. detected HHV-6 in up to 6.7% of ocular MALT tissues, while an earlier team documented a positive rate of 28.6% (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B38">38</xref>). Among some studies, the ability to draw conclusions is limited by small sample sizes, even when the HHV-6 species is typed, the viral load is quantified, and types of lymphoma are differentiated (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B36">36</xref>). While the percentages of positive samples can be intriguing when viewed alone, the small sample sizes do not allow for adequate comparison. Lack of differentiation among NHL types in other studies also limits analysis.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with Non-Hodgkin Lymphoma.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of Lymphoma in patient cohort, if specified</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Notes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kiani et al. (<xref ref-type="bibr" rid="B8">8</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">8*/22 <bold>(36%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%, 0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*6/10 cases diffuse large cell, 2/7 cases Burkitt lymphoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Usui et al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Conjunctival MALT</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/19 <bold>(5.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/23 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal conjunctiva</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Usui et al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Orbital MALT</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/15 <bold>(6.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/23 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal conjunctiva</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Usui et al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Orbital DLBCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/23 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal conjunctiva</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yoon et al. (<xref ref-type="bibr" rid="B32">32</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/11 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">4/66 (6.1%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymphoma, MF, PL, and normal skin, LN tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zhou et al. (<xref ref-type="bibr" rid="B33">33</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">19/42 <bold>(45.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%;<break></break>89% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">HHV-6 exclusively found in histological pattern II or III cases, and was present in significantly more cases with pattern III (17/29 = 58.6%) than pattern II (2/12 = 16.7%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kolonic et al. (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PMLBCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/24 <bold>(4.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hernández-Losa et al. (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B- and T-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">14/63 <bold>(22%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">17/52 (33%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal spleen lymphocytes, reactive lymphadenitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">Most HHV-6+ samples were EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Vrsalovic et al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">4*/18 <bold>(22%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">25% EBV +</td>
<td align="left" colspan="1" rowspan="1" valign="top">*TCR-gamma clonal</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Collot et al. (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-, T-, NK-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/49 <bold>(22.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">51/68 (75%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal saliva</td>
<td align="left" colspan="1" rowspan="1" valign="top">9%, 91%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*8 B-cell, 3 T-/NK-cell</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Allory et al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HPS-associated B- and NK-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">2*/3 <bold>(66.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*2/2 DLBCL</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Asou et al. (<xref ref-type="bibr" rid="B37">37</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Various</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">28*/160 <bold>(17.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">2/31 (6.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CD and reactive lymphadenopathy biopsies</td>
<td align="left" colspan="1" rowspan="1" valign="top">PEL: HHV-8+ and EBV+<break></break>AIDS NHL: 25% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">*0/10 (0%) MALTomas, 1/21 (5%) PELs, 19/104 (18%) non-AIDS NHL, 8/25 (32%) AIDS NHL</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Daibata et al. (<xref ref-type="bibr" rid="B38">38</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ocular MALT lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">4/14 <bold>(28.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">25% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ohyashiki et al. (<xref ref-type="bibr" rid="B39">39</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T- and B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">5/14 <bold>(35.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/5 (100%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">IL and CD</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NHL viral load: 6.4–810 copies/microgram DNA<break></break>Control viral load: 5.5–3,705 copies/microgram DNA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Dolcetti et al. (<xref ref-type="bibr" rid="B18">18</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV+, HIV-</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/17 <bold>(6%)</bold> HIV+, 0/35 <bold>(0%)</bold> HIV-</td>
<td align="left" colspan="1" rowspan="1" valign="top">15*/30 (50%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*12 HHV-6B, 1 A/B coinfection in HIV+ controls; 2 HHV-6B in HIV- controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Razzaque et al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T- and B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/6 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Valente et al. (<xref ref-type="bibr" rid="B15">15</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">10/15 <bold>(66.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">13/19 (68.4%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Carbone et al. (<xref ref-type="bibr" rid="B16">16</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV+ SNCC, ALC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1*/14 <bold>(7.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%; EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">*SNCC</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Di Luca et al. (<xref ref-type="bibr" rid="B19">19</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">HIV-, HIV+<sup>*</sup></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/45 <bold>(2.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">8/45 (17%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Healthy donor PBLs</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%; HIV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">*35 HIV-, 10 HIV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Brice et al. (<xref ref-type="bibr" rid="B40">40</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cutaneous T-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/30 <bold>(3.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/19 (5.3%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">LP and PL tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B41">41</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/12 <bold>(58.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/11 (9.1%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hyperplastic, non-hyperplastic LNs</td>
<td align="left" colspan="1" rowspan="1" valign="top">40%, 40%, (20%);<break></break>57% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">In one HHV-6A+ patient, HHV-6A was also found in liver and spleen (likely ciHHV-6A)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Sumiyoshi et al. (<xref ref-type="bibr" rid="B21">21</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B- and T-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">42/70 <bold>(60%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">55/56 (98.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Reactive lymphadenopathy</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Torelli et al. (<xref ref-type="bibr" rid="B23">23</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T- and B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/41 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Fox et al. (<xref ref-type="bibr" rid="B42">42</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">SS-associated, B- and T-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/6 <bold>(16.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Buchbinder et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Various<xref ref-type="table-fn" rid="TN9"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">20/23 <bold>(87%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">52/63 (83%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Peripheral blood of AIDS patients</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Types of lymphoma and RH not differentiated in results</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Josephs et al. (<xref ref-type="bibr" rid="B44">44</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/&gt;50 <bold>(&lt;6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Jarrett et al. (<xref ref-type="bibr" rid="B24">24</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B- and T-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">2*/53 <bold>(3.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/35 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-lymphomatous tissues**</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*1 gastric DLBCL with SS, 1 TCL with preceding AITL<break></break>**Reactive LNs, cancers, neoplasms, sarcoidosis, Sjögren's syndrome, miscellaneous</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Daibata et al. (<xref ref-type="bibr" rid="B38">38</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">MALT lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/14 <bold>(14.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Positive cells randomly spread in the neoplastic tissues. Number of positive cells varied from case to case</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN7"><sup>a</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/16 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-neoplastic LNs<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AITL<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN8"><sup>b</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/5 <bold>(100%)</bold></td>
<td colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-neoplastic LNs<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Scattered plasma cells positive for p101K, gp106, and gp116.<break></break>Isolated cells from controls positive for p101K, gp106, gp116</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B26">26</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN7"><sup>a</sup></xref><sup>,</sup><xref ref-type="table-fn" rid="TN8"><sup>b</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/15 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0 (for p41)/16 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-neoplastic LNs<xref ref-type="table-fn" rid="TN10"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0 samples with neoplastic cells only were p101K+. Cytoplasmic staining observed for p101K in rare plasma cells among neoplastic cells and isolated stromal cells in the LN capsule/surrounding tissue. Isolated cells stained for gp106, gp116</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Razzaque et al. (<xref ref-type="bibr" rid="B17">17</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T- and B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">2*/6 <bold>(28.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">~30% of cells were positive for antigens<break></break>*1 B-cell, 1 T-cell</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rojo et al. (<xref ref-type="bibr" rid="B28">28</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T- and B-cell</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">19/22 <bold>(86.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">13/13 (100%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">LNs from APL and RH</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">By IHC, fewer cells (usually rare scattered lymphoid cells and monocytes expressing p41 and HAR) were positive for HHV-6 antigens in NHL cases than APL cases</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yin et al. (<xref ref-type="bibr" rid="B45">45</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/45 <bold>(17.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Buchbinder et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Various<xref ref-type="table-fn" rid="TN9"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/23 <bold>(13%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">In positive samples, 1/10,000 cells was positive<break></break>Lymphomas and RH not differentiated in results</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/43 <bold>(2.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Strong et al. (<xref ref-type="bibr" rid="B46">46</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">Next-generation RNA-sequencing, RNA CoMPASS</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/118 <bold>(1.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%;<break></break>50% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>AIDS, acquired immune deficiency syndrome; AILD, angioimmunoblastic lymphadenopathy with dysproteinaemia; AITL, angioimmunoblastic T cell lymphoma; ALC, anaplastic large cell; APL, atypical polyclonal lymphoproliferation; CD, Castleman's disease; DLBCL, diffuse large B-cell lymphoma; HIV, human immunodeficiency virus; HL, Hodgkin lymphoma; HPS, hemophagocytic syndrome; IHC, immunohistochemistry; IL, immunoblastic lymphadenopathy; ISH, in situ hybridization; LN, lymph node; LP, lymphomatoid papulosis; MALT, mucosa-associated lymphoid tissue; MF, mycosis fungoides; NA, not available; NHL, non-Hodgkin lymphoma; NKTL, NK T cell lymphoma; PBLs, peripheral blood lymphocytes; PCLBCL, primary cutaneous large B-cell lymphoma; PEL, primary effusion lymphoma; PL, pityriasis lichenoides; PMLBCL, primary mediastinal large B-cell lymphoma; PTCL, peripheral T cell lymphoma; RH, reactive lymphoid hyperplasia; SB, southern blot; SNC, small noncleaved cell; SS, Sjogren's syndrome; TCL, T cell lymphoma; VirusScan, VirusScan bioinformatics system; WM, Waldenstrom's macroglobulinemia</italic>.</p>
<p><italic><sup>*</sup>For those studies that employed both PCR and Southern Blot, only PCR results are presented</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><sup>*</sup>IHC was performed using antibodies against</p>
<fn id="TN7">
<label>a</label>
<p>p41 and</p>
</fn>
<fn id="TN8">
<label>b</label>
<p><italic>p101K, gp106, gp116</italic>.</p>
</fn>
<fn id="TN9">
<label>1</label>
<p><italic>HL (3), NHL (10), AILD (1), atypical RH (5), RH (4)</italic>.</p>
</fn>
<fn id="TN10">
<label>2</label>
<p><italic>Samples HHV-6 positive by PCR</italic>.</p>
</fn>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>By IHC/ISH, HHV-6 DNA and antigens have been detected in AITL, MALT lymphoma, unspecified NHL, and unspecified T- and B-cell lymphomas, but the signal was localized in scattered cells, often plasma cells, rather than neoplastic cells (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B43">43</xref>). RNA and DNA sequencing has identified HHV-6 in only up to 2.3% of NHL cases. On the whole, neither HHV-6A nor HHV-6B appear to be causative agents in NHL development, but investigation into specific subtypes of NHL, such as DLBCL, may be more constructive than viewing all types together. Moreover, the absence of viral DNA and antigens in neoplastic cells suggests that HHV-6 likely does not cause the development of most NHL, but it remains to be seen whether the virus might contribute to local immune dysfunction, or exacerbation of oncogenic effects of other agents, that predisposes to lymphomagenesis.</p>
</sec>
<sec>
<title>Leukemia (Table <xref ref-type="table" rid="T3">3</xref>)</title>
<p>To date, the preponderance of data suggests no association between HHV-6 and leukemia. Contrasting findings, and differences in HHV-6 species predominating in bone marrow of leukemia patients, may stem from the use of different probes for HHV-6A and/or divergence in HHV-6A across geographical areas (<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B54">54</xref>). If this is the case, false negatives may have resulted. Likewise, PCR testing of blood samples has failed to demonstrate a strong association between HHV-6 viral load and leukemia (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B114">114</xref>, <xref ref-type="bibr" rid="B115">115</xref>), and while serological testing has shown increased titers of HHV-6 antibody in leukemia (<xref ref-type="bibr" rid="B116">116</xref>–<xref ref-type="bibr" rid="B124">124</xref>), this is expected since HHV-6 reactivates in response to immunosuppression and chemotherapy (<xref ref-type="bibr" rid="B50">50</xref>). The inclusion of different subtypes of leukemia may result in skewed conclusions because HHV-6 may not have the same role across subtypes, as in the case of HL.</p>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Detection of HHV-6 in blood/bone marrow from patients with Leukemia.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of leukemia in patient cohort, if specified</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Notes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nefzi et al. (<xref ref-type="bibr" rid="B47">47</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">17*/20 <bold>(85%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*5 samples only positive at diagnosis, 3 positive at diagnosis and remission, 9 positive only at remission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Morales-Sánchez et al. (<xref ref-type="bibr" rid="B48">48</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">66 B-cell, 4 T-cell ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/70 <bold>(9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">BM samples</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Gravel et al. (<xref ref-type="bibr" rid="B49">49</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/293 <bold>(3.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/288 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB</td>
<td align="left" colspan="1" rowspan="1" valign="top">11%, 89% (all ciHHV-6A)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Detection threshold: ≥200 copies of HHV-6/μg DNA<break></break>*10 pre-B, 1 pre-T</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Faten et al. (<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/62 <bold>(12.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Median load in blood: 206 copies/million cells Median load in BM: 79 copies/million cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Faten et al. (<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Faten et al. (<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">4/64 <bold>(6.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%, (25% iciHHV-6B)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Median load in blood: 206 copies/million cells<break></break>Median load in BM: 34 copies/million cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hubacek et al. (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric, 318 ALL, 21 AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">86/339 <bold>(25.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Community strains of HHV-6 only (not iciHHV-6)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hubacek et al. (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric, 318 ALL, 21 AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">5/339 <bold>(1.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">80%, 20%</td>
<td align="left" colspan="1" rowspan="1" valign="top">Testing for iciHHV-6 strains only</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Seror et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">16*/31 <bold>(51.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*3 samples only positive at diagnosis, 2 positive at diagnosis and remission, 11 positive only at remission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Seror et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric T-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1*/5 <bold>(20%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Negative at diagnosis, positive at remission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Csire et al. (<xref ref-type="bibr" rid="B53">53</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">MM</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">13/69 <bold>(18.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">4*/26 (15.4%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">MGUS and WM tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-CLL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">3*/21 <bold>(14.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/24 (20.8%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Blood samples</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1*/29 <bold>(3.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/24 (20.8%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Blood sample</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1*/16 <bold>(6.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/24 (20.8%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*BM sample</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-CLL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/21 <bold>(52.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/24 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%, 0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*All positive were blood samples</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">10*/29 <bold>(34.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/24 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%, 0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*3 blood samples, 7 BM</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hermouet et al. (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6*/16 <bold>(37.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/24 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NB and BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">100%, 0%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*All positive were BM samples</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric T-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">14/16*<bold>(87.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">B-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/10 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CLL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/4 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">BM</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Krueger et al. (<xref ref-type="bibr" rid="B56">56</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CML*</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">19/36 <bold>(54%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*BM cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T-ALL<xref ref-type="table-fn" rid="TN11"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/8 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">% Positive cells varied between 20 and 58%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">IA (early antigen)</td>
<td align="left" colspan="1" rowspan="1" valign="top">4/8 <bold>(50%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">% Positive cells varied between 2 and 7%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luka et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">T-ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">IA (late antigen)</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/8 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/173 <bold>(0.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Not specified</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/161 <bold>(0.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; BM, bone marrow; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; IA, immunofluorescence assay; IHC, immunohistochemistry; ISH, in situ hybridization; MGUS, monoclonal gammopathy of unknown significance; NA, not available; NB, normal blood; Pickaxe, Pickaxe virus detection and discovery computational pipeline; VirusScan, VirusScan bioinformatics system; WM, Waldenstrom's macroglobulinemia</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><italic><sup>*</sup>IHC was performed using antibodies against p41</italic>.</p>
<fn id="TN11">
<label>1</label>
<p><italic>Samples HHV-6 positive by PCR</italic>.</p>
</fn>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Only one group has investigated HHV-6 antigen expression in leukemia, with intriguing results: HHV-6 early antigen p41 was detected in bone marrow cells—blasts and megakaryocytes—of 54% of 36 patients with chronic myelogenous leukemia (<xref ref-type="bibr" rid="B56">56</xref>). Since bone marrow biopsies from healthy individuals were not readily available, comparison between these two populations were not carried out. While this has been one of the strongest studies on HHV-6 and leukemia as it revealed active infection in approximately half of patients, standing alone, it is not enough to draw any clinically significant conclusions <italic>per se</italic>. Unfortunately, serological testing and PCR analysis of blood are inadequate in determining the role of HHV-6 in leukemia, and these methods fall short in differentiating between pathological and background HHV-6 infections. As blood is a relevant sample used in evaluating leukemia, this presents another hurdle; latent HHV-6 or HHV-6 undergoing low-level reactivation is occasionally present in healthy individuals. For these reasons, although many studies have made preliminary investigations into HHV-6 in several types of leukemia, forward progress of our understanding of the virus in these cancers has been stunted by the reliance upon blood PCR and serological analysis.</p>
</sec>
</sec>
<sec>
<title>Neurological (Table <xref ref-type="table" rid="T4">4</xref>)</title>
<sec>
<title>Glial tumors</title>
<p>Both HHV-6A and HHV-6B are neurotropic viruses, with glial cells being the most common viral reservoir in the nervous system. HHV-6B infection of the brain is associated with encephalitis and febrile seizures, while the presence of HHV-6A has been studied in the context of multiple sclerosis. Several studies have shown that HHV-6 infects human astrocytes and oligodendrocytes (<xref ref-type="bibr" rid="B125">125</xref>–<xref ref-type="bibr" rid="B128">128</xref>), and both species impair glutamate uptake (<xref ref-type="bibr" rid="B129">129</xref>) and induce chemokine/cytokine dysregulation in persistently infected glial cells (<xref ref-type="bibr" rid="B130">130</xref>). Long-term latent infection is also implicated in demyelination, especially in white matter (<xref ref-type="bibr" rid="B131">131</xref>).</p>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with cancers of the nervous system.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Notes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zheng et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PA, non-invasive</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/30 <bold>(23.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%;<break></break>43% HPV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">Positive rate of HPV16 and HHV6-B infection positively correlated with PA invasiveness</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zheng et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PA, invasive</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">16/30 <bold>(53.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%;<break></break>63% HPV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">Positive rate of HPV16 and HHV6-B infection positively correlated with PA invasiveness</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lin et al. (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioblastoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">ddPCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/39 <bold>(15.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">2/32 (6.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lin et al. (<xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Astrocytoma grade III, OCT-preserved</td>
<td align="left" colspan="1" rowspan="1" valign="top">ddPCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/10 <bold>(20%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">2/32 (6.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Astrocytoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/17 <bold>(41.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/13 (7.7%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioblastoma multiforme</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/14 <bold>(50%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/13 (7.7%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oligodendroglioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/9 <bold>(33.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/13 (7.7%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR (U57)</td>
<td align="left" colspan="1" rowspan="1" valign="top">42/66 <bold>(63.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">7*/32 (22%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">74%, 26%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR (U31)</td>
<td align="left" colspan="1" rowspan="1" valign="top">47/66 <bold>(71.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/32 (34%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">74%, 26%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*4/11 (33%) HHV-6A in controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric non-glial brain tumors<xref ref-type="table-fn" rid="TN16"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR (U57)</td>
<td align="left" colspan="1" rowspan="1" valign="top">26/54 <bold>(48.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">7/32 (22%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">67%, 33%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric non-glial brain tumors<xref ref-type="table-fn" rid="TN16"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR (U31)</td>
<td align="left" colspan="1" rowspan="1" valign="top">26/54 <bold>(48.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">11*/32 (34%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">67%, 33%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*4/11 (33%) HHV-6A in controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adult CNS tumors*</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">14/30 <bold>(47%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">43%, 57%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*25 astrocytoma, 4 oligodendroglioma, 1 neuronal tumor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neves et al. (<xref ref-type="bibr" rid="B62">62</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pilocytic astrocytoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/35 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/10 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem cerebellum without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cuomo et al. (<xref ref-type="bibr" rid="B63">63</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNS tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">43/115 <bold>(37.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">10*/31 (32.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">77%, 23%</td>
<td align="left" colspan="1" rowspan="1" valign="top">*70% HHV-6A, 30% HHV-6B in controls</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chan et al. (<xref ref-type="bibr" rid="B64">64</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNS tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/98 <bold>(8.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">38.5%, 62.5%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Luppi et al. (<xref ref-type="bibr" rid="B65">65</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glial tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/37 <bold>(16.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">10*/16 (62.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND, BT from patients who died of AIDS</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*4/10 (57%) HIV+, 6/10 (66%) HIV-</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Liedtke et al. (<xref ref-type="bibr" rid="B66">66</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cerebral lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">3/20 (15%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT and spleen from cases without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Paulus et al. (<xref ref-type="bibr" rid="B67">67</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Primary cerebral lymphomas</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/40 <bold>(2.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zheng et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pituitary adenoma, non-invasive</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN13"><sup>a</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">7/30 <bold>(23.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zheng et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pituitary adenoma, invasive</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN13"><sup>a</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">16/30 <bold>(53.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Astrocytoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN14"><sup>b</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/17 <bold>(29.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/13 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Strong nuclear and cytoplasmic staining, 1/4 glioma cyst fluid samples was HHV-6+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioblastoma multiforme</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN14"><sup>b</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/14 <bold>(35.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/13 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Strong nuclear and cytoplasmic staining,1/4 glioma cyst fluid samples was HHV-6+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chi et al. (<xref ref-type="bibr" rid="B59">59</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oligodendroglioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN14"><sup>b</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">3/9 <bold>(33.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/13 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Strong nuclear and cytoplasmic staining, 1/4 glioma cyst fluid samples was HHV-6+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">73/128 <bold>(57%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">10/32 (31%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">More positivity in tumor tissue than adjacent normal BT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric non-glial brain tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">10/22 <bold>(45%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">10/32 (31%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">More positivity in tumor tissue than adjacent normal BT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN15"><sup>c</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">48/102 <bold>(47%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/32 (18%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Staining of astrocytes. Increased positivity in glial compared to non-glial tumors. Significant difference in immunopositivity between lower and higher grade gliomas observed (42 and 19% positive, respectively)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B60">60</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric non-glial brain tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN15"><sup>c</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">2/22 <bold>(9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/32 (18%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pediatric post-mortem BT without ND</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNS tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">106/224 <bold>(47%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Perinuclear/cytoplasmic staining, predominantly in tumor, not vessels/non-tumor tissue</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glial tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN15"><sup>d</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">62/217 <bold>(29%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Staining in cytosol, relatively heterogeneous distribution</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glial tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN14"><sup>c</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">78/224 <bold>(35%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Staining in cytosol, relatively heterogeneous distribution</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-glial brain tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN15"><sup>d</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/60 <bold>(10%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Staining in cytosol, relatively heterogeneous distribution</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Crawford et al. (<xref ref-type="bibr" rid="B61">61</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-glial brain tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN14"><sup>c</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/58 <bold>(10%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/25 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-tumor BT, BT from other ND<xref ref-type="table-fn" rid="TN17"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Staining in cytosol, relatively heterogeneous distribution</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cuomo et al. (<xref ref-type="bibr" rid="B63">63</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CNS tumors</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC<xref ref-type="table-fn" rid="TN15"><sup>d</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">4/6 <bold>(66.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Post-mortem BT without ND (HHV-6 DNA+)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Focal or scattered staining, nuclear or nucleo-cytoplasmic localization in neoplastic cells. Endothelial cells, not inflammatory cells, stained in glioblastoma tissues</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioblastoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/162 <bold>(1.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low grade glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/100 <bold>(1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioblastoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/169 <bold>(0.59%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Low grade glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/530 <bold>(0.57%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Strong et al. (<xref ref-type="bibr" rid="B68">68</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Glioma</td>
<td align="left" colspan="1" rowspan="1" valign="top">RNA sequencing</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/170 <bold>(0.59%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal BT</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duncan et al. (<xref ref-type="bibr" rid="B69">69</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Brain tumors*</td>
<td align="left" colspan="1" rowspan="1" valign="top">Digital karyotyping</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/41 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Glioblastoma multiforme, astrocytoma, oligodendroglioma, medulloblastoma</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>BM, bone marrow; BT, brain tissue; CNS, central nervous system; ddPCR, droplet digital PCR; HPV16, human papillomavirus 16; IHC, immunohistochemistry; ISH, in situ hybridization; IV, intravenous; NA, not available; ND, neurological diseases; PA, pituitary adenoma; PCR, polymerase chain reaction; Pickaxe, Pickaxe virus detection and discovery computational pipeline; VirusScan, VirusScan bioinformatics system</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><sup>*</sup>IHC was performed using</p>
<fn id="TN12">
<label>a</label>
<p><italic>unnamed anti-HHV-6B antibody</italic>,</p>
</fn>
<fn id="TN13">
<label>b</label>
<p><italic>unnamed anti-HHV-6 monoclonal antibody</italic>,</p>
</fn>
<fn id="TN14">
<label>c</label>
<p>antibodies against gp116/64/54 and</p>
</fn>
<fn id="TN15">
<label>d</label>
<p><italic>p41</italic>.</p>
</fn>
<fn id="TN16">
<label>1</label>
<p><italic>Meningioma, medulloblastoma, germinoma</italic>.</p>
</fn>
<fn id="TN17">
<label>2</label>
<p><italic>Other ND listed: Stroke, Alzheimer's, Parkinson's, subarachnoid hemorrhage, contusion</italic>.</p>
</fn>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>One small study using droplet digital PCR (ddPCR) reported HHV-6B in 3 of 19 (15.8%) formalin-fixed paraffin embedded (FFPE) glioblastoma samples, 3 of 20 (15%) frozen glioblastoma samples, and 2 of 10 (20%) frozen astrocytoma grade III specimens. All were negative for cytomegalovirus (CMV) and HHV-6A (<xref ref-type="bibr" rid="B58">58</xref>). The viral loads of HHV-6B in tumors ranged from &lt;100 to &gt;20,000 copies/million cells. While the low viral loads likely indicate latency, the high loads suggest active infection, or potentially iciHHV-6. Of note, nested PCR is more sensitive, but also more prone to false positives, than ddPCR or sequencing analysis (<xref ref-type="bibr" rid="B132">132</xref>).</p>
<p>Analysis of 120 pediatric gliomas from 88 untreated patients using ISH, IHC, and nested PCR revealed higher rates of expression of the proteins U57 (major capsid protein) and U31 (large tegument protein) in tumors than in non-tumor controls (<xref ref-type="bibr" rid="B60">60</xref>). HHV-6 antigens were identified in 58% of low-grade gliomas compared to 19% of high-grade gliomas and 25% of non-glial tumors. The same group investigated the presence of HHV-6 in adult glial tumors and found that 47% of tumors tested positive for U57 compared to 0 of 25 controls (<xref ref-type="bibr" rid="B61">61</xref>). Moreover, HHV-6A early and HHV-6B late antigens were detected three times more frequently in glial tumors than in non-glial tumors, signifying more frequent active infection among those with glial tumors. Whether this correlation represents opportunistic reactivation due to the tumor will be an important avenue to explore.</p>
<p>These findings are supported by a more recent study, which analyzed 40 glioma tissue specimens and 13 normal brain tissue specimens (<xref ref-type="bibr" rid="B59">59</xref>). Using nested PCR, HHV-6 DNA was identified in 17 of 40 (42.5%) glioma tissue samples, compared to only 1 of 13 (7.7%) control samples. Along the same lines, 13 of 40 (32.5%) other glioma specimens stained positively for HHV-6, while no HHV-6 immunoreactivity was detected in normal brain tissues. Of note, HHV-6A was isolated from the glioma cyst fluids, and the HHV-6-infected specimens displayed higher levels of interleukin-6 (IL-6), IL-8, and transforming growth factor-β (TGF-β).</p>
<p>Taken together, the <italic>in vitro</italic> and <italic>in vivo</italic> data suggests that both species of HHV-6 are present in glioma. The greater prevalence of HHV-6 DNA and proteins among glial tumors compared to controls and the altered cytokine profile in HHV-6-positive specimens is suggestive of a potential role in gliomagenesis. To confirm this hypothesis, further studies are necessary to determine the localization of HHV-6 antigens, longitudinally investigating the effects of HHV-6 infection in animal models of glioma. Ultimately, a clinical trial is warranted to determine what role, if any HHV-6 plays in adult and pediatric glioma.</p>
</sec>
<sec>
<title>Pituitary adenomas</title>
<p>HHV-6B was recently implicated in the progression of invasive pituitary adenomas (PAs) through the toll-like receptor 3 (TLR3) signaling pathway. TLR3 is known to recognize double stranded RNA; however, studies have shown that the TLR3 cascade can also be activated by herpesviruses (<xref ref-type="bibr" rid="B133">133</xref>). Among 30 patients with invasive PAs and 30 patients with non-invasive PAs, HHV-6B DNA was detected in biopsy samples from 53.55% of invasive cases and 30% of non-invasive cases (<xref ref-type="bibr" rid="B57">57</xref>). Similarly, in invasive PA, TLR3 mRNA and protein were significantly higher than in noninvasive PA. TLR3 activity contributes to the innate immune response during viral infection via recognition of virus-associated double stranded RNA, but it has also been noted for its involvement in generating a pro-tumorigenic local environment and in promoting tumor cell invasion and proliferaation.</p>
<p>Rat pituitary adenoma G3 cells challenged with polyinosinic:polycytidylic acid (Poly(I:C)), a TLR3 agonist serving as a viral mimic, increased TLR3 expression and cell proliferation through the TLR3 signaling pathway (<xref ref-type="bibr" rid="B57">57</xref>). In addition, these cells expressed higher levels of Bcl-2, which can inhibit apoptosis, and lower levels of cleaved caspase 3. NF-κB, which is involved in cell proliferation, promotion of tumor invasion, and activation of inflammatory cytokines, was also activated, as were NF-κB-regulated genes for the inflammatory cytokines MMP9, IL-6, IL-1β, and TNF-α. Further studies on whether HHV-6 plays a direct role in TLR3 activation are necessary to confirm the significance of this association. This is the only study of its kind, but it suggests that perhaps the immunomodulatory capacity of HHV-6, and particularly its effects on innate immune effectors and mediators, leads to neurological dysfunction over time, as has recently been suggested in Alzheimer's disease (Readhead 2018), that may promote oncogenesis.</p>
</sec>
</sec>
<sec>
<title>Gastrointestinal (Table <xref ref-type="table" rid="T5">5</xref>)</title>
<p>Gastrointestinal cancer (GIC) typically develops from a benign polyp, becomes an adenoma, and finally transforms into a carcinoma (<xref ref-type="bibr" rid="B134">134</xref>). One study detected HHV-6 in the GI tract of 63% of healthy individuals (<xref ref-type="bibr" rid="B135">135</xref>), whereas another study detected HHV-6 in 23% of liver transplant patients and 19% of immunocompetent patients (<xref ref-type="bibr" rid="B136">136</xref>). HHV-6 causes a range of GI symptoms, including diarrhea, colitis, and bacterial infection of the digestive tract (<xref ref-type="bibr" rid="B137">137</xref>), and an association between biliary complications and HHV-6 has been reported in many studies (<xref ref-type="bibr" rid="B136">136</xref>, <xref ref-type="bibr" rid="B138">138</xref>).</p>
<table-wrap id="T5" position="float">
<label>Table 5</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with gastrointestinal cancers.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method (ISH/IHC)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 variant (A/B); Coinfections</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Halme et al. (<xref ref-type="bibr" rid="B70">70</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colon adenoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/8 <bold>(87.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal mucosal biopsies</td>
<td align="left" colspan="1" rowspan="1" valign="top">HHV-6B</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Halme et al. (<xref ref-type="bibr" rid="B70">70</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colon adenoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">5/8 <bold>(62.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal mucosal biopsies</td>
<td align="left" colspan="1" rowspan="1" valign="top">HHV-6B; 3/8 total samples CMV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Esophageal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">8/125 <bold>(6.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stomach cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">5/127 <bold>(3.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/16 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Stomach cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">10/285 <bold>(3.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colon cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">19/407 <bold>(4.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/21 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colon cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">27/468 <bold>(5.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rectal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/156 <bold>(3.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/5 (20%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rectal cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/164 <bold>(3.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pancreatic cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/40 <bold>(5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/1 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pancreatic cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/179 <bold>(1.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duncan et al. (<xref ref-type="bibr" rid="B69">69</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colorectal carcinomas</td>
<td align="left" colspan="1" rowspan="1" valign="top">Digital karyotyping</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/7 (71.4%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Matched normal samples from individuals with colorectal liver metastases</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duncan et al. (<xref ref-type="bibr" rid="B69">69</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Colorectal liver metastases</td>
<td align="left" colspan="1" rowspan="1" valign="top">Digital karyotyping</td>
<td align="left" colspan="1" rowspan="1" valign="top">3/7 <bold>(42.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/7 (71.4%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Matched normal samples from the same individuals with colorectal liver metastases</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Liver cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/68 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/36 (16.7%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Liver cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/269 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>IHC, immunohistochemistry; ISH, in situ hybridization; NA, not available; Pickaxe, Pickaxe virus detection and discovery computational pipeline; VirusScan, VirusScan bioinformatics system</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Using a bioinformatics and sequencing approach to investigate the viral basis of 6,813 tumors and 559 adjacent normal samples, Cao et al. found HHV-6 at a relatively high prevalence in GICs (<xref ref-type="bibr" rid="B29">29</xref>). Specifically, HHV-6 was detected in 26 cases of colon adenocarcinomas (5.8% of total cases), 9 cases of stomach adenocarcinomas (3.5%), 7 cases of esophageal cancer (6.4%), and 6 cases of rectal adenocarcinomas (3.7%). The virus was not detected in paired adjacent normal samples. Cantalupo et al. analyzed tumor sample sequences from The Cancer Genome Atlas (TCGA) as well and identified HHV-6 sequences in 3.9% of stomach cancer samples and 4.7% of colon cancers. In contrast, the virus was neither found in 16 paired normal stomach samples nor in 21 normal colon samples (<xref ref-type="bibr" rid="B30">30</xref>). Rectal cancer samples were positive at a comparable frequency (3.8%), but 1 of 5 normal controls was also positive. EBV and CMV were also frequently detected in GIC, and together with HHV-6, they were the most commonly identified viruses in stomach and colorectal tumors. In some cases, HHV-6 was detected by both DNA-sequencing and RNA-sequencing. This sequencing approach has a low risk of false-positives.</p>
<p>In addition, HHV-6B was frequently detected in adenomatous polyps of the colon, while mucosal biopsies from patients without adenomas revealed neither IHC nor ISH positivity (<xref ref-type="bibr" rid="B70">70</xref>). Gastrointestinal cancers, in addition to oral cancer, brain tumors (particularly glial tumors), and NSHL represent malignancies that deserve priority for future studies on the oncogenic capacity of HHV-6A and HHV-6B.</p>
</sec>
<sec>
<title>Gynecological (Table <xref ref-type="table" rid="T6">6</xref>)</title>
<sec>
<title>Ovarian cancer</title>
<p>HHV-6A also emerged as a pathogen of interest in ovarian cancer in view of a broad-scale investigation of the ovarian cancer oncobiome using the microarray system PathoChip, which identified species of bacteria, fungi, parasites, and viruses that predominated in cancer tissue when compared to control tissue (<xref ref-type="bibr" rid="B71">71</xref>). Conserved and specific probes for both HHV-6A and−6B were found in the cancer biopsies but were absent in the 20 matched ovarian tissue samples and 20 non-matched ovarian biopsies. Ten instances of HHV-6A integration in various chromosomes were detected, with U47, encoding envelope glycoprotein O, identified as the most commonly inserted viral sequence. Most integrations were found in intronic or intergenic regions, but some were present at exonic and sub-telomeric loci. Of the genes that HHV-6A sequences were found to be integrated into or located near, most were significantly associated with cancers, and six, including CPLX1, IGFBP3, and the oncogene SH3RF2, were associated with malignant tumor formation (<italic>p</italic> = 8.45 × 10<sup>−7</sup>). Although HHV-6A was one of many pathogens detected more frequently in cancer tissues than in matched controls, the association between the genes that the virus integrated into or near to and the development of cancer, as well as the lack of HHV-6 in non-cancerous samples, makes a case for closer examination of integrated HHV-6 in ovarian cancer. A single study is insufficient to draw strong conclusions from, so reproduction of these initial findings is a logical next step.</p>
<table-wrap id="T6" position="float">
<label>Table 6</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with gynecological cancers.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Banerjee et al. (<xref ref-type="bibr" rid="B71">71</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ovarian cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">PathoChip, next-generation sequencing</td>
<td align="left" colspan="1" rowspan="1" valign="top">16/99 <bold>(16.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/40 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">20 matched, 20 unmatched ovarian tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">63%, 37%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ovarian cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/93 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Duncan et al. (<xref ref-type="bibr" rid="B69">69</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Ovarian carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Digital karyotyping</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Uterine carcinosarcoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/95 <bold>(1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Uterine carcinosarcoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">0/57 <bold>(0%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical SCC, endocervical adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/255 <bold>(0.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/208 (0.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical SCC, endocervical adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/252 <bold>(0.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Broccolo et al. (<xref ref-type="bibr" rid="B72">72</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia<xref ref-type="table-fn" rid="TN18"><sup>1</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">39/103 <bold>(37.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">9/66 (14%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal CT</td>
<td align="left" colspan="1" rowspan="1" valign="top">22/23 with high grade dysplasia had high-risk HPV</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Tran-Thanh et al. (<xref ref-type="bibr" rid="B73">73</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia<xref ref-type="table-fn" rid="TN19"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/195 <bold>(3.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/125 (0.8%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal CT</td>
<td align="left" colspan="1" rowspan="1" valign="top">86% HPV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chan et al. (<xref ref-type="bibr" rid="B74">74</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia<xref ref-type="table-fn" rid="TN19"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/187 <bold>(3.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">7/201 (3.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CT, normal or inflamed</td>
<td align="left" colspan="1" rowspan="1" valign="top">57% HPV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Romano et al. (<xref ref-type="bibr" rid="B75">75</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia<xref ref-type="table-fn" rid="TN19"><sup>2</sup></xref></td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">1/51 <bold>(2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/58 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CT, normal or inflamed</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 100%; HPV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Wang et al. (<xref ref-type="bibr" rid="B76">76</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">2/8 <bold>(25%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">50% 50%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B77">77</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical carcinoma, intraepithelial neoplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB, ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/72 <bold>(18.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/30 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">CT, normal and cervicitis</td>
<td align="left" colspan="1" rowspan="1" valign="top">66.7% HPV+</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Arivananthan et al. (<xref ref-type="bibr" rid="B78">78</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">10/30 <bold>(33.3%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal oral, salivary gland tissues, CT</td>
<td align="left" colspan="1" rowspan="1" valign="top">20%, 50%, (30%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B79">79</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">10/26 <bold>(38.5%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1/8 (12.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal CT</td>
<td align="left" colspan="1" rowspan="1" valign="top">28.6%, 28.6%, (42.8%)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B79">79</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cervical neoplasia</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">14<xref ref-type="table-fn" rid="TN20"><sup>3</sup></xref>/26 <bold>(53.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/8 (62.5%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal CT</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>CT, cervical tissue; HGSIL, high grade squamous intraepithelial lesion; IHC, immunohistochemistry; HPV, human papillomavirus; ISH, in situ hybridization; LGSIL, low grade squamous intraepithelial lesion; NA, not available; Pickaxe, Pickaxe virus detection and discovery computational pipeline; SB, southern blot; SCC, squamous cell carcinoma; VirusScan, VirusScan bioinformatics system</italic>.</p>
<p><italic><sup>*</sup>For studies that employed both PCR and SB or ISH, only PCR results are presented</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><italic><sup>*</sup>IHC was performed using antibodies against gp116/64/54 and p41/38</italic>.</p>
<fn id="TN18">
<label>1</label>
<p><italic>LGSIL, HGSIL</italic>.</p>
</fn>
<fn id="TN19">
<label>2</label>
<p><italic>LGSIL, HGSIL, SCC, adenocarcinoma</italic>.</p>
</fn>
<fn id="TN20">
<label>3</label>
<p><italic>Staining in transformed cells. In normal tissue, staining in endocervical ciliated columnar-epithelial cells, some cells in subepithelial mucosa</italic>.</p>
</fn>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec>
<title>Head and neck (Table <xref ref-type="table" rid="T7">7</xref>)</title>
<p>Oral cancer is often linked to tobacco and/or alcohol use, as well as to HPV infections. The salivary glands serve as a reservoir for HHV-6, which is persistently shed in the saliva. While HHV-6 has not been shown to cause oral cancer, by facilitating the transformation process, HHV-6 may serve as a co-factor with HPV and chemical carcinogens found in tobacco and alcohol.</p>
<table-wrap id="T7" position="float">
<label>Table 7</label>
<caption>
<p>Detection of HHV-6 in tumor tissue from patients with head and neck cancers.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection method</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive patients/Total number of patients (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive controls/Total number of controls (%)</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Type of control tissue</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Of typed samples: HHV-6A%, HHV-6B%, (HHV-6A/B Coinfection%); Coinfections with other viruses</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Notes</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Head/neck squamous cell carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pickaxe</td>
<td align="left" colspan="1" rowspan="1" valign="top">11/517 <bold>(2.1%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">6/515 (1.2%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Adjacent normal tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Head/neck squamous cell carcinoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">VirusScan</td>
<td align="left" colspan="1" rowspan="1" valign="top">12/498 <bold>(2.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Arivananthan et al. (<xref ref-type="bibr" rid="B78">78</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Laryngeal</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">4/4 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal oral, cervical, salivary gland tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 75%, (25%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Arivananthan et al. (<xref ref-type="bibr" rid="B78">78</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Salivary gland</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">6/8 <bold>(75%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal oral, cervical, salivary gland tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">0%, 50%, (50%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Arivananthan et al. (<xref ref-type="bibr" rid="B78">78</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">16/21 <bold>(76.2%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/7 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal oral, cervical, salivary gland tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">13%, 31%, (56%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B80">80</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">33/42 <bold>(78.6%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">12/30 (40%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal mucosa, LP, leukoplakia</td>
<td align="left" colspan="1" rowspan="1" valign="top">9%, 42%, (48%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B80">80</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">41/51 <bold>(80.4%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">15/25 (60%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal mucosa, LP, leukoplakia</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cytoplasmic and nuclear staining in some cells.<break></break>60% of 15 screened SCC expressed only a limited number of antigens</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B81">81</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">7/7 <bold>(100%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/3 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NPC</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cytoplasmic staining of transformed SCC cells, sometimes also strong positivity in the membrane and nucleus of squamous cells</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Saravani et al. (<xref ref-type="bibr" rid="B82">82</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">13/45 <bold>(28.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">No correlation between mean viral load and SCC grade</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B80">80</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">19/24 <bold>(79%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">5/35 (14.3%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Normal mucosa, LP, leukoplakia, breast cancer</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Yadav et al. (<xref ref-type="bibr" rid="B81">81</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Oral SCC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">11/16 <bold>(68.8%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Shanehsazzadeh et al. (<xref ref-type="bibr" rid="B83">83</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Salivary gland cancer*</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">28/60 <bold>(46.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">64% HHV-7+</td>
<td align="left" colspan="1" rowspan="1" valign="top">*Pleomorphic and monomorphic adenoma, mucoepidermoid carcinoma</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Chen et al. (<xref ref-type="bibr" rid="B84">84</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NPC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, ISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">13/42 <bold>(30.9%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">1*/48 (2.1%*)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nasopharynx, precancerous and normal</td>
<td align="left" colspan="1" rowspan="1" valign="top">95% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">*precancerous sample</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Kositanont et al. (<xref ref-type="bibr" rid="B85">85</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NPC</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">5/34 <bold>(14.7%)</bold></td>
<td align="left" colspan="1" rowspan="1" valign="top">0/5 (0%)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Non-cancerous tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">94% EBV+</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>BCC, basal-cell carcinoma; EBV, Epstein-Barr virus; HHV-7, human herpesvirus 7; IHC, immunohistochemistry; ISH, in situ hybridization; LP, lichen planus; NA, not available; NPC, nasopharyngeal carcinoma; Pickaxe, Pickaxe virus detection and discovery computational pipeline; SCC, squamous cell carcinoma; VirusScan, VirusScan bioinformatics system</italic>.</p>
<p><italic><sup>*</sup>For studies that employed both PCR and ISH, only PCR results are presented</italic>.</p>
<p><italic><sup>*</sup>If quantitative data is unavailable for any given method or for controls, the data is excluded</italic>.</p>
<p><italic><sup>*</sup>Cao et al. (<xref ref-type="bibr" rid="B29">29</xref>) and Cantalupo et al. (<xref ref-type="bibr" rid="B30">30</xref>) both analyzed samples from the same database containing deep-sequencing reads from human tumors</italic>.</p>
<p><italic><sup>*</sup>IHC was performed using antibodies against gp116/64/54</italic>.</p>
<p><italic>Bold values represent the percentage of HHV-6-positive samples among samples tested</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Both HHV-6 DNA and antigens were detected in early studies using tissue samples from oral mucosal tumors (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>), but they were undetectable in controls. Antigen (HHV-6 glycoprotein) was detected by immunoperoxidase staining in transformed squamous cells of all samples, where it was localized in the cytoplasm, cell membrane, and nucleus; it was not found in cells surrounding the carcinomas. Of seven HHV-6 antigen-positive tumor samples, only five were positive for HHV-6 DNA, suggesting relatively low levels of HHV-6 DNA within these cells (<xref ref-type="bibr" rid="B81">81</xref>). The failure to detect DNA in the antigen-expressing cells could also mean that the virus acts using a “hit-and-run” method, in which it participates in the early phases of tumor development by spurring oncogenic changes within the cell, but then effectively disappears (<xref ref-type="bibr" rid="B139">139</xref>). Additionally, elevated levels of IgA antibodies to HHV-6 were detected in five patients with advanced oral carcinoma, but in none of the controls.</p>
<p>Follow up investigations revealed HHV-6 DNA and antigens by PCR, ISH, and IHC in oral squamous cell, laryngeal, and salivary gland carcinomas but not in normal oral and salivary gland biopsies (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B80">80</xref>). Many HHV-6-positive carcinoma samples revealed HHV-6A/HHV-6B co-infection. Most recently, HHV-6 DNA was found in 27% of FFPE tissue samples from oral squamous cell carcinomas (<xref ref-type="bibr" rid="B82">82</xref>). No association with mean viral load or histopathologic grade was identified. The level of contrast in HHV-6 DNA and proteins between oral cancer and control tissues is intriguing and merits further study. The presence of the virus in transformed cells- and not in cells outside of the tumor- is of particular consequence, and efforts should be made to replicate this finding with larger sample sizes. As only a single report on HHV-6 in oral cancer has been published since the turn of the century, renewed efforts are due to detect the presence of the virus- active or latent- in tumor cells.</p>
</sec>
<sec>
<title>Weak associations</title>
<p>Qualitative PCR performed on non-melanoma skin cancer specimens revealed that 32% of tumors were HHV-6 positive as compared to 15% of healthy skin specimens (<xref ref-type="bibr" rid="B140">140</xref>), and Cao et al. found HHV-6 in only 0.4% of melanomas via sequencing (<xref ref-type="bibr" rid="B29">29</xref>). The current data, though very limited in scope, does not favor the involvement of HHV-6 in skin cancers and points instead to opportunistic reactivation. A similar situation is seen in such heterogeneous conditions as multiple myeloma, sarcoma, and prostate, uterine, liver, kidney, thyroid, and pancreatic cancers, for which few studies have been carried out, and associations are weak and not supportive of an etiological role for HHV-6.</p>
<p>Several studies indicate that HHV-6 does not contribute to breast cancer (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B141">141</xref>). Interestingly, the HHV-6B U54 tegument protein inhibits MCF-7 breast cancer cell proliferation <italic>in vitro</italic> by inhibiting NFAT activity (<xref ref-type="bibr" rid="B142">142</xref>).</p>
</sec>
</sec>
<sec id="s4">
<title>HHV-6 coinfections</title>
<p>HHV-6 has been detected in conjunction with several other pathogens in a range of conditions. Describing each such study is beyond the scope of this review, so only those studies providing the most meaningful data, in terms of their contributions to an understanding of cooperative activity between HHV-6 and other viruses, will be detailed.</p>
<sec>
<title>HHV-8 in NHL (Table <xref ref-type="table" rid="T2">2</xref>)</title>
<p>HHV-6 DNA has been detected in many cases of B- and T-cell NHL (<xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B44">44</xref>), sometimes in addition to other viruses. Nakayama-Ichiyama et al. (<xref ref-type="bibr" rid="B88">88</xref>, <xref ref-type="bibr" rid="B89">89</xref>) reported dual HHV-6/HHV-8 infection in 2 cases, a primary cutaneous large B cell lymphoma and a diffuse large B-cell lymphoma (DLBCL) with dual HHV-6/HHV-8 positive, EBV-negative tumor cells, and negative serology for HIV and human T lymphotropic virus 1 (HTLV-1). The co-localization of these viruses in tumor cells of B-cell lymphomas is quite compelling and deserves follow-up. In a study of 191 primary effusion lymphoma (PEL) cases, HHV-6 was detected in 18% of HHV-8-negative tumors and in 5% of HHV-8-positive tumors (<xref ref-type="bibr" rid="B37">37</xref>). Since all PEL tumors are currently defined as HHV-8-positive, the diagnosis of PEL is questionable in some of these cases. HHV-6 infection of the HHV-8 positive B-cell lymphoma line BCBL-1 induces HHV-8 lytic activation (<xref ref-type="bibr" rid="B143">143</xref>), and it has been proposed that the simultaneous activity of an HHV-6 gene homologous to the adeno-associated virus (AAV) type 2 rep gene (<xref ref-type="bibr" rid="B144">144</xref>) and HHV-8 regulatory genes could play a role in lymphomagenesis (<xref ref-type="bibr" rid="B145">145</xref>, <xref ref-type="bibr" rid="B146">146</xref>).</p>
</sec>
<sec>
<title>EBV</title>
<sec>
<title>NHL (Table <xref ref-type="table" rid="T2">2</xref>)</title>
<p>B-cell (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B46">46</xref>) and T-cell (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B41">41</xref>) lymphomas with dual HHV-6 and EBV positivity have also been described, often using PCR. Standing alone, these PCR-based studies have not provided overly compelling evidence for or against a cooperative relationship in lymphomagenesis. In a recent case-control study of 214 NHL cases and 214 matched controls from three population-based prospective cohorts, seropositivity for HHV-6A immediate-early 1 protein (IE1A), but not HHV-6B IE1, was significantly associated with a greater risk of developing NHL of any type (OR 1.85, 95% CI 1.04–3.29) (<xref ref-type="bibr" rid="B147">147</xref>). However, levels of antibodies against EBV proteins ZEBRA and EA-D were slightly correlated with IE1A seropositivity, and the correlation between HHV-6A IE1A and NHL development was somewhat weaker after adjusting for these EBV-specific antibodies, suggesting that HHV-6A activity may interact with EBV and increase the risk of NHL. Alternatively, an immunosuppressive or otherwise altered environment in individuals at risk for NHL may set the stage for HHV-6A reactivation, although the finding that HHV-6B IE1 was not correlated with NHL argues against this. However, if this is the case, HHV-6A activity may serve as a biomarker that can be a predictive factor for NHL. The longitudinal nature of this study, the differentiation between HHV-6A and HHV-6B, and the use of a newly developed serological assay that can identify active HHV-6 were definite strengths. Subtype-specific analysis would be a worthwhile avenue to pursue going forward.</p>
<p>Among lymphomas demonstrating coinfection, the potential of a cooperative role has been most thoroughly described in the setting of angioimmunoblastic T-cell lymphoma (AITL). EBV and HHV-6 have been detected in B cells and plasma cells, respectively, of patients with AITL; neither virus was detected in these patients' neoplastic CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Among a cohort of EBV-positive AITL cases with advanced pattern III histology, some were HHV-6B-positive, whereas none of the dual-infected cases were typed as early pattern I histology (<xref ref-type="bibr" rid="B33">33</xref>). While the presence of both HHV-6 and EBV may indicate a cooperative pathogenic role, it is also possible that it merely indicates a level of immune dysfunction that allows for viral reactivation from latency. Interestingly, however, HHV-6 and EBV viral loads in the dual-positive tumors displayed an inverse relationship (i.e., samples with the highest EBV or HHV-6 load had relatively low levels of the other virus) (<xref ref-type="bibr" rid="B33">33</xref>). Early studies also reported evidence of HHV-6 infection in HIV-associated non-Hodgkin lymphoma (NHL). In this immunocompromised population, HHV-6 was found in up to 32% of B-cell lymphomas (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>HHV-6 has been isolated from NHL biopsies at highly variable rates, and the wide range of detection methods used on neoplastic tissues, as well as the difficulty in obtaining healthy lymph nodes for use as controls, limits the ability to unequivocally confirm the involvement of HHV-6 in triggering malignant transformation in NHL. However, in the face of such ambiguity, comparison of other relevant factors can be helpful in determining how HHV-6 affects the development of NHL. For example, Zhou et al. found that HHV-6B viral load was dramatically higher in AITL tissue with pattern III histology (median 40 copies/10<sup>3</sup> cells) than in samples with pattern II histology (median 0.7 copies/10<sup>3</sup> cells) (<xref ref-type="bibr" rid="B33">33</xref>). While a high rate of AITL tissue samples were positive for HHV-6, the virus was not detected within malignant T cells; instead, infection of plasma cells was apparent in these samples (<xref ref-type="bibr" rid="B26">26</xref>). These results suggest that HHV-6-infected plasma cells may thrive in the immunosuppressive tumor microenvironment. Similarly, EBV-infected large B cells are typically present within AITL tumor tissue. The presence of these two herpesviruses (HHV-6 and EBV) in non-malignant cells within the tumor lends credence to the notion that these viruses are opportunistic pathogens that thrive in the immunosuppressive tumor microenvironment. Nevertheless, a secondary supportive or contributory role for these viruses in tumor growth cannot be ruled out.</p>
</sec>
<sec>
<title>Nasopharyngeal (Table <xref ref-type="table" rid="T7">7</xref>)</title>
<p>A trend of HHV-6/EBV coinfection has been observed in EBV-associated nasopharyngeal carcinoma (NPC). Among 34 NPC tumor samples tested by PCR, all of which were either World Health Organization type 2 or 3, 14.7 and 94.1% were positive for HHV-6 and EBV DNA, respectively, while none of the nasopharyngeal tissue samples from five controls were positive (<xref ref-type="bibr" rid="B85">85</xref>). HHV-6 infection of NPC specimens has also been correlated with heightened expression of EBV LMP-1 (<xref ref-type="bibr" rid="B84">84</xref>). Whether this phenomenon is a result of HHV-6 activity or whether HHV-6 reactivation results from the effects of NPC remains to be determined. The difference in prevalence between HHV-6 and EBV suggests that, if HHV-6 is involved in some cases of NPC, it is involved in a more limited subset, and likely is not sufficient for transformation.</p>
</sec>
<sec>
<title>Pulmonary</title>
<p>Neoplastic cells isolated from pulmonary adenocarcinomas that contained HHV-6 by PCR (25%) were all co-infected with EBV (<xref ref-type="bibr" rid="B148">148</xref>). Cantalupo et al. identified HHV-6 DNA and/or RNA sequences in a small number (3.5%) of lung tumors and paired normal lung tissue (<xref ref-type="bibr" rid="B30">30</xref>). HHV-6 is likely not a primary carcinogenic agent in lung cancer, but its detection in some tumor cells supports a possibly contributory role.</p>
</sec>
</sec>
<sec>
<title>HPV</title>
<sec>
<title>Cervical (Table <xref ref-type="table" rid="T6">6</xref>)</title>
<p>There are over 100 types of HPV, of which at least 13 are important in the etiology of cervical cancer. HHV-6 has been shown to productively infect HPV-immortalized cells, transactivate HPV gene expression of oncoproteins, and enhance the expression of HPV RNA (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B149">149</xref>). Notably, two HHV-6 clones that were previously found to upregulate the expression of HPV-transforming genes were also found to transactivate the long terminal repeat of HIV-1 when combined with the HIV-1 transactivator TAT-1 in cervical carcinoma cell lines (<xref ref-type="bibr" rid="B150">150</xref>).</p>
<p>In an early analysis of squamous cell carcinoma (SCC) and cervical intraepithelial neoplasia, HHV-6A and/or B were detected by PCR in 8% of neoplastic cases compared to 0% of negative controls (<xref ref-type="bibr" rid="B77">77</xref>). In another early study, HHV-6 was detected by IHC in 54% of cervical carcinoma samples vs. 63% of normal tissues. However, in HHV-6+ carcinomas, virus was present within tumor cells, raising the possibility of differential viral activity across individuals through which HHV-6 may be relatively common in healthy cervical tissues, but may act as a contributory factor in cervical carcinogenesis in predisposed individuals. Of note, while HHV-6B was found in both cancerous and control samples, HHV-6A was only found in the cancerous tissues (<xref ref-type="bibr" rid="B79">79</xref>). Recent literature has implicated HHV-6A in cases of unexplained female infertility (<xref ref-type="bibr" rid="B151">151</xref>) and tissue taken from infertile women with endometrial HHV-6A infections has revealed an altered immune profile that points to local immune dysregulation in response to infection. HHV-6B has been found in the semen of healthy sperm donors as well as in the vaginal canal of healthy women (<xref ref-type="bibr" rid="B152">152</xref>, <xref ref-type="bibr" rid="B153">153</xref>). It is possible that HHV-6A may be more pathogenic than HHV-6B in the female reproductive tract.</p>
<p>The presence of HHV-6 in HPV-infected women has also been correlated with a higher grade of squamous intraepithelial lesions; while 41% of high-grade lesions were HHV-6+, none of the normal HPV+ cervixes were HHV-6+ (<xref ref-type="bibr" rid="B72">72</xref>). A previous cohort, however, did not express this pattern, and although HHV-6 was found in 8.3% (2/24 samples) of cervical carcinomas, no carcinoma was coinfected with HPV (<xref ref-type="bibr" rid="B74">74</xref>).</p>
</sec>
<sec>
<title>Urological</title>
<p>Conflicting PCR results have been presented on the presence of HHV-6 in bladder cancer specimens. In one cohort, 7% of cases were HHV-6B+, compared to 0% of non-malignant bladder tissue. Of the HHV-6B+ positive cases, 40% were HPV co-infected (<xref ref-type="bibr" rid="B154">154</xref>). In another study, HHV-6 was found in both tumor and normal bladder tissues in equal proportion, and HPV was not detected in any sample (<xref ref-type="bibr" rid="B155">155</xref>). At present, these results are too limited in scope to draw firm conclusions but point to a bystander role for HHV-6.</p>
</sec>
</sec>
</sec>
<sec id="s5">
<title>Inherited chromosomally integrated HHV-6</title>
<p>It has been suggested that iciHHV-6 might predispose the formation of marker chromosomes. In the case of a patient with DLBCL and iciHHV-6 integration in chromosome 17p, 10% of the metaphases analyzed contained a clone with a second HHV-6 signal in an extra marker chromosome (<xref ref-type="bibr" rid="B86">86</xref>) (Table <xref ref-type="table" rid="T8">8</xref>). The authors pointed out that structurally abnormal chromosomes are commonly found in DLBCL, and that the high expression of HHV-6 U94, a protein with DNA-binding, exonuclease, and helicase-ATP activities, may have been involved in tumorigenesis.</p>
<table-wrap id="T8" position="float">
<label>Table 8</label>
<caption>
<p>HHV-6 detection in individual cancer patients.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>References</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Cancer type</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Detection methods</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 positive tissues</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 cellular localization</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Antigen detection</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>HHV-6 variant</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Disease course</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Campioni et al. (<xref ref-type="bibr" rid="B86">86</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">DLBCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, RT-PCR, FISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bone marrow, pleural effusion derived mesothelial cells, peripheral blood</td>
<td align="left" colspan="1" rowspan="1" valign="top">17p chromosome region of a marker chromosome</td>
<td align="left" colspan="1" rowspan="1" valign="top">U94 exhibited levels of transcription (100 ± 15 transcripts/1 μg RNA)</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6A</td>
<td align="left" colspan="1" rowspan="1" valign="top">An 82-years-old man with DLBCL died of respiratory insufficiency</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Zhang et al. (<xref ref-type="bibr" rid="B87">87</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PEL-like lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, FISH, ddPCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tumor tissue, peripheral blood</td>
<td align="left" colspan="1" rowspan="1" valign="top">19q telomere absent from lymphoma cells despite retention of both copies of chromosome 19</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6A</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 73-years-old woman developed an HHV-8-unrelated PEL-like lymphoma that resolved following R-CHOP therapy, and she remained in remission for 9 years, eventually dying from complications of diabetes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nakayama-Ichiyama et al. (<xref ref-type="bibr" rid="B88">88</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCLBCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tumor tissue of the leg (HHV-8 coinfection)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleoli of lymphoma cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 91-years-old woman developed PCLBCL, leg type. Lymphadenopathy disappeared and skin lesions showed improvement after R-CHOP therapy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Nakayama-Ichiyama et al. (<xref ref-type="bibr" rid="B89">89</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">DLBCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">IHC</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tumor tissue of the leg (HHV-8 coinfection)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Nucleoli of lymphoma cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 69-years-old woman developed DLBCL, not otherwise specified (NOS), nongerminal center B-cell–like subtype, stage IIIA. Symptoms and lesions disappeared after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lohi et al. (<xref ref-type="bibr" rid="B90">90</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Blood</td>
<td align="left" colspan="1" rowspan="1" valign="top">22q-tel chromosome region</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 3.5-years old girl was diagnosed with ALL. High-copy numbers of HHV-6 were found during induction therapy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hubacek et al. (<xref ref-type="bibr" rid="B91">91</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, FISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hair follicles, blood, all sampled tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">Integrated on a marker chromosome of unknown origin</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6A</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 33-years old woman with AML was found to have high levels of HHV-6A DNA in blood during treatment. She died of CMV pneumonitis after HSCT</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Hubacek et al. (<xref ref-type="bibr" rid="B91">91</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, FISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Hair follicles, blood, all sampled tissues</td>
<td align="left" colspan="1" rowspan="1" valign="top">18p11.3 chromosome region</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6B</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 6-years old boy with ALL developed GvHD post-transplant and later died of CMV pneumonitis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Lin et al. (<xref ref-type="bibr" rid="B92">92</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">TCL</td>
<td align="left" colspan="1" rowspan="1" valign="top">Viral culture</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bone marrow</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 48-years-old man developed gammadelta T-cell lymphoma 4 years after undergoing kidney transplantation. Long term remission was not achieved</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Daibata et al. (<xref ref-type="bibr" rid="B93">93</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pre-B-cell ALL</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR, SB, ISH, FISH</td>
<td align="left" colspan="1" rowspan="1" valign="top">Liver, spleen, lungs, and brain, PBMC</td>
<td align="left" colspan="1" rowspan="1" valign="top">1q44 chromosome region<break></break>Nuclei of 80% of PBMCs and the majority of leukemic cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">iciHHV-6B</td>
<td align="left" colspan="1" rowspan="1" valign="top">An 83-years-old woman developed pre-B-cell ALL with a t(9;22)(q24; q11) chromosomal abnormality resulting in generation of Philadelphia (Ph1) chromosome</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Daibata et al. (<xref ref-type="bibr" rid="B94">94</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">AML and AILD</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymph node, pericardial effusion, liver, BM, lungs, spleen, kidneys, heart</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">HHV-6B</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 47-years-old man with AML was diagnosed with AILD 4 months after induction of chemotherapy and died of fulminant hepatitis</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Bandobashi et al. (<xref ref-type="bibr" rid="B95">95</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Burkitt's Lymphoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">Bone marrow</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymphoma cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 58-years-old woman developed Burkitt's lymphoma. Chemotherapeutic response was minimal, the disease progressed into a leukemic phase, and she died of septicemia 6 weeks after admission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Maeda et al. (<xref ref-type="bibr" rid="B96">96</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">NSHL</td>
<td align="left" colspan="1" rowspan="1" valign="top">ISH, IHC, Serology</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lymph nodes</td>
<td align="left" colspan="1" rowspan="1" valign="top">Macrophages and lymphocytes, predominantly in lymphoid follicles, but not in RS nor Hodgkin cells</td>
<td align="left" colspan="1" rowspan="1" valign="top">Antigens detected in lymph nodes</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 7-years-old boy showed changes developed HL of the NS-LD subtype. Chemotherapy resulted in complete remission</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Stödberg et al. (<xref ref-type="bibr" rid="B97">97</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Diffuse leptomeningeal oligodendrogliomatosis</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">CSF, serum, and tumor tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">Limited attempts at antigen detection were unsuccessful</td>
<td align="left" colspan="1" rowspan="1" valign="top">HHV-6A</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 2-years-old boy developed a leptomeningeal tumor. After chemotherapy and complementary antiviral therapy, the boy's clinical condition stabilized, and his predominant problem became a gradually more evident autistic disorder</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Rantala et al. (<xref ref-type="bibr" rid="B98">98</xref>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pilocytic astrocytoma</td>
<td align="left" colspan="1" rowspan="1" valign="top">PCR</td>
<td align="left" colspan="1" rowspan="1" valign="top">CSF initially, tumor tissue</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">NA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 14-months old girl developed a pilocytic astrocytoma in the cerebellum 11 months after a period of fever, exanthema, encephalitis, carditis, and intractable seizures, during which time HHV-6 was identified in the CSF. After removal of the tumor, she still had severe hypotonia, poor social contact, and up to 5 series of infantile spasms daily</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>AILD, angioimmunoblastic lymphadenopathy with dysproteinaemia (also known as AITL); ALL, acute lymphocytic leukemia; AML, acute myeloblastic leukemia; CMV, cytomegalovirus; CSF, cerebrospinal fluid; ddPCR, droplet digital PCR; DLBCL, diffuse large B-cell lymphoma; FISH, fluorescence in situ hybridization; GvHD, graft vs. host disease; HL, Hodgkin's lymphoma; IHC, immunohistochemistry; ISH, in situ hybridization; NA, not available; NHL, non-Hodgkin lymphoma; NSHL, nodular sclerosis Hodgkin lymphoma; NS-LD, nodular sclerosis lymphocyte depleted; PBMCs, peripheral blood mononuclear cells; PCLBCL, primary cutaneous large B-cell lymphoma; PEL, primary effusion lymphoma; RS, Reed-Sternberg; RT-PCR, reverse transcriptase polymerase chain reaction; TCL, T cell lymphoma</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>Recently, iciHHV-6 was found in 2 of 35 pediatric adrenocortical tumors, and fluorescence <italic>in situ</italic> hybridization (FISH) revealed that the HHV-6 sequences were integrated at the telomeric region of 11p15, a site that is commonly implicated in this condition (<xref ref-type="bibr" rid="B156">156</xref>). In both cases, loss of heterozygosity (LOH) of chromosome 11 and heightened expression of IGF2 were demonstrated, as was paternal transmission of the integrated virus. LOH of chromosome 11p, via duplication of the paternal chromosome and loss of the maternal chromosome, as well as LOH at chromosome 17 appear to be early markers of adrenocortical carcinoma progression (<xref ref-type="bibr" rid="B157">157</xref>, <xref ref-type="bibr" rid="B158">158</xref>). Integration of HHV-6 can also occur at chromosome 17p13 (<xref ref-type="bibr" rid="B159">159</xref>, <xref ref-type="bibr" rid="B160">160</xref>), a locus that contains the TP53 tumor suppressor gene.</p>
<p>On the other end of the spectrum, a single report has documented the loss of iciHHV-6A from the telomere of chromosome 19q in an HHV-8-negative PEL-like lymphoma (<xref ref-type="bibr" rid="B87">87</xref>). Notably, loss of the integrated HHV-6A appeared to have occurred in the early stages of lymphoma development, raising the possibility of HHV-6A involvement in early chromosomal dysfunction. The unique nature of iciHHV-6 among human herpesviruses is an area deserving of greater investigation, and the effects of integration on chromosomal stability may be among the most intriguing subtopics in this field.</p>
</sec>
<sec id="s6">
<title>Potential mechanisms of HHV-6-associated neoplasia</title>
<p>Transfection of normal mouse and human cells with HHV-6 DNA fragments, and with the entire genome, led to the induction of tumors in nude mice, as initially shown by Puri, Razzaque et al. (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B161">161</xref>). Although the mechanism of transformation was not determined, loss of normal chromosomes and the presence of extra marker chromosomes were detected. In examining viral genes (Figure <xref ref-type="fig" rid="F2">2</xref>), Kashanchi et al. demonstrated that HHV-6 ORF-1 (DR-7) gene expression led to tumor production (<xref ref-type="bibr" rid="B113">113</xref>). The ORF-1-associated oncoprotein has been detected in non-Hodgkin lymphoma, glioblastoma, and in RS cells of Hodgkin lymphoma (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B99">99</xref>), and it is thought that it may act by binding to and inhibiting expression of the tumor suppressor p53, which can also be bound by the HHV-6 U14 protein (<xref ref-type="bibr" rid="B162">162</xref>). Specifically, HHV-6 infection is thought to inhibit p53 nuclear localization, thereby limiting its ability to inhibit cell growth and promote apoptosis (<xref ref-type="bibr" rid="B163">163</xref>). These findings support the possibility that HHV-6 is oncogenic (<xref ref-type="bibr" rid="B113">113</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>HHV-6A and HHV-6B genomic map. Representative coverage maps of HHV-6B Z29 and HHV-6A GS reference strains. Shotgun DNAsequencing reads from cultured virus were mapped to the NCBI HHV-6B and HHV-6A reference genomes, NC_000898 and NC_001664, respectively. The green stacked lines indicate the gene models for the respective viral species. <bold>(A)</bold> HHV-6B strain Z29 yielded a homogeneous 983-bp tandem repeat that was present at ~12.5 times higher coverage than the rest of the genome. Sequences at the 5 = and 3 = ends of the tandem repeat in strain Z29 are depicted and are different than those indicated previously (31). <bold>(B)</bold> HHV-6A strain GS yielded a heterogeneous 1,254-bp tandem repeat that was present at ~11.4 times higher coverage than the rest of the genome. Sequences at the 5 = and 3 = ends of the heterogeneous tandem repeat in strain GS are depicted. <bold>(C)</bold> ABI quantitative DNA material for HHV-6A GS and HHV-6B Z29 also demonstrated similar origin tandem repeats with additional loci with copy number differences in the GS strain. Long-distance rearrangements between U12 to U20, U73 to R3, U86 to U95, and the U91-to-U100/DR intergenic region are represented by curved dashed lines, and the estimated viral subpopulation containing the respective deletion is indicated by the percentage. From Greninger et al. (<xref ref-type="bibr" rid="B111">111</xref>).</p>
</caption>
<graphic xlink:href="fonc-08-00512-g0002"></graphic>
</fig>
<p>Another HHV-6 protein, U24, has weaker associations with oncogenicity, but recent developments merit its mention. HNedd4L-WW3<sup>*</sup> domain (human neural precursor cell expressed developmentally down-regulated protein 4-like) has newly been identified as a cognate ligand of the HHV-6A U24 protein, which is expressed in the early stages of infection (<xref ref-type="bibr" rid="B164">164</xref>). Notably, Nedd4 dysregulation has been observed in glioma (<xref ref-type="bibr" rid="B165">165</xref>, <xref ref-type="bibr" rid="B166">166</xref>) and glioblastoma multiforme (<xref ref-type="bibr" rid="B167">167</xref>).</p>
<p>The HHV-6B immediate-early gene U95 protein interacts with GRIM-19 and is associated with loss of mitochondrial membrane potential (<xref ref-type="bibr" rid="B168">168</xref>). GRIM-19 is involved in the oxidative phosphorylation system and in regulation of cell death, and it is also bound by KSHV, HPV type 16, and simian virus 40 LT proteins, as well as CMV RNA (<xref ref-type="bibr" rid="B169">169</xref>). The HHV-6B U95 promoter is regulated by R3, a repetitive region of HHV-6B with NF-κB-binding sites (<xref ref-type="bibr" rid="B170">170</xref>). NF-κB is important in the control of cellular proliferation and survival. As noted previously, initial data pointed to possible HHV-6B-induced TLR3, Bcl-2, and NF-κB up-regulation as well as down-regulation of cleaved caspase 3 in rat pituitary adenoma cells. However, in order to distinguish causation from correlation, this requires follow up and use of HHV-6B rather than a viral mimic (<xref ref-type="bibr" rid="B57">57</xref>).</p>
<p>IHC performed on some cancer samples has revealed an absence of HHV-6 antigens in neoplastic cells, suggesting that if HHV-6 plays a role in neoplasia, it may participate indirectly (<xref ref-type="bibr" rid="B26">26</xref>), perhaps by modulating the tumor microenvironment or enhancing the potential for a primary tumorigenic virus to induce neoplasia (<xref ref-type="bibr" rid="B99">99</xref>). In one study, adult T cell leukemia cells that were persistently infected with HHV-6B triggered the growth of uninfected, neighboring cells, indicating that HHV-6 may affect inter-cellular signaling pathways to stimulate the growth of transformed cells that are not themselves infected (<xref ref-type="bibr" rid="B171">171</xref>). Both species have robust immunomodulatory abilities and are able to impact cytokine and chemokine expression and networks (<xref ref-type="bibr" rid="B172">172</xref>). The ways by which each virus may produce both immunosuppressive and inflammatory responses, both of which can impact carcinogenesis, are myriad and too extensive to comprehensively describe in this review.</p>
<p>Of interest, the HHV-6A/B gene U94 exhibits anti-tumorigenic effects in some <italic>in-vitro</italic> carcinoma models. Expression of HHV-6B U94 in breast cancer and cervical cancer cell lines decreased the migration and invasiveness of the cells <italic>in vitro</italic>, and the injection of U94-expressing cancer cells into mice resulted in reduced tumor growth and more limited vasculature in the resulting tumors (<xref ref-type="bibr" rid="B173">173</xref>). Earlier, HHV-6A was found to reduce lymphangiogenesis and angiogenesis <italic>in vitro</italic> (<xref ref-type="bibr" rid="B174">174</xref>) and limit migration of endothelial cells (<xref ref-type="bibr" rid="B174">174</xref>) and oligodendrocyte progenitor cells (<xref ref-type="bibr" rid="B175">175</xref>). As noted previously, U54 also inhibited breast cancer cell proliferation <italic>in vitro</italic> (<xref ref-type="bibr" rid="B142">142</xref>). While the express use of the U94 gene in vector form, in the absence of the rest of the genome, may hold potential in arresting the development of certain cancers, it is unclear what these anti-oncogenic properties mean when viewed holistically, and how this particular viral gene interacts with others that are expressed during the infectious course.</p>
<p>In spite of high molecular homology between the two HHV-6 species, it is obvious that their pathomechanisms, including carcinogenic and co-carcinogenic effects, are different. The two species utilize different receptors for cellular entry; consequently, their intracellular signal transduction pathways differ on a basic level. HHV-6A binds to CD46, which is a complement regulatory protein (<xref ref-type="bibr" rid="B176">176</xref>). CD46 signal transduction exerts positive regulation on T cell proliferation, regulatory T cell differentiation, and IL-10 production, which is regarded as immunosuppressive. Expression of CD46 is upregulated in many tumors (<xref ref-type="bibr" rid="B177">177</xref>).</p>
<p>HHV-6B, on the other hand, typically binds to CD134, also known as OX40 or tumor necrosis factor receptor superfamily member 4 (TNFRSF4) (<xref ref-type="bibr" rid="B178">178</xref>, <xref ref-type="bibr" rid="B179">179</xref>). Binding of a ligand to CD134 blocks apoptosis, preventing the death of proliferating T cells and positively regulating B cell proliferation by modulating Th1 and Th2 mediated function (<xref ref-type="bibr" rid="B180">180</xref>, <xref ref-type="bibr" rid="B181">181</xref>). These effects on the immune system might relate to immune dysregulation and lymphomagenesis.</p>
<p>Lately, there has been increased recognition of the importance of regulation of gene expression at the posttranscriptional level. Among small non-coding RNA (sncRNA) products, microRNA (miRNA) produced by both infected cells and by viruses are able to mutually regulate cellular and viral mRNA translation through base-pair complementarity. Abnormal activity of cellular miRNA has been associated with cancer and viral immune evasion. Viruses express functional miRNA that target both viral and cellular transcripts to suppress or destabilize mRNA. The net result of either process is reduced synthesis of proteins encoded by target mRNA.</p>
<p>Roseoloviruses, which are phylogenetically ancient viruses, have not developed miRNA-associated regulatory mechanisms as sophisticated as those of the gamma herpesviruses. Both EBV and KSHV encode viral miRNAs (44 and 25, respectively) that have been directly linked with malignant transformation. Of interest, some herpesvirus miRNA (EBV-miR-BART2-5p and KSHV-miR-K12-7), despite having evolved independently, suppress identical cellular mRNA targets, thus developing similar strategies to modulate host cell transformation (<xref ref-type="bibr" rid="B182">182</xref>).</p>
<p>Little attention has been paid to roseolovirus miRNA. Only recently, five novel HHV-6A encoded sncRNAs have been identified in Jjhan cells infected by strain U1102, one of which is a miRNA. This HHV-6 miRNA targets the HHV-6A immediate early (IE) gene U86 and is consequently named miR-U86. Overexpression of miR-U86 in transduced Jjhan cells results in significant growth retardation and reduced cell viability (<xref ref-type="bibr" rid="B183">183</xref>). Current data suggest that miR-U86 has no role in tumorigenesis. HHV-6A alters cellular miRNA expression in infected T cells, but too little information is currently available to draw conclusions about the relationship between these changes and oncogenesis (<xref ref-type="bibr" rid="B184">184</xref>).</p>
<p>Infection of Sup-T1 cells with HHV-6B, on the other hand, results in an abundant production of sncRNAs derived from either the direct repeat regions or the lytic origin of replication that give rise to smaller RNA species. Four miRNAs were identified and named hhv6b-miR-Ro6-1,−2,−3, and−6. Ro6-2 is a seed ortholog of the human miR-582-5p, which is upregulated in certain pituitary adenomas and downregulates expression of TGF-β (<xref ref-type="bibr" rid="B185">185</xref>). Similar to the HHV-8 miR-155 ortholog miR-K12, HHV-6B Ro6-2 may share a broad range of cellular mRNA targets with human miR-582-5p and may modulate the host-pathogen relationship. In cells (e.g., CD4<sup>+</sup> T cells) that do not normally express cellular miRNA-582-5p, HHV-6B infection may lead to Ro6-2 miRNA-mediated suppression of TGF-β. HHV-6B encoded miRNAs are expressed in low abundance, similar to the oncogenic Marek's disease virus, but in contrast to other herpesviruses (<xref ref-type="bibr" rid="B186">186</xref>). All in all, the similarities between HHV-6B encoded miRNAs and oncogenic KSHV and human miRNAs suggest that they may play roles in tumorigenesis, though more work is needed to clarify their effects.</p>
<p>Roseoloviruses can also regulate cell-virus interactions through the release of microvesicles. Viruses have evolved to insert viral components into uninfected cells via microvesicles (MV) that are shed from the plasma membrane, as well as exosomes, which originate within microvesicular bodies (MVBs) and are released into the extracellular environment. Both can be isolated from any bodily fluid or excretion, and they can cross the blood-brain-barrier. They can include cellular and viral proteins, mRNAs, miRNAs, lipids, and carbohydrates. Once released, they can be taken up through phagocytosis or pinocytosis by neighboring or distant cells, where the contents can have direct consequences by manipulating gene expression of the recipient cells. HHV-6 infection dramatically increases MVB formation. HHV-6B redirects MHC class I molecules into MVBs, and along with gB viral proteins, they are released in exosomes. It is possible that the MHC molecules can assist viral entry in other cells (<xref ref-type="bibr" rid="B187">187</xref>). A reduction in MHC class I molecules may also contribute to ineffective immune targeting and clearance of transformed cells (<xref ref-type="bibr" rid="B188">188</xref>). In addition, HHV-6A infected HSB-2 cells tend to form MVBs, which can contain mature virions, and the small vesicles inside the MVBs carry the envelope glycoproteins gM and gB. It is presumed that viral glycoproteins expressed in exosomes may interact to form a virological synapse and promote the efficient spreading of HHV-6A from infected to uninfected cells. Furthermore, several reports on other viruses have shown T cell activation in response to exosomes secreted by antigen presenting cells (<xref ref-type="bibr" rid="B189">189</xref>).</p>
<p>Lately, studies on extracellular vesicles have indicated that they play a significant role in tumor progression (<xref ref-type="bibr" rid="B190">190</xref>). Although data on HHV-6-associated microvesicle pathomechanisms is limited, comparisons with other carcinogenic herpesviruses might help to elucidate their possible tumorigenic effects. EBV, for example, can introduce viral antigens, RNA, and growth factors into other cells. Unfortunately, the absence of active viral infection in these targeted cells may hamper the verification of a causal link between the virus and diseases in which viral infection has been implicated. KSHV was also found to modulate the microenvironment through packaging of viral factors in exosomes. The viral factors increased cell migration and IL-6 production, and promoted a switch to glycolytic metabolism in recipient endothelial cells (<xref ref-type="bibr" rid="B191">191</xref>), all of which have been implicated in carcinogenesis (<xref ref-type="bibr" rid="B192">192</xref>, <xref ref-type="bibr" rid="B193">193</xref>). Further studies on HHV-6A and HHV-6B associated MVs and exosomes are required to verify their direct or indirect carcinogenic effects.</p>
<p>Finally, both iciHHV-6 and community strains (<xref ref-type="bibr" rid="B71">71</xref>) of HHV-6 may affect chromosomal stability or transcription of genes associated with malignancy through integration into the cellular genome. Depending on the site of integration, telomeric disruption, loss of chromosomal integrity, and/or disruption of genes associated with cancers may result, in turn promoting oncogenesis. Proposed mechanisms of HHV-6-associated oncogenesis and oncomodulation are summarized in Figures <xref ref-type="fig" rid="F3">3</xref>, <xref ref-type="fig" rid="F4">4</xref>.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Potential mechanisms of HHV-6A-associated oncogenesis and oncomodulation. Several HHV-6A-mediated changes may contribute to disruption of apoptosis, cellular transformation, invasion, and proliferation pathways, and transactivation of other viruses may contribute to their oncogenic activity. EBV, Epstein-Barr virus; HERV, human endogenous retrovirus; HPV, human papillomavirus; HIV-1, human immunodeficiency virus-1; MVB, microvesicular bodies; Treg, regulatory T cell.</p>
</caption>
<graphic xlink:href="fonc-08-00512-g0003"></graphic>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Potential mechanisms of HHV-6B-associated oncogenesis and oncomodulation. Several HHV-6B-mediated changes may contribute to disruption of apoptosis, cellular transformation, invasion, and proliferation pathways, and transactivation of other viruses may contribute to their oncogenic activity. In addition, HHV-6B-infected cells may promote cellular growth in neighboring uninfected cells through a presently unknown mechanism. MVB, microvesicular bodies.</p>
</caption>
<graphic xlink:href="fonc-08-00512-g0004"></graphic>
</fig>
</sec>
<sec id="s7">
<title>Risk factors and molecular epidemiology</title>
<p>HHV-6 tends to reactivate during periods of stress and immunosuppression. Like HHV-8, immunosuppressive conditions- present through inherited, environmental, or age-associated means may be key to pathogenic reactivation of HHV-6 resulting in oncogenic changes. While immunosuppression triggers viral reactivation from latency, both HHV-6A and HHV-6B are also immunomodulatory viruses that affect the functions of natural killer cells and T cells, as well as other immune cells, cytokines, and chemokines (<xref ref-type="bibr" rid="B172">172</xref>). In establishing persistence, the viruses employ strategies to evade detection and elimination by immune cells, which can result in down-modulation of immune cell activities. The effects of infection are myriad, time-dependent, and vary across individuals. Genetic factors are likely to affect the extent of HHV-6-asscoiated immunomodulation and outcomes during and after primary HHV-6 infection, although the contribution of genetics in HHV-6-associated illness is largely unknown. Likewise, environmental influences may impact the types of changes that the viral infection induces in individuals. In terms of HHV-6A and HHV-6B themselves, it is possible that certain variants are more prone to contributing to oncogenesis or in dampening the immune response.</p>
<p>HHV-6B reactivates frequently in patients after receiving hematopoietic stem cell transplantation for hematological malignancies (<xref ref-type="bibr" rid="B194">194</xref>) and has been shown to impair late reconstitution of CD4<sup>+</sup> T cells, likely by affecting thymopoiesis (<xref ref-type="bibr" rid="B195">195</xref>–<xref ref-type="bibr" rid="B197">197</xref>). A weaker immune response as a consequence of HHV-6 infection may allow for circumstances beneficial for the continuation of neoplasia, as immune cells may be less effective in detecting and destroying abnormal cells. It has been suggested that HHV-6 infection contributes to the progression of GIC through the promotion of lymphopenia and immunosuppression (<xref ref-type="bibr" rid="B134">134</xref>), and in some instances, atypical lymphoproliferative disorders progress to overt malignant lymphoma, particularly in the setting of immunodeficiency (<xref ref-type="bibr" rid="B198">198</xref>, <xref ref-type="bibr" rid="B199">199</xref>). Virus-mediated dysregulation of cell proliferation, differentiation, and cell death may play a role (<xref ref-type="bibr" rid="B200">200</xref>, <xref ref-type="bibr" rid="B201">201</xref>).</p>
<p>While both viruses have shown oncogenic potential themselves, HHV-6A and –B-mediated transactivation of other oncogenic agents may also play an indirect role in tumorigenesis. In general, herpesviruses, but especially beta herpesviruses, are known for transactivating each other and several other heterologous viruses. HHV-6A U16 and U30 gene products transactivate E6 and E7 of HPV-16 in cervical epithelial cells (<xref ref-type="bibr" rid="B149">149</xref>). Additionally, HHV-6A activates EBV from latency (<xref ref-type="bibr" rid="B202">202</xref>), increases EBV early gene expression (<xref ref-type="bibr" rid="B203">203</xref>), and bolsters its transformative capacity. Meanwhile, EBV renders B cells susceptible to HHV-6 infection (<xref ref-type="bibr" rid="B203">203</xref>, <xref ref-type="bibr" rid="B204">204</xref>). HHV-6A has also been shown to transactivate the long terminal repeat of HIV-1 in double infected cells (<xref ref-type="bibr" rid="B205">205</xref>), and several gene products of HHV-6A have been identified as possessing HIV-1 activating potential independently of each other (<xref ref-type="bibr" rid="B206">206</xref>). Soluble mediators (e.g., TNF-α) released from HHV-6A–infected lymphoid cells also upregulated HIV-1 infection in other cells carrying the virus (<xref ref-type="bibr" rid="B207">207</xref>). All of these effects could consequently facilitate AIDS and AIDS–associated tumor progression. HHV-6A (<xref ref-type="bibr" rid="B208">208</xref>) and HHV-6B (<xref ref-type="bibr" rid="B209">209</xref>) activate human endogenous retrovirus (HERV) K18 superantigen expression, and some HERV species have been implicated in teratocarcinoma and other germline tumors.</p>
<p>Exploring biomarkers and performing functional studies to investigate interactions between HHV-6 activity and genetic variants related to molecular/cellular pathways involved in immune surveillance and clearance of transformed cells, as well as to susceptibility to other infections, will be valuable going forward.</p>
</sec>
<sec id="s8">
<title>Concluding remarks</title>
<p>Detection of viral RNA/DNA in tumor tissue by PCR and sequencing is the first step in elucidating the role of a virus in tumors. Given the presence of numerous reactive inflammatory cells and stromal cells within tumor tissue, PCR positivity may arise from non-tumor cells. As such, the next step would be direct localization of virus to tumor cells by immunohistochemistry, <italic>in-situ</italic> hybridization, and/or electron microscopy. These techniques require high quality tumor tissue, high sensitivity and specificity of the detection reagents, and simultaneous running of proper positive and negative controls. Even if the virus is localized to tumor cells, the percent positivity of tumor cells is likely important since one would expect that if the virus is involved in tumor growth, then it should be present in at least a significant fraction of tumor cells.</p>
<p>Cancer development follows a multistep selection course with acquisition of genetic defects leading from a benign polyclonal process to a malignant monoclonal process (<xref ref-type="bibr" rid="B210">210</xref>). In some settings, HHV-6A/B may play a supportive role in this process. Even if not overtly oncogenic in terms of inducing or activating oncogenes in susceptible cells, HHV-6 may indirectly stimulate growth and/or block apoptosis in infected cells, interfere with epigenetic regulation and post-translational events, or potentiate the role of other viruses, in susceptible individuals (<xref ref-type="bibr" rid="B211">211</xref>). Although no definitive evidence of a direct role for HHV-6 as a tumorigenic virus has been produced, further investigation is warranted, especially for nodular sclerosis Hodgkin Lymphoma, glial tumors, gastrointestinal tumors, and oral cancers.</p>
</sec>
<sec id="s9">
<title>Author contributions</title>
<p>EE, EL, JP, JO, GK, JC, TP, DA, and SH: all contributed to the content of the manuscript and edited as needed.</p>
<sec>
<title>Conflict of interest statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>We thank Dr. Paul Levine, Dr. Mario Luppi, and Kristin Loomis for their valuable input in the preparation of this manuscript. We also thank Elaine O'Leary for her work in obtaining permission for our figures, and Sheryl Lunsford for her work on the mechanism figures.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablashi</surname><given-names>D</given-names></name><name><surname>Agut</surname><given-names>A</given-names></name><name><surname>Berneman</surname><given-names>Z</given-names></name><name><surname>Campadelli-Fiume</surname><given-names>G</given-names></name><name><surname>Carrigan</surname><given-names>D</given-names></name><name><surname>Ceccerini-Nelli</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Human herpesvirus-6 strain groups: a nomenclature</article-title>. <source/>Arch Virol. (<year>1993</year>) <volume>129</volume>:<fpage>363</fpage>–<lpage>6</lpage>.<pub-id pub-id-type="pmid">8385923</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ablashi</surname><given-names>D</given-names></name><name><surname>Agut</surname><given-names>H</given-names></name><name><surname>Alvarez-Lafuente</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>DA</given-names></name><name><surname>Dewhurst</surname><given-names>S</given-names></name><name><surname>DiLuca</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Classification of HHV-6A and HHV-6B as distinct viruses</article-title>. <source/>Arch Virol. (<year>2014</year>) <volume>159</volume>:<fpage>863</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s00705-013-1902-5</pub-id><pub-id pub-id-type="pmid">24193951</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Markham</surname><given-names>PD</given-names></name><name><surname>Josephs</surname><given-names>SF</given-names></name><name><surname>Sturzenegger</surname><given-names>S</given-names></name><name><surname>Kaplan</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders</article-title>. <source/>Science (<year>1986</year>) <volume>234</volume>:<fpage>596</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="pmid">2876520</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puri</surname><given-names>RK</given-names></name><name><surname>Leland</surname><given-names>P</given-names></name><name><surname>Razzaque</surname><given-names>A</given-names></name></person-group>. <article-title>Antigen(s)-specific tumour-infiltrating lymphocytes from tumour induced by human herpes virus-6 (HHV-6) DNA transfected NIH 3T3 transformants</article-title>. <source/>Clin Exp Immunol. (<year>1991</year>) <volume>83</volume>:<fpage>96</fpage>–<lpage>101</lpage>. <pub-id pub-id-type="pmid">1703057</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josephs</surname><given-names>SF</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Schachter</surname><given-names>F</given-names></name><name><surname>Wong-Staal</surname><given-names>F</given-names></name><name><surname>Gallo</surname><given-names>RC</given-names></name></person-group>. <article-title>Genomic analysis of the human B-lymphotropic virus (HBLV)</article-title>. <source/>Science (<year>1986</year>) <volume>234</volume>:<fpage>601</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="pmid">3020691</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishi</surname><given-names>M</given-names></name><name><surname>Harada</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><name><surname>Nonoyama</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>A repeat sequence, GGGTTA, is shared by DNA of human herpesvirus 6 and Marek's disease virus</article-title>. <source/>J Virol. (<year>1988</year>) <volume>62</volume>:<fpage>4824</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">2846894</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaque</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>O</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Rhim</surname><given-names>JS</given-names></name></person-group>. <article-title>Neoplastic transformation of immortalized human epidermal keratinocytes by two HHV-6 DNA clones</article-title>. <source/>Virology (<year>1993</year>) <volume>195</volume>:<fpage>113</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1993.1351</pub-id><pub-id pub-id-type="pmid">8391179</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiani</surname><given-names>H</given-names></name><name><surname>Makvandi</surname><given-names>M</given-names></name><name><surname>Samarbafzadeh</surname><given-names>A</given-names></name><name><surname>Teimoori</surname><given-names>A</given-names></name><name><surname>Nisi</surname><given-names>N</given-names></name><name><surname>Mehravaran</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Association of HHV-6 with Hodgkin and non Hodgkin lymphoma</article-title>. <source/>Iran J Microbiol. (<year>2016</year>) <volume>8</volume>:<fpage>153</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">27307982</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddon</surname><given-names>A</given-names></name><name><surname>Lozovatsky</surname><given-names>L</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Hudnall</surname><given-names>SD</given-names></name></person-group>. <article-title>Human herpesvirus 6 positive Reed-Sternberg cells in nodular sclerosis Hodgkin lymphoma</article-title>. <source/>Br J Haematol. (<year>2012</year>) <volume>158</volume>:<fpage>635</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09206.x</pub-id><pub-id pub-id-type="pmid">22757777</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Jaccard</surname><given-names>A</given-names></name><name><surname>Rouzioux</surname><given-names>C</given-names></name><name><surname>Piguet</surname><given-names>C</given-names></name><name><surname>Petit</surname><given-names>B</given-names></name><name><surname>Bordessoule</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>HHV-6 and EBV DNA quantitation in lymph nodes of 86 patients with Hodgkin's lymphoma</article-title>. <source/>J Med Virol. (<year>2007</year>) <volume>79</volume>:<fpage>1349</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20868</pub-id><pub-id pub-id-type="pmid">17607791</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez-Losa</surname><given-names>J</given-names></name><name><surname>Fedele</surname><given-names>CG</given-names></name><name><surname>Pozo</surname><given-names>F</given-names></name><name><surname>Tenorio</surname><given-names>A</given-names></name><name><surname>Fernandez</surname><given-names>V</given-names></name><name><surname>Castellvi</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Lack of association of polyomavirus and herpesvirus types 6 and 7 in human lymphomas</article-title>. <source/>Cancer (<year>2005</year>) <volume>103</volume>:<fpage>293</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/cncr.20801</pub-id><pub-id pub-id-type="pmid">15593086</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collot</surname><given-names>S</given-names></name><name><surname>Petit</surname><given-names>B</given-names></name><name><surname>Bordessoule</surname><given-names>D</given-names></name><name><surname>Alain</surname><given-names>S</given-names></name><name><surname>Touati</surname><given-names>M</given-names></name><name><surname>Denis</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Real-time PCR for quantification of human herpesvirus 6 DNA from lymph nodes and saliva</article-title>. <source/>J Clin Microbiol. (<year>2002</year>) <volume>40</volume>:<fpage>2445</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.40.7.2445-2451.2002</pub-id><pub-id pub-id-type="pmid">12089260</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiramizu</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>CW</given-names></name><name><surname>Cairo</surname><given-names>MS</given-names></name></person-group>. <article-title>Absence of human herpesvirus-6 genome by polymerase chain reaction in children with Hodgkin disease: a Children's Cancer Group Lymphoma Biology Study</article-title>. <source/>J Pediatr Hematol Oncol. (<year>2001</year>) <volume>23</volume>:<fpage>282</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">11464983</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CA</given-names></name><name><surname>Oettle</surname><given-names>H</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Binder</surname><given-names>T</given-names></name><name><surname>Wilborn</surname><given-names>F</given-names></name><name><surname>Huhn</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Presence of human beta- and gamma-herpes virus DNA in Hodgkin's disease</article-title>. <source/>Leuk Res. (<year>2000</year>) <volume>24</volume>:<fpage>865</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0145-2126(00)00042-4</pub-id><pub-id pub-id-type="pmid">10996205</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>G</given-names></name><name><surname>Secchiero</surname><given-names>P</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name><name><surname>Abete</surname><given-names>MC</given-names></name><name><surname>Jemma</surname><given-names>C</given-names></name><name><surname>Reato</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and <italic>in situ</italic> hybridization</article-title>. <source/>Am J Pathol. (<year>1996</year>) <volume>149</volume>:<fpage>1501</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="pmid">8909240</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Dolcetti</surname><given-names>R</given-names></name><name><surname>Gloghini</surname><given-names>A</given-names></name><name><surname>Maestro</surname><given-names>R</given-names></name><name><surname>Vaccher</surname><given-names>E</given-names></name><name><surname>di Luca</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study</article-title>. <source/>Hum Pathol. (<year>1996</year>) <volume>27</volume>:<fpage>133</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="pmid">8617454</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaque</surname><given-names>A</given-names></name><name><surname>Francillon</surname><given-names>Y</given-names></name><name><surname>Jilly</surname><given-names>PN</given-names></name><name><surname>Varricchio</surname><given-names>F</given-names></name></person-group>. <article-title>Detection of human herpesvirus 6 sequences in lymphoma tissues by immunohistochemistry and polymerase chain reactions</article-title>. <source/>Cancer Lett. (<year>1996</year>) <volume>106</volume>:<fpage>221</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="pmid">8844976</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolcetti</surname><given-names>R</given-names></name><name><surname>Di Luca</surname><given-names>D</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><name><surname>Mirandola</surname><given-names>P</given-names></name><name><surname>De Vita</surname><given-names>S</given-names></name><name><surname>Vaccher</surname><given-names>E</given-names></name><etal></etal></person-group>
<article-title>Human herpesvirus 6 in human immunodeficiency virus-infected individuals: association with early histologic phases of lymphadenopathy syndrome but not with malignant lymphoproliferative disorders</article-title>. <source/>J Med Virol. (<year>1996</year>) <volume>48</volume>:<fpage>344</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1096-9071(199604)48:4&lt;344::AID-JMV8&gt;3.0.CO;2-7</pub-id><pub-id pub-id-type="pmid">8699167</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Luca</surname><given-names>D</given-names></name><name><surname>Dolcetti</surname><given-names>R</given-names></name><name><surname>Mirandola</surname><given-names>P</given-names></name><name><surname>De Re</surname><given-names>V</given-names></name><name><surname>Secchiero</surname><given-names>P</given-names></name><name><surname>Carbone</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6: a survey of presence and variant distribution in normal peripheral lymphocytes and lymphoproliferative disorders</article-title>. <source/>J Infect Dis. (<year>1994</year>) <volume>170</volume>:<fpage>211</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">8014502</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trovato</surname><given-names>R</given-names></name><name><surname>Di Lollo</surname><given-names>S</given-names></name><name><surname>Calzolari</surname><given-names>A</given-names></name><name><surname>Torelli</surname><given-names>G</given-names></name><name><surname>Ceccherini-Nelli</surname><given-names>L</given-names></name></person-group>. <article-title>Detection of human herpesvirus-6 and Epstein-Barr virus genome in childhood Hodgkin's disease</article-title>. <source/>Pathologica (<year>1994</year>) <volume>86</volume>:<fpage>500</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="pmid">7739874</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumiyoshi</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>M</given-names></name><name><surname>Ohshima</surname><given-names>K</given-names></name><name><surname>Takeshita</surname><given-names>M</given-names></name><name><surname>Eizuru</surname><given-names>Y</given-names></name><name><surname>Minamishima</surname><given-names>Y</given-names></name></person-group>. <article-title>Analysis of human herpes virus-6 genomes in lymphoid malignancy in Japan</article-title>. <source/>J Clin Pathol. (<year>1993</year>) <volume>46</volume>:<fpage>1137</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">8282842</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gledhill</surname><given-names>S</given-names></name><name><surname>Gallagher</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>DB</given-names></name><name><surname>Krajewski</surname><given-names>AS</given-names></name><name><surname>Alexander</surname><given-names>FE</given-names></name><name><surname>Klee</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Viral involvement in Hodgkin's disease: detection of clonal type A Epstein-Barr virus genomes in tumour samples</article-title>. <source/>Br J Cancer (<year>1991</year>) <volume>64</volume>:<fpage>227</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="pmid">1654072</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torelli</surname><given-names>G</given-names></name><name><surname>Marasca</surname><given-names>R</given-names></name><name><surname>Luppi</surname><given-names>M</given-names></name><name><surname>Selleri</surname><given-names>L</given-names></name><name><surname>Ferrari</surname><given-names>S</given-names></name><name><surname>Narni</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus-6 in human lymphomas: identification of specific sequences in Hodgkin's lymphomas by polymerase chain reaction</article-title>. <source/>Blood (<year>1991</year>) <volume>77</volume>:<fpage>2251</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">1674220</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jarrett</surname><given-names>RF</given-names></name><name><surname>Gledhill</surname><given-names>S</given-names></name><name><surname>Qureshi</surname><given-names>F</given-names></name><name><surname>Crae</surname><given-names>SH</given-names></name><name><surname>Madhok</surname><given-names>R</given-names></name><name><surname>Brown</surname><given-names>I</given-names></name><etal></etal></person-group>. <article-title>Identification of human herpesvirus 6-specific DNA sequences in two patients with non-Hodgkin's lymphoma</article-title>. <source/>Leukemia (<year>1988</year>) <volume>2</volume>:<fpage>496</fpage>–<lpage>502</lpage>. <pub-id pub-id-type="pmid">3412023</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A</given-names></name><name><surname>Collot-Teixeira</surname><given-names>S</given-names></name><name><surname>Mardivirin</surname><given-names>L</given-names></name><name><surname>Jaccard</surname><given-names>A</given-names></name><name><surname>Petit</surname><given-names>B</given-names></name><name><surname>Piguet</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein</article-title>. <source/>Clin Cancer Res. (<year>2010</year>) <volume>16</volume>:<fpage>4711</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-0470</pub-id><pub-id pub-id-type="pmid">20858841</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luppi</surname><given-names>M</given-names></name><name><surname>Barozzi</surname><given-names>P</given-names></name><name><surname>Garber</surname><given-names>R</given-names></name><name><surname>Maiorana</surname><given-names>A</given-names></name><name><surname>Bonacorsi</surname><given-names>G</given-names></name><name><surname>Artusi</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Expression of human herpesvirus-6 antigens in benign and malignant lymphoproliferative diseases</article-title>. <source/>Am J Pathol. (<year>1998</year>) <volume>153</volume>:<fpage>815</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)65623-4</pub-id><pub-id pub-id-type="pmid">9736030</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Guenther</surname><given-names>A</given-names></name><name><surname>Knuefermann</surname><given-names>R</given-names></name><name><surname>Kluppelberg</surname><given-names>U</given-names></name><name><surname>Luka</surname><given-names>J</given-names></name><name><surname>Pearson</surname><given-names>GR</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus-6 (HHV-6) in Hodgkin's disease: cellular expression of viral antigens as compared to oncogenes met and fes, tumor suppressor gene product p53, and interleukins 2 and 6</article-title>. <italic>in vivo</italic> (<year>1994</year>) <volume>8</volume>:<fpage>501</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="pmid">7893977</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojo</surname><given-names>J</given-names></name><name><surname>Ferrer Argote</surname><given-names>VE</given-names></name><name><surname>Klueppelberg</surname><given-names>U</given-names></name><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Eidt</surname><given-names>E</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><etal></etal></person-group>. <article-title>Semi-quantitative <italic>in situ</italic> hybridization and immunohistology for antigen expression of human herpesvirus-6 in various lymphoproliferative diseases</article-title>. <italic>in vivo</italic> (<year>1994</year>) <volume>8</volume>:<fpage>517</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="pmid">7893978</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Wendl</surname><given-names>MC</given-names></name><name><surname>Wyczalkowski</surname><given-names>MA</given-names></name><name><surname>Wylie</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Jayasinghe</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Divergent viral presentation among human tumors and adjacent normal tissues</article-title>. <source/>Sci Rep. (<year>2016</year>) <volume>6</volume>:<fpage>28294</fpage>. <pub-id pub-id-type="doi">10.1038/srep28294</pub-id><pub-id pub-id-type="pmid">27339696</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cantalupo</surname><given-names>PG</given-names></name><name><surname>Katz</surname><given-names>JP</given-names></name><name><surname>Pipas</surname><given-names>JM</given-names></name></person-group>. <article-title>Viral sequences in human cancer</article-title>. <source/>Virology (<year>2018</year>) <volume>513</volume>:<fpage>208</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2017.10.017</pub-id><pub-id pub-id-type="pmid">29107929</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usui</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Takase</surname><given-names>H</given-names></name><name><surname>Tsubota</surname><given-names>K</given-names></name><name><surname>Umazume</surname><given-names>K</given-names></name><name><surname>Diaz-Aguilar</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Comprehensive polymerase chain reaction assay for detection of pathogenic DNA in lymphoproliferative disorders of the ocular adnexa</article-title>. <source/>Sci Rep. (<year>2016</year>) <volume>6</volume>:<fpage>36621</fpage>. <pub-id pub-id-type="doi">10.1038/srep36621</pub-id><pub-id pub-id-type="pmid">27830722</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>GS</given-names></name><name><surname>Choi</surname><given-names>YK</given-names></name><name><surname>Bak</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Kim</surname><given-names>MN</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Angioimmunoblastic T cell lymphomas: frequent cutaneous skin lesions and absence of human herpes viruses</article-title>. <source/>Ann Dermatol. (<year>2009</year>) <volume>21</volume>:<fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5021/ad.2009.21.1.1</pub-id><pub-id pub-id-type="pmid">20548847</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Attygalle</surname><given-names>AD</given-names></name><name><surname>Chuang</surname><given-names>SS</given-names></name><name><surname>Diss</surname><given-names>T</given-names></name><name><surname>Ye</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load</article-title>. <source/>Br J Haematol. (<year>2007</year>) <volume>138</volume>:<fpage>44</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2007.06620.x</pub-id><pub-id pub-id-type="pmid">17555446</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolonic</surname><given-names>SO</given-names></name><name><surname>Dzebro</surname><given-names>S</given-names></name><name><surname>Kusec</surname><given-names>R</given-names></name><name><surname>Planinc-Peraica</surname><given-names>A</given-names></name><name><surname>Dominis</surname><given-names>M</given-names></name><name><surname>Jaksic</surname><given-names>B</given-names></name></person-group>. <article-title>Primary mediastinal large B-cell lymphoma: a single-center study of clinicopathologic characteristics</article-title>. <source/>Int J Hematol. (<year>2006</year>) <volume>83</volume>:<fpage>331</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1532/IJH97.E0529</pub-id><pub-id pub-id-type="pmid">16757434</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vrsalovic</surname><given-names>MM</given-names></name><name><surname>Korac</surname><given-names>P</given-names></name><name><surname>Dominis</surname><given-names>M</given-names></name><name><surname>Ostojic</surname><given-names>S</given-names></name><name><surname>Mannhalter</surname><given-names>C</given-names></name><name><surname>Kusec</surname><given-names>R</given-names></name></person-group>. <article-title>T- and B-cell clonality and frequency of human herpes viruses-6,−8 and Epstein Barr virus in angioimmunoblastic T-cell lymphoma</article-title>. <source/>Hematol Oncol. (<year>2004</year>) <volume>22</volume>:<fpage>169</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1002/hon.740</pub-id><pub-id pub-id-type="pmid">16134192</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allory</surname><given-names>Y</given-names></name><name><surname>Challine</surname><given-names>D</given-names></name><name><surname>Haioun</surname><given-names>C</given-names></name><name><surname>Copie-Bergman</surname><given-names>C</given-names></name><name><surname>Delfau-Larue</surname><given-names>MH</given-names></name><name><surname>Boucher</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Bone marrow involvement in lymphomas with hemophagocytic syndrome at presentation: a clinicopathologic study of 11 patients in a Western institution</article-title>. <source/>Am J Surg Pathol. (<year>2001</year>) <volume>25</volume>:<fpage>865</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="pmid">11420457</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asou</surname><given-names>H</given-names></name><name><surname>Tasaka</surname><given-names>T</given-names></name><name><surname>Said</surname><given-names>JW</given-names></name><name><surname>Daibata</surname><given-names>M</given-names></name><name><surname>Kamada</surname><given-names>N</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group>. <article-title>Co-infection of HHV-6 and HHV-8 is rare in primary effusion lymphoma</article-title>. <source/>Leuk Res. (<year>2000</year>) <volume>24</volume>:<fpage>59</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/S0145-2126(99)00144-7</pub-id><pub-id pub-id-type="pmid">10634647</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daibata</surname><given-names>M</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name></person-group>. <article-title>Human herpesviruses in primary ocular lymphoma</article-title>. <source/>Leuk Lymphoma (<year>2000</year>) <volume>37</volume>:<fpage>361</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.3109/10428190009089436</pub-id><pub-id pub-id-type="pmid">10752987</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohyashiki</surname><given-names>JH</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Ojima</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>P</given-names></name><name><surname>Zhou</surname><given-names>CF</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA</article-title>. <source/>Leuk Res. (<year>1999</year>) <volume>23</volume>:<fpage>625</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="pmid">10400183</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brice</surname><given-names>SL</given-names></name><name><surname>Jester</surname><given-names>JD</given-names></name><name><surname>Friednash</surname><given-names>M</given-names></name><name><surname>Golitz</surname><given-names>LE</given-names></name><name><surname>Leahy</surname><given-names>MA</given-names></name><name><surname>Stockert</surname><given-names>SS</given-names></name><etal></etal></person-group>. <article-title>Examination of cutaneous T-cell lymphoma for human herpesviruses by using the polymerase chain reaction</article-title>. <source/>J Cutan Pathol. (<year>1993</year>) <volume>20</volume>:<fpage>304</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">8227605</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luppi</surname><given-names>M</given-names></name><name><surname>Marasca</surname><given-names>R</given-names></name><name><surname>Barozzi</surname><given-names>P</given-names></name><name><surname>Artusi</surname><given-names>T</given-names></name><name><surname>Torelli</surname><given-names>G</given-names></name></person-group>. <article-title>Frequent detection of human herpesvirus-6 sequences by polymerase chain reaction in paraffin-embedded lymph nodes from patients with angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma</article-title>. <source/>Leuk Res. (<year>1993</year>) <volume>17</volume>:<fpage>1003</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="pmid">8231227</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>RI</given-names></name><name><surname>Saito</surname><given-names>I</given-names></name><name><surname>Chan</surname><given-names>EK</given-names></name><name><surname>Josephs</surname><given-names>S</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Ahlashi</surname><given-names>DV</given-names></name><etal></etal></person-group>. <article-title>Viral genomes in lymphomas of patients with Sjogren's syndrome</article-title>. <source/>J Autoimmun. (<year>1989</year>) <volume>2</volume>:<fpage>449</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="pmid">2571338</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchbinder</surname><given-names>A</given-names></name><name><surname>Josephs</surname><given-names>SF</given-names></name><name><surname>Ablashi</surname><given-names>D</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Klotman</surname><given-names>ME</given-names></name><name><surname>Manak</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Polymerase chain reaction amplification and <italic>in situ</italic> hybridization for the detection of human B-lymphotropic virus</article-title>. <source/>J Virol Methods (<year>1988</year>) <volume>21</volume>:<fpage>191</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">3182954</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Josephs</surname><given-names>SF</given-names></name><name><surname>Buchbinder</surname><given-names>A</given-names></name><name><surname>Streicher</surname><given-names>HZ</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Guo</surname><given-names>HG</given-names></name><etal></etal></person-group>. <article-title>Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B cell lymphoma tissues of three patients</article-title>. <source/>Leukemia (<year>1988</year>) <volume>2</volume>:<fpage>132</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">3258048</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>SY</given-names></name><name><surname>Ming</surname><given-names>HA</given-names></name><name><surname>Jahan</surname><given-names>N</given-names></name><name><surname>Manak</surname><given-names>M</given-names></name><name><surname>Jaffe</surname><given-names>ES</given-names></name><name><surname>Levine</surname><given-names>PH</given-names></name></person-group>. <article-title><italic>In situ</italic> hybridization detection of human herpesvirus 6 in biopsy specimens from Chinese patients with non-Hodgkin's lymphoma</article-title>. <source/>Arch Pathol Lab Med. (<year>1993</year>) <volume>117</volume>:<fpage>502</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="pmid">8387767</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>MJ</given-names></name><name><surname>O'Grady</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Baddoo</surname><given-names>M</given-names></name><name><surname>Parsons</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Epstein-Barr virus and human herpesvirus 6 detection in a non-Hodgkin's diffuse large B-cell lymphoma cohort by using RNA sequencing</article-title>. <source/>J Virol. (<year>2013</year>) <volume>87</volume>:<fpage>13059</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02380-13</pub-id><pub-id pub-id-type="pmid">24049168</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nefzi</surname><given-names>F</given-names></name><name><surname>Lambert</surname><given-names>C</given-names></name><name><surname>Gautheret-Dejean</surname><given-names>A</given-names></name><name><surname>Fisson</surname><given-names>S</given-names></name><name><surname>Khebizi</surname><given-names>Q</given-names></name><name><surname>Khelif</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Cytokine and cellular responses to human herpesvirus-6B in patients with B-acute lymphoblastic leukemia</article-title>. <source/>Microbiol Immunol. (<year>2016</year>) <volume>60</volume>:<fpage>770</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12452</pub-id><pub-id pub-id-type="pmid">27862208</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morales-Sanchez</surname><given-names>A</given-names></name><name><surname>Pompa-Mera</surname><given-names>EN</given-names></name><name><surname>Fajardo-Gutierrez</surname><given-names>A</given-names></name><name><surname>Alvarez-Rodriguez</surname><given-names>FJ</given-names></name><name><surname>Bekker-Mendez</surname><given-names>VC</given-names></name><name><surname>Flores-Chapa</surname><given-names>Jde D</given-names></name><etal></etal></person-group>. <article-title>EBV, HCMV, HHV6, and HHV7 screening in bone marrow samples from children with acute lymphoblastic leukemia</article-title>. <source/>Biomed Res Int. (<year>2014</year>) <volume>2014</volume>:<fpage>548097</fpage>. <pub-id pub-id-type="doi">10.1155/2014/548097</pub-id><pub-id pub-id-type="pmid">25309913</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Sinnett</surname><given-names>D</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name></person-group>. <article-title>Frequency of chromosomally-integrated human herpesvirus 6 in children with acute lymphoblastic leukemia</article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e84322</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0084322</pub-id><pub-id pub-id-type="pmid">24386368</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faten</surname><given-names>N</given-names></name><name><surname>Agnes</surname><given-names>GD</given-names></name><name><surname>Nadia</surname><given-names>BF</given-names></name><name><surname>Nabil</surname><given-names>AB</given-names></name><name><surname>Monia</surname><given-names>Z</given-names></name><name><surname>Abderrahim</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Quantitative analysis of human herpesvirus-6 genome in blood and bone marrow samples from Tunisian patients with acute leukemia: a follow-up study</article-title>. <source/>Infect Agent Cancer (<year>2012</year>) <volume>7</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/1750-9378-7-31</pub-id><pub-id pub-id-type="pmid">23146098</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>P</given-names></name><name><surname>Muzikova</surname><given-names>K</given-names></name><name><surname>Hrdlickova</surname><given-names>A</given-names></name><name><surname>Cinek</surname><given-names>O</given-names></name><name><surname>Hyncicova</surname><given-names>K</given-names></name><name><surname>Hrstkova</surname><given-names>H</given-names></name><etal></etal></person-group>
<article-title>Prevalence of HHV-6 integrated chromosomally among children treated for acute lymphoblastic or myeloid leukemia in the Czech Republic</article-title>. <source/>J Med Virol. (<year>2009</year>) <volume>81</volume>:<fpage>258</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21371</pub-id><pub-id pub-id-type="pmid">19107978</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seror</surname><given-names>E</given-names></name><name><surname>Coquerel</surname><given-names>B</given-names></name><name><surname>Gautheret-Dejean</surname><given-names>A</given-names></name><name><surname>Ballerini</surname><given-names>P</given-names></name><name><surname>Landman-Parker</surname><given-names>J</given-names></name><name><surname>Leverger</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Quantitation of Human herpes virus 6 genome in children with acute lymphoblastic leukemia</article-title>. <source/>J Med Virol. (<year>2008</year>) <volume>80</volume>:<fpage>689</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21118</pub-id><pub-id pub-id-type="pmid">18297709</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Csire</surname><given-names>M</given-names></name><name><surname>Mikala</surname><given-names>G</given-names></name><name><surname>Peto</surname><given-names>M</given-names></name><name><surname>Janosi</surname><given-names>J</given-names></name><name><surname>Juhasz</surname><given-names>A</given-names></name><name><surname>Tordai</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Detection of four lymphotropic herpesviruses in Hungarian patients with multiple myeloma and lymphoma</article-title>. <source/>FEMS Immunol Med Microbiol. (<year>2007</year>) <volume>49</volume>:<fpage>62</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.2006.00171.x</pub-id><pub-id pub-id-type="pmid">17132141</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermouet</surname><given-names>S</given-names></name><name><surname>Sutton</surname><given-names>CA</given-names></name><name><surname>Rose</surname><given-names>TM</given-names></name><name><surname>Greenblatt</surname><given-names>RJ</given-names></name><name><surname>Corre</surname><given-names>I</given-names></name><name><surname>Garand</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Qualitative and quantitative analysis of human herpesviruses in chronic and acute B cell lymphocytic leukemia and in multiple myeloma</article-title>. <source/>Leukemia (<year>2003</year>) <volume>17</volume>:<fpage>185</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1038/sj.leu.2402748</pub-id><pub-id pub-id-type="pmid">12529677</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luka</surname><given-names>J</given-names></name><name><surname>Pirruccello</surname><given-names>SJ</given-names></name><name><surname>Kersey</surname><given-names>JH</given-names></name></person-group>. <article-title>HHV-6 genome in T-cell acute lymphoblastic leukaemia</article-title>. <source/>Lancet (<year>1991</year>) <volume>338</volume>:<fpage>1277</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">1682676</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Kudlimay</surname><given-names>D</given-names></name><name><surname>Ramon</surname><given-names>A</given-names></name><name><surname>Klueppelberg</surname><given-names>U</given-names></name><name><surname>Schumacher</surname><given-names>K</given-names></name></person-group>. <article-title>Demonstration of active and latent Epstein-Barr virus and human herpevirus-6 infections in bone marrow cells of patients with myelodysplasia and chronic myeloproliferative diseases</article-title>. <italic>in vivo</italic> (<year>1994</year>) <volume>8</volume>:<fpage>533</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="pmid">7893980</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Zang</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Pei</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Evidence for possible role of toll-like receptor 3 mediating virus-induced progression of pituitary adenomas</article-title>. <source/>Mol Cell Endocrinol. (<year>2016</year>) <volume>426</volume>:<fpage>22</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2016.02.009</pub-id><pub-id pub-id-type="pmid">26891958</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>CT</given-names></name><name><surname>Leibovitch</surname><given-names>EC</given-names></name><name><surname>Almira-Suarez</surname><given-names>MI</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group>. <article-title>Human herpesvirus multiplex ddPCR detection in brain tissue from low- and high-grade astrocytoma cases and controls</article-title>. <source/>Infect Agent Cancer (<year>2016</year>) <volume>11</volume>:<fpage>32</fpage>. <pub-id pub-id-type="doi">10.1186/s13027-016-0081-x</pub-id><pub-id pub-id-type="pmid">27462365</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 latent infection in patients with glioma</article-title>. <source/>J Infect Dis. (<year>2012</year>) <volume>206</volume>:<fpage>1394</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jis513</pub-id><pub-id pub-id-type="pmid">22962688</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>JR</given-names></name><name><surname>Santi</surname><given-names>MR</given-names></name><name><surname>Thorarinsdottir</surname><given-names>HK</given-names></name><name><surname>Cornelison</surname><given-names>R</given-names></name><name><surname>Rushing</surname><given-names>EJ</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Detection of human herpesvirus-6 variants in pediatric brain tumors: association of viral antigen in low grade gliomas</article-title>. <source/>J Clin Virol. (<year>2009</year>) <volume>46</volume>:<fpage>37</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2009.05.011</pub-id><pub-id pub-id-type="pmid">19505845</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>JR</given-names></name><name><surname>Santi</surname><given-names>MR</given-names></name><name><surname>Cornelison</surname><given-names>R</given-names></name><name><surname>Sallinen</surname><given-names>SL</given-names></name><name><surname>Haapasalo</surname><given-names>H</given-names></name><name><surname>MacDonald</surname><given-names>TJ</given-names></name></person-group>. <article-title>Detection of human herpesvirus-6 in adult central nervous system tumors: predominance of early and late viral antigens in glial tumors</article-title>. <source/>J Neurooncol. (<year>2009</year>) <volume>95</volume>:<fpage>49</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s11060-009-9908-2</pub-id><pub-id pub-id-type="pmid">19424665</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neves</surname><given-names>AM</given-names></name><name><surname>Thompson</surname><given-names>G</given-names></name><name><surname>Carvalheira</surname><given-names>J</given-names></name><name><surname>Trindade</surname><given-names>JC</given-names></name><name><surname>Rueff</surname><given-names>J</given-names></name><name><surname>Caetano</surname><given-names>JM</given-names></name><etal></etal></person-group>. <article-title>Detection and quantitative analysis of human herpesvirus in pilocytic astrocytoma</article-title>. <source/>Brain Res. (<year>2008</year>) <volume>1221</volume>:<fpage>108</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2008.05.009</pub-id><pub-id pub-id-type="pmid">18565499</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuomo</surname><given-names>L</given-names></name><name><surname>Trivedi</surname><given-names>P</given-names></name><name><surname>Cardillo</surname><given-names>MR</given-names></name><name><surname>Gagliardi</surname><given-names>FM</given-names></name><name><surname>Vecchione</surname><given-names>A</given-names></name><name><surname>Caruso</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 infection in neoplastic and normal brain tissue</article-title>. <source/>J Med Virol. (<year>2001</year>) <volume>63</volume>:<fpage>45</fpage>–<lpage>51</lpage>
<pub-id pub-id-type="doi">10.1002/1096-9071(200101)63:1&lt;45::AID-JMV1006&gt;3.0.CO;2-K</pub-id><pub-id pub-id-type="pmid">11130886</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name><name><surname>Cheng</surname><given-names>AF</given-names></name></person-group>. <article-title>Detection of human herpesviruses 6 and 7 genomic sequences in brain tumours</article-title>. <source/>J Clin Pathol. (<year>1999</year>) <volume>52</volume>:<fpage>620</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="pmid">10645234</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luppi</surname><given-names>M</given-names></name><name><surname>Barozzi</surname><given-names>P</given-names></name><name><surname>Maiorana</surname><given-names>A</given-names></name><name><surname>Marasca</surname><given-names>R</given-names></name><name><surname>Trovato</surname><given-names>R</given-names></name><name><surname>Fano</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus-6: a survey of presence and distribution of genomic sequences in normal brain and neuroglial tumors</article-title>. <source/>J Med Virol. (<year>1995</year>) <volume>47</volume>:<fpage>105</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="pmid">8551252</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liedtke</surname><given-names>W</given-names></name><name><surname>Trubner</surname><given-names>K</given-names></name><name><surname>Schwechheimer</surname><given-names>K</given-names></name></person-group>. <article-title>On the role of human herpesvirus 6 in viral latency in nervous tissue and in cerebral lymphoma</article-title>. <source/>J Neurol Sci. (<year>1995</year>) <volume>134</volume>:<fpage>184</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">8747864</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paulus</surname><given-names>W</given-names></name><name><surname>Jellinger</surname><given-names>K</given-names></name><name><surname>Hallas</surname><given-names>C</given-names></name><name><surname>Ott</surname><given-names>G</given-names></name><name><surname>Muller-Hermelink</surname><given-names>HK</given-names></name></person-group>. <article-title>Human herpesvirus-6 and Epstein-Barr virus genome in primary cerebral lymphomas</article-title>. <source/>Neurology (<year>1993</year>) <volume>43</volume>:<fpage>1591</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="pmid">8394522</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strong</surname><given-names>MJ</given-names></name><name><surname>Blanchard</surname><given-names>ET</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Morris</surname><given-names>CA</given-names></name><name><surname>Baddoo</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>CM</given-names></name><etal></etal></person-group>. <article-title>A comprehensive next generation sequencing-based virome assessment in brain tissue suggests no major virus–tumor association</article-title>. <source/>Acta Neuropathol Commun. (<year>2016</year>) <volume>4</volume>:<fpage>71</fpage>. <pub-id pub-id-type="doi">10.1186/s40478-016-0338-z</pub-id><pub-id pub-id-type="pmid">27402152</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>CG</given-names></name><name><surname>Leary</surname><given-names>RJ</given-names></name><name><surname>Lin</surname><given-names>JC</given-names></name><name><surname>Cummins</surname><given-names>J</given-names></name><name><surname>Di</surname><given-names>C</given-names></name><name><surname>Schaefer</surname><given-names>CF</given-names></name><etal></etal></person-group>. <article-title>Identification of microbial DNA in human cancer</article-title>. <source/>BMC Med Genomics (<year>2009</year>) <volume>2</volume>:<fpage>22</fpage>. <pub-id pub-id-type="doi">10.1186/1755-8794-2-22</pub-id><pub-id pub-id-type="pmid">19426505</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halme</surname><given-names>L</given-names></name><name><surname>Loginov</surname><given-names>R</given-names></name><name><surname>Arola</surname><given-names>J</given-names></name><name><surname>Turunen</surname><given-names>U</given-names></name><name><surname>Lautenschlager</surname><given-names>I</given-names></name></person-group>. <article-title>HHV-6 antigen and HHV-6 DNA expression in sporadic adenomatous polyps of the colon</article-title>. <source/>Scand J Gastroenterol. (<year>2013</year>) <volume>48</volume>:<fpage>1423</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3109/00365521.2013.843200</pub-id><pub-id pub-id-type="pmid">24099308</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Shih</surname><given-names>N</given-names></name><name><surname>Feldman</surname><given-names>MD</given-names></name><name><surname>Alwine</surname><given-names>JC</given-names></name><etal></etal></person-group>. <article-title>The ovarian cancer oncobiome</article-title>. <source/>Oncotarget (<year>2017</year>) <volume>8</volume>:<fpage>36225</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.16717</pub-id><pub-id pub-id-type="pmid">28410234</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Broccolo</surname><given-names>F</given-names></name><name><surname>Cassina</surname><given-names>G</given-names></name><name><surname>Chiari</surname><given-names>S</given-names></name><name><surname>Garcia-Parra</surname><given-names>R</given-names></name><name><surname>Villa</surname><given-names>A</given-names></name><name><surname>Leone</surname><given-names>BE</given-names></name><etal></etal></person-group>. <article-title>Frequency and clinical significance of human beta-herpesviruses in cervical samples from Italian women</article-title>. <source/>J Med Virol. (<year>2008</year>) <volume>80</volume>:<fpage>147</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.21054</pub-id><pub-id pub-id-type="pmid">18041029</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tran-Thanh</surname><given-names>D</given-names></name><name><surname>Koushik</surname><given-names>A</given-names></name><name><surname>Provencher</surname><given-names>D</given-names></name><name><surname>Drouin</surname><given-names>P</given-names></name><name><surname>Dubuc-Lissoir</surname><given-names>J</given-names></name><name><surname>Gauthier</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix</article-title>. <source/>J Med Virol. (<year>2002</year>) <volume>68</volume>:<fpage>606</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.10229</pub-id><pub-id pub-id-type="pmid">12376970</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>PK</given-names></name><name><surname>Chan</surname><given-names>MY</given-names></name><name><surname>Li</surname><given-names>WW</given-names></name><name><surname>Chan</surname><given-names>DP</given-names></name><name><surname>Cheung</surname><given-names>JL</given-names></name><name><surname>Cheng</surname><given-names>AF</given-names></name></person-group>
<article-title>Association of human beta-herpesviruses with the development of cervical cancer: bystanders or cofactors</article-title>. <source/>J Clin Pathol. (<year>2001</year>) <volume>54</volume>:<fpage>48</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1136/jcp.54.1.48</pub-id><pub-id pub-id-type="pmid">11271789</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>N</given-names></name><name><surname>Romano</surname><given-names>FM</given-names></name><name><surname>Viviano</surname><given-names>E</given-names></name><name><surname>Vitale</surname><given-names>F</given-names></name><name><surname>Villafrate</surname><given-names>MR</given-names></name><name><surname>Perna</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>Rare association of human herpesvirus 6 DNA with human papillomavirus DNA in cervical smears of women with normal and abnormal cytologies</article-title>. <source/>J Clin Microbiol. (<year>1996</year>) <volume>34</volume>:<fpage>1589</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="pmid">8735129</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Berneman</surname><given-names>ZN</given-names></name><name><surname>Delgado</surname><given-names>G</given-names></name><name><surname>DiPaolo</surname><given-names>JA</given-names></name></person-group>. <article-title>Detection of human herpesvirus-6 in paraffin-embedded tissue of cervical cancer by polymerase chain reaction</article-title>. <source/>J Virol Methods (<year>1994</year>) <volume>47</volume>:<fpage>297</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="pmid">8071418</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Woodworth</surname><given-names>CD</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name><name><surname>Berneman</surname><given-names>Z</given-names></name><name><surname>Kingma</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Detection of human herpesvirus 6 and human papillomavirus 16 in cervical carcinoma</article-title>. <source/>Am J Pathol. (<year>1994</year>) <volume>145</volume>:<fpage>1509</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="pmid">7992853</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arivananthan</surname><given-names>M</given-names></name><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>Detection of HHV-6 genotypes by <italic>in situ</italic> hybridization with variant-specific oligonucleotide probes</article-title>. <source/>J Virol Methods (<year>1997</year>) <volume>66</volume>:<fpage>5</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="pmid">9220385</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Arivananthan</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>HHV-6 antigen and viral DNA detected in cervical cells from archived tissue using histochemical staining and hybridization</article-title>. <source/>Clin Diagn Virol. (<year>1996</year>) <volume>7</volume>:<fpage>23</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">9077427</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Arivananthan</surname><given-names>M</given-names></name><name><surname>Chandrashekran</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>BS</given-names></name><name><surname>Hashim</surname><given-names>BY</given-names></name></person-group>. <article-title>Human herpesvirus-6 (HHV-6) DNA and virus-encoded antigen in oral lesions</article-title>. <source/>J Oral Pathol Med. (<year>1997</year>) <volume>26</volume>:<fpage>393</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="pmid">9385576</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadav</surname><given-names>M</given-names></name><name><surname>Chandrashekran</surname><given-names>A</given-names></name><name><surname>Vasudevan</surname><given-names>DM</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name></person-group>. <article-title>Frequent detection of human herpesvirus 6 in oral carcinoma</article-title>. <source/>J Natl Cancer Inst. (<year>1994</year>) <volume>86</volume>:<fpage>1792</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="pmid">7966419</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saravani</surname><given-names>S</given-names></name><name><surname>Miri-Moghaddam</surname><given-names>E</given-names></name><name><surname>Sanadgol</surname><given-names>N</given-names></name><name><surname>Kadeh</surname><given-names>H</given-names></name><name><surname>Nazeri</surname><given-names>MR</given-names></name></person-group>. <article-title>Human herpesvirus-6 and epstein-barr virus infections at different histopathological grades of oral squamous cell carcinomas</article-title>. <source/>Int J Prev Med. (<year>2014</year>) <volume>5</volume>:<fpage>1231</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">25400880</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanehsazzadeh</surname><given-names>M</given-names></name><name><surname>Rad</surname><given-names>JS</given-names></name><name><surname>Pourazar</surname><given-names>A</given-names></name><name><surname>Behbahani</surname><given-names>M</given-names></name></person-group>. <article-title>Epidemiology of herpes human virus 6 and 7 infections in salivary gland neoplasms in Isfahan, Iran</article-title>. <source/>Med Arch. (<year>2014</year>) <volume>68</volume>:<fpage>276</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.5455/medarh.2014.68.276-278</pub-id><pub-id pub-id-type="pmid">25568552</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Jian</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group>
<article-title>The study on clinical significance of human herpesvirus 6 infection of NPC tissues</article-title>. <source/>Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi (<year>1999</year>) <volume>13</volume>:<fpage>262</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">12569760</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kositanont</surname><given-names>U</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Chongkolwatana</surname><given-names>C</given-names></name><name><surname>Metheetrairut</surname><given-names>C</given-names></name><name><surname>Puthavathana</surname><given-names>P</given-names></name><name><surname>Chantarakul</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Detection of Epstein-Barr virus DNA and HHV-6 DNA in tissue biopsies from patients with nasopharyngeal carcinoma by polymerase chain reaction</article-title>. <source/>Southeast Asian J Trop Med Public Health (<year>1993</year>) <volume>24</volume>:<fpage>455</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="pmid">8160052</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campioni</surname><given-names>D</given-names></name><name><surname>Gentili</surname><given-names>V</given-names></name><name><surname>Cavazzini</surname><given-names>F</given-names></name><name><surname>Bortolotti</surname><given-names>D</given-names></name><name><surname>Nacheva</surname><given-names>EP</given-names></name><name><surname>Cuneo</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Detection of inherited chromosomally integrated HHV-6 (ciHHV-6) in a marker chromosome</article-title>. <source/>Eur J Haematol. (<year>2017</year>) <volume>98</volume>:<fpage>635</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/ejh.12872</pub-id><pub-id pub-id-type="pmid">28244148</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Cotton</surname><given-names>VE</given-names></name><name><surname>Hidalgo-Bravo</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Bell</surname><given-names>AJ</given-names></name><name><surname>Jarrett</surname><given-names>RF</given-names></name><etal></etal></person-group>. <article-title>HHV-8-unrelated primary effusion-like lymphoma associated with clonal loss of inherited chromosomally-integrated human herpesvirus-6A from the telomere of chromosome 19q</article-title>. <source/>Sci Rep. (<year>2016</year>) <volume>6</volume>:<fpage>22730</fpage>. <pub-id pub-id-type="doi">10.1038/srep22730</pub-id><pub-id pub-id-type="pmid">26947392</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama-Ichiyama</surname><given-names>S</given-names></name><name><surname>Yokote</surname><given-names>T</given-names></name><name><surname>Iwaki</surname><given-names>K</given-names></name><name><surname>Miyoshi</surname><given-names>T</given-names></name><name><surname>Takubo</surname><given-names>T</given-names></name><name><surname>Tsuji</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Co-infection of human herpesvirus-6 and human herpesvirus-8 in primary cutaneous diffuse large B-cell lymphoma, leg type</article-title>. <source/>Br J Haematol. (<year>2011</year>) <volume>155</volume>:<fpage>514</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2011.08702.x</pub-id><pub-id pub-id-type="pmid">21517824</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama-Ichiyama</surname><given-names>S</given-names></name><name><surname>Yokote</surname><given-names>T</given-names></name><name><surname>Oka</surname><given-names>S</given-names></name><name><surname>Iwaki</surname><given-names>K</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><name><surname>Hirata</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Diffuse large B-cell lymphoma, not otherwise specified, associated with coinfection of human herpesvirus 6 and 8</article-title>. <source/>J Clin Oncol. (<year>2011</year>) <volume>29</volume>:<fpage>e636</fpage>–<lpage>637</lpage>. <pub-id pub-id-type="doi">10.1200/JCO.2011.35.1254</pub-id><pub-id pub-id-type="pmid">21606415</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohi</surname><given-names>O</given-names></name><name><surname>Arola</surname><given-names>M</given-names></name><name><surname>Lautenschlager</surname><given-names>I</given-names></name><name><surname>Nacheva</surname><given-names>EP</given-names></name><name><surname>Vettenranta</surname><given-names>K</given-names></name></person-group>. <article-title>A high circulating copy number of HHV-6 due to chromosomal integration in a child with acute lymphoblastic leukemia</article-title>. <source/>Pediatr Blood Cancer (<year>2010</year>) <volume>55</volume>:<fpage>1236</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/pbc.22671</pub-id><pub-id pub-id-type="pmid">20589623</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubacek</surname><given-names>P</given-names></name><name><surname>Virgili</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>KN</given-names></name><name><surname>Pohlreich</surname><given-names>D</given-names></name><name><surname>Keslova</surname><given-names>P</given-names></name><name><surname>Goldova</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>HHV-6 DNA throughout the tissues of two stem cell transplant patients with chromosomally integrated HHV-6 and fatal CMV pneumonitis</article-title>. <source/>Br J Haematol. (<year>2009</year>) <volume>145</volume>:<fpage>394</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2009.07622.x</pub-id><pub-id pub-id-type="pmid">19222466</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Moore</surname><given-names>JO</given-names></name><name><surname>Mann</surname><given-names>KP</given-names></name><name><surname>Traweek</surname><given-names>ST</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name></person-group>. <article-title>Post transplant CD8<sup>+</sup> gammadelta T-cell lymphoma associated with human herpes virus-6 infection</article-title>. <source/>Leuk Lymphoma (<year>1999</year>) <volume>33</volume>:<fpage>377</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="pmid">10221519</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daibata</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Kamioka</surname><given-names>M</given-names></name><name><surname>Kubonishi</surname><given-names>I</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name><name><surname>Miyoshi</surname><given-names>I</given-names></name></person-group>. <article-title>Identification of integrated human herpesvirus 6 DNA in early pre-B cell acute lymphoblastic leukemia</article-title>. <source/>Leukemia (<year>1998</year>) <volume>12</volume>:<fpage>1002</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="pmid">9639436</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daibata</surname><given-names>M</given-names></name><name><surname>Ido</surname><given-names>E</given-names></name><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Kuzume</surname><given-names>T</given-names></name><name><surname>Kubonishi</surname><given-names>I</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Angioimmunoblastic lymphadenopathy with disseminated human herpesvirus 6 infection in a patient with acute myeloblastic leukemia</article-title>. <source/>Leukemia (<year>1997</year>) <volume>11</volume>:<fpage>882</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">9177444</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandobashi</surname><given-names>K</given-names></name><name><surname>Daibata</surname><given-names>M</given-names></name><name><surname>Kamioka</surname><given-names>M</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Kubonishi</surname><given-names>I</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 (HHV-6)-positive Burkitt's lymphoma: establishment of a novel cell line infected with HHV-6</article-title>. <source/>Blood (<year>1997</year>) <volume>90</volume>:<fpage>1200</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">9242553</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>A</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Enzan</surname><given-names>H</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Wakiguchi</surname><given-names>H</given-names></name><name><surname>Kurashige</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>The evidence of human herpesvirus 6 infection in the lymph nodes of Hodgkin's disease</article-title>. <source/>Virchows Arch A Pathol Anat Histopathol. (<year>1993</year>) <volume>423</volume>:<fpage>71</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">8212537</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stödberg</surname><given-names>T</given-names></name><name><surname>Deniz</surname><given-names>Y</given-names></name><name><surname>Esteitie</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>A case of diffuse leptomeningeal oligodendrogliomatosis associated with HHV-6 variant A</article-title>. <source/>Neuropediatrics (<year>2002</year>) <volume>33</volume>:<fpage>266</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1055/s-2002-36739</pub-id><pub-id pub-id-type="pmid">12536370</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rantala</surname><given-names>H</given-names></name><name><surname>Mannonen</surname><given-names>L</given-names></name><name><surname>Ahtiluoto</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus-6 associated encephalitis with subsequent infantile spasms and cerebellar astrocytoma</article-title>. <source/>Dev Med Child Neurol. (<year>2000</year>) <volume>42</volume>:<fpage>418</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-8749.2000.tb00123.x</pub-id><pub-id pub-id-type="pmid">10875530</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>JR</given-names></name></person-group>
<article-title>HHV-6A and HHV-6B in cancer</article-title>. In: <person-group person-group-type="editor"><name><surname>Flamand</surname><given-names>LI</given-names></name><name><surname>Krueger</surname><given-names>GRF</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name></person-group>, editors. <source/>Human Herpesviruses HHV-6A, HHV-6B &amp; HHV-7, <edition>3rd ed.</edition>
<publisher-loc>Boston, MA</publisher-loc>: <publisher-name>Elsevier</publisher-name> (<year>2014</year>). p. <fpage>297</fpage>–<lpage>310</lpage>.</mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bolle</surname><given-names>L</given-names></name><name><surname>Naesens</surname><given-names>L</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name></person-group>. <article-title>Update on human herpesvirus 6 biology, clinical features, and therapy</article-title>. <source/>Clin Microbiol Rev. (<year>2005</year>) <volume>18</volume>:<fpage>217</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.18.1.217-245.2005</pub-id><pub-id pub-id-type="pmid">15653828</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alibek</surname><given-names>K</given-names></name><name><surname>Baiken</surname><given-names>Y</given-names></name><name><surname>Kakpenova</surname><given-names>A</given-names></name><name><surname>Mussabekova</surname><given-names>A</given-names></name><name><surname>Zhussupbekova</surname><given-names>S</given-names></name><name><surname>Akan</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Implication of human herpesviruses in oncogenesis through immune evasion and supression</article-title>. <source/>Infect Agent Cancer (<year>2014</year>) <volume>9</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1750-9378-9-3</pub-id><pub-id pub-id-type="pmid">24438207</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biggs</surname><given-names>PM</given-names></name></person-group>. <article-title>Oncogenic herpesvirus infections of animals</article-title>. <source/>J Clin Pathol Suppl (R Coll Pathol). (<year>1972</year>) <volume>6</volume>:<fpage>65</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="pmid">4376157</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufer</surname><given-names>BB</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name></person-group>. <article-title>Chromosomally integrated HHV-6: impact on virus, cell and organismal biology</article-title>. <source/>Curr Opin Virol. (<year>2014</year>) <volume>9</volume>:<fpage>111</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.coviro.2014.09.010</pub-id><pub-id pub-id-type="pmid">25462442</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellett</surname><given-names>PE</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Ambros</surname><given-names>PF</given-names></name><name><surname>Agut</surname><given-names>H</given-names></name><name><surname>Caserta</surname><given-names>MT</given-names></name><name><surname>Descamps</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Chromosomally integrated human herpesvirus 6: questions and answers</article-title>. <source/>Rev Med Virol. (<year>2012</year>) <volume>22</volume>:<fpage>144</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1002/rmv.715</pub-id><pub-id pub-id-type="pmid">22052666</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arbuckle</surname><given-names>JH</given-names></name><name><surname>Medveczky</surname><given-names>MM</given-names></name><name><surname>Luka</surname><given-names>J</given-names></name><name><surname>Hadley</surname><given-names>SH</given-names></name><name><surname>Luegmayr</surname><given-names>A</given-names></name><name><surname>Ablashi</surname><given-names>D</given-names></name><etal></etal></person-group>
<article-title>The latent human herpesvirus-6A genome specifically integrates in telomeres of human chromosomes <italic>in vivo</italic> and <italic>in vitro</italic></article-title>. <source/>Proc Natl Acad Sci USA. (<year>2010</year>) <volume>197</volume>:<fpage>5563</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0913586107</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>A</given-names></name><name><surname>Watanabe</surname><given-names>K</given-names></name><name><surname>Ohye</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Matsubara</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Molecular and virological evidence of viral activation from chromosomally integrated human herpesvirus 6A in a patient with X-linked severe combined immunodeficiency</article-title>. <source/>Clin Infect Dis. (<year>2014</year>) <volume>59</volume>:<fpage>545</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu323</pub-id><pub-id pub-id-type="pmid">24803376</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Hidalgo-Bravo</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name><name><surname>Cotton</surname><given-names>VE</given-names></name><name><surname>Mendez-Bermudez</surname><given-names>A</given-names></name><name><surname>Wig</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Human telomeres that carry an integrated copy of human herpesvirus 6 are often short and unstable, facilitating release of the viral genome from the chromosome</article-title>. <source/>Nucleic Acids Res. (<year>2014</year>) <volume>42</volume>:<fpage>315</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkt840</pub-id><pub-id pub-id-type="pmid">24057213</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Calado</surname><given-names>RT</given-names></name><name><surname>Ly</surname><given-names>H</given-names></name><name><surname>Kajigaya</surname><given-names>S</given-names></name><name><surname>Baerlocher</surname><given-names>GM</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><etal></etal></person-group>. <article-title>Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia</article-title>. <source/>N Engl J Med. (<year>2005</year>) <volume>352</volume>:<fpage>1413</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa042980</pub-id><pub-id pub-id-type="pmid">15814878</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Politikos</surname><given-names>I</given-names></name><name><surname>McMasters</surname><given-names>M</given-names></name><name><surname>Bryke</surname><given-names>C</given-names></name><name><surname>Avigan</surname><given-names>D</given-names></name><name><surname>Boussiotis</surname><given-names>VA</given-names></name></person-group>. <article-title>Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor</article-title>. <source/>Blood Adv. (<year>2018</year>) <volume>2</volume>:<fpage>1367</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2018015982</pub-id><pub-id pub-id-type="pmid">29898877</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonnafous</surname><given-names>P</given-names></name><name><surname>Marlet</surname><given-names>J</given-names></name><name><surname>Bouvet</surname><given-names>D</given-names></name><name><surname>Salamé</surname><given-names>E</given-names></name><name><surname>Tellier</surname><given-names>AC</given-names></name><name><surname>Guyetant</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Fatal outcome after reactivation of inherited chromosomally integrated HHV-6A (iciHHV-6A) transmitted through liver transplantation</article-title>. <source/>Am J Transplant. (<year>2018</year>) <volume>18</volume>:<fpage>1548</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/ajt.14657</pub-id><pub-id pub-id-type="pmid">29316259</pub-id></mixed-citation>
</ref>
<ref id="B111">
<label>111.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greninger</surname><given-names>AL</given-names></name><name><surname>Roychoudhury</surname><given-names>P</given-names></name><name><surname>Makhsous</surname><given-names>N</given-names></name><name><surname>Hanson</surname><given-names>D</given-names></name><name><surname>Chase</surname><given-names>J</given-names></name><name><surname>Krueger</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Copy number heterogeneity, large origin tandem repeats, and interspecies recombination in human herpesvirus 6A (HHV-6A) and HHV-6B reference strains</article-title>. <source/>J Virol. (<year>2018</year>) <volume>92</volume>:<fpage>e00135-18</fpage>. <pub-id pub-id-type="doi">10.1128/JVI.00135-18</pub-id><pub-id pub-id-type="pmid">29491155</pub-id></mixed-citation>
</ref>
<ref id="B112">
<label>112.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eliassen</surname><given-names>E</given-names></name><name><surname>Krueger</surname><given-names>G</given-names></name><name><surname>Luppi</surname><given-names>M</given-names></name><name><surname>Ablashi</surname><given-names>D</given-names></name></person-group>. <article-title>Lymphoproliferative syndromes associated with human herpesvirus-6A and human herpesvirus-6B</article-title>. <source/>Mediterr J Hematol Infect Dis. (<year>2018</year>) <volume>10</volume>:<fpage>e2018035</fpage>. <pub-id pub-id-type="doi">10.4084/MJHID.2018.035</pub-id><pub-id pub-id-type="pmid">29755712</pub-id></mixed-citation>
</ref>
<ref id="B113">
<label>113.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kashanchi</surname><given-names>F</given-names></name><name><surname>Araujo</surname><given-names>J</given-names></name><name><surname>Doniger</surname><given-names>J</given-names></name><name><surname>Muralidhar</surname><given-names>S</given-names></name><name><surname>Hoch</surname><given-names>R</given-names></name><name><surname>Khleif</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 (HHV-6) ORF-1 transactivating gene exhibits malignant transforming activity and its protein binds to p53</article-title>. <source/>Oncogene (<year>1997</year>) <volume>14</volume>:<fpage>359</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1038/sj.onc.1200840</pub-id><pub-id pub-id-type="pmid">9018122</pub-id></mixed-citation>
</ref>
<ref id="B114">
<label>114.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Sugahara</surname><given-names>K</given-names></name><name><surname>Uemura</surname><given-names>A</given-names></name><name><surname>Akamatsu</surname><given-names>N</given-names></name><name><surname>Hirakata</surname><given-names>Y</given-names></name><name><surname>Murata</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Usefulness of a comprehensive PCR-based assay for human herpes viral DNA in blood mononuclear cell samples</article-title>. <source/>Lab Hematol. (<year>2005</year>) <volume>11</volume>:<fpage>163</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1532/LH96.05027</pub-id><pub-id pub-id-type="pmid">16174601</pub-id></mixed-citation>
</ref>
<ref id="B115">
<label>115.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogdanovic</surname><given-names>G</given-names></name><name><surname>Pou</surname><given-names>C</given-names></name><name><surname>Barrientos-Somarribas</surname><given-names>M</given-names></name><name><surname>Bjerkner</surname><given-names>A</given-names></name><name><surname>Honkaniemi</surname><given-names>E</given-names></name><name><surname>Allander</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Virome characterisation from Guthrie cards in children who later developed acute lymphoblastic leukaemia</article-title>. <source/>Br J Cancer (<year>2016</year>) <volume>115</volume>:<fpage>1008</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/bjc.2016.261</pub-id><pub-id pub-id-type="pmid">27552439</pub-id></mixed-citation>
</ref>
<ref id="B116">
<label>116.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DA</given-names></name><name><surname>Alexander</surname><given-names>FE</given-names></name><name><surname>McKinney</surname><given-names>PA</given-names></name><name><surname>Roberts</surname><given-names>BE</given-names></name><name><surname>O'Brien</surname><given-names>C</given-names></name><name><surname>Jarrett</surname><given-names>RF</given-names></name><etal></etal></person-group>. <article-title>The seroepidemiology of human herpesvirus-6 (HHV-6) from a case-control study of leukaemia and lymphoma</article-title>. <source/>Int J Cancer (<year>1990</year>) <volume>45</volume>:<fpage>829</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">2159435</pub-id></mixed-citation>
</ref>
<ref id="B117">
<label>117.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>PH</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Saxinger</surname><given-names>WC</given-names></name><name><surname>Connelly</surname><given-names>RR</given-names></name></person-group>. <article-title>Antibodies to human herpes virus-6 in patients with acute lymphocytic leukemia</article-title>. <source/>Leukemia (<year>1992</year>) <volume>6</volume>:<fpage>1229</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="pmid">1331626</pub-id></mixed-citation>
</ref>
<ref id="B118">
<label>118.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyall</surname><given-names>EG</given-names></name></person-group>. <article-title>Serological response of paediatric oncology patients to human herpesvirus-6</article-title>. <source/>J Med Virol. (<year>1994</year>) <volume>43</volume>:<fpage>373</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">7964647</pub-id></mixed-citation>
</ref>
<ref id="B119">
<label>119.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlehofer</surname><given-names>B</given-names></name><name><surname>Blettner</surname><given-names>M</given-names></name><name><surname>Geletneky</surname><given-names>K</given-names></name><name><surname>Haaf</surname><given-names>HG</given-names></name><name><surname>Kaatsch</surname><given-names>P</given-names></name><name><surname>Michaelis</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Sero-epidemiological analysis of the risk of virus infections for childhood leukaemia</article-title>. <source/>Int J Cancer (<year>1996</year>) <volume>65</volume>:<fpage>584</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1097-0215(19960301)65:5&lt;584::aid-ijc5&gt;3.0.co;2-z</pub-id><pub-id pub-id-type="pmid">8598307</pub-id></mixed-citation>
</ref>
<ref id="B120">
<label>120.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gentile</surname><given-names>G</given-names></name><name><surname>Mele</surname><given-names>A</given-names></name><name><surname>Ragona</surname><given-names>G</given-names></name><name><surname>Faggioni</surname><given-names>A</given-names></name><name><surname>Zompetta</surname><given-names>C</given-names></name><name><surname>Tosti</surname><given-names>ME</given-names></name><etal></etal></person-group>. <article-title>Human herpes virus-6 seroprevalence and leukaemias: a case-control study</article-title>. GIMEMA (Gruppo Italiano Malattie Ematologiche dell' Adulto)<source/>. Br J Cancer (<year>1999</year>) <volume>80</volume>:<fpage>1103</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/sj.bjc.6690471</pub-id><pub-id pub-id-type="pmid">10362124</pub-id></mixed-citation>
</ref>
<ref id="B121">
<label>121.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salonen</surname><given-names>MJ</given-names></name><name><surname>Siimes</surname><given-names>MA</given-names></name><name><surname>Salonen</surname><given-names>EM</given-names></name><name><surname>Vaheri</surname><given-names>A</given-names></name><name><surname>Koskiniemi</surname><given-names>M</given-names></name></person-group>. <article-title>Antibody status to HHV-6 in children with leukaemia</article-title>. <source/>Leukemia (<year>2002</year>) <volume>16</volume>:<fpage>716</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/sj.leu.2402437</pub-id><pub-id pub-id-type="pmid">11960354</pub-id></mixed-citation>
</ref>
<ref id="B122">
<label>122.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assem</surname><given-names>MM</given-names></name><name><surname>Gad</surname><given-names>WH</given-names></name><name><surname>El-Sharkawy</surname><given-names>NM</given-names></name><name><surname>El-Rouby</surname><given-names>MN</given-names></name><name><surname>Ghaleb</surname><given-names>FM</given-names></name><name><surname>Tarek</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Prevalence of anti human herpes virus-6 IgG and its receptor in acute leukemia (membrane cofactor protein: MCP, CD46)</article-title>. <source/>J Egypt Natl Canc Inst. (<year>2005</year>) <volume>17</volume>:<fpage>29</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="pmid">16353080</pub-id></mixed-citation>
</ref>
<ref id="B123">
<label>123.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steininger</surname><given-names>C</given-names></name><name><surname>Rassenti</surname><given-names>LZ</given-names></name><name><surname>Vanura</surname><given-names>K</given-names></name><name><surname>Eigenberger</surname><given-names>K</given-names></name><name><surname>Jager</surname><given-names>U</given-names></name><name><surname>Kipps</surname><given-names>TJ</given-names></name><etal></etal></person-group>. <article-title>Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia</article-title>. <source/>Eur J Clin Invest. (<year>2009</year>) <volume>39</volume>:<fpage>497</fpage>–<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2362.2009.02131.x</pub-id><pub-id pub-id-type="pmid">19490058</pub-id></mixed-citation>
</ref>
<ref id="B124">
<label>124.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tacyildiz</surname><given-names>N</given-names></name><name><surname>Dincaslan</surname><given-names>HU</given-names></name><name><surname>Ozdemir</surname><given-names>H</given-names></name><name><surname>Yavuz</surname><given-names>G</given-names></name><name><surname>Unal</surname><given-names>E</given-names></name><name><surname>Ikinciogullari</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The seroprevalence of Kaposi's sarcoma associated herpes virus and human herpes virus-6 in pediatric patients with cancer and healthy children in a Turkish pediatric oncology center</article-title>. <source/>Indian J Med Paediatr Oncol. (<year>2014</year>) <volume>35</volume>:<fpage>221</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4103/0971-5851.142039</pub-id><pub-id pub-id-type="pmid">25336794</pub-id></mixed-citation>
</ref>
<ref id="B125">
<label>125.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albright</surname><given-names>AV</given-names></name><name><surname>Lavi</surname><given-names>E</given-names></name><name><surname>Black</surname><given-names>JB</given-names></name><name><surname>Goldberg</surname><given-names>S</given-names></name><name><surname>O'Connor</surname><given-names>MJ</given-names></name><name><surname>Gonzalez-Scarano</surname><given-names>F</given-names></name></person-group>. <article-title>The effect of human herpesvirus-6 (HHV-6) on cultured human neural cells: oligodendrocytes and microglia</article-title>. <source/>J Neurovirol. (<year>1998</year>) <volume>4</volume>:<fpage>486</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="pmid">9839646</pub-id></mixed-citation>
</ref>
<ref id="B126">
<label>126.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahlqvist</surname><given-names>J</given-names></name><name><surname>Fotheringham</surname><given-names>J</given-names></name><name><surname>Akhyani</surname><given-names>N</given-names></name><name><surname>Yao</surname><given-names>K</given-names></name><name><surname>Fogdell-Hahn</surname><given-names>A</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group>. <article-title>Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes</article-title>. <source/>J Neurovirol. (<year>2005</year>) <volume>11</volume>:<fpage>384</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1080/13550280591002379</pub-id><pub-id pub-id-type="pmid">16162481</pub-id></mixed-citation>
</ref>
<ref id="B127">
<label>127.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bolle</surname><given-names>L</given-names></name><name><surname>Van Loon</surname><given-names>J</given-names></name><name><surname>De Clercq</surname><given-names>E</given-names></name><name><surname>Naesens</surname><given-names>L</given-names></name></person-group>. <article-title>Quantitative analysis of human herpesvirus 6 cell tropism</article-title>. <source/>J Med Virol. (<year>2005</year>) <volume>75</volume>:<fpage>76</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.20240</pub-id><pub-id pub-id-type="pmid">15543581</pub-id></mixed-citation>
</ref>
<ref id="B128">
<label>128.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donati</surname><given-names>D</given-names></name><name><surname>Martinelli</surname><given-names>E</given-names></name><name><surname>Cassiani-Ingoni</surname><given-names>R</given-names></name><name><surname>Ahlqvist</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Major</surname><given-names>EO</given-names></name><etal></etal></person-group>. <article-title>Variant-specific tropism of human herpesvirus 6 in human astrocytes</article-title>. <source/>J Virol. (<year>2005</year>) <volume>79</volume>:<fpage>9439</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.15.9439-9448.2005</pub-id><pub-id pub-id-type="pmid">16014907</pub-id></mixed-citation>
</ref>
<ref id="B129">
<label>129.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fotheringham</surname><given-names>J</given-names></name><name><surname>Williams</surname><given-names>EL</given-names></name><name><surname>Akhyani</surname><given-names>N</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group>. <article-title>Human herpesvirus 6 (HHV-6) induces dysregulation of glutamate uptake and transporter expression in astrocytes</article-title>. <source/>J Neuroimmune Pharmacol. (<year>2008</year>) <volume>3</volume>:<fpage>105</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1007/s11481-007-9084-0</pub-id><pub-id pub-id-type="pmid">18247129</pub-id></mixed-citation>
</ref>
<ref id="B130">
<label>130.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynaud</surname><given-names>JM</given-names></name><name><surname>Jegou</surname><given-names>JF</given-names></name><name><surname>Welsch</surname><given-names>JC</given-names></name><name><surname>Horvat</surname><given-names>B</given-names></name></person-group>. <article-title>Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9</article-title>. <source/>J Virol. (<year>2014</year>) <volume>88</volume>:<fpage>5421</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03763-13</pub-id><pub-id pub-id-type="pmid">24574405</pub-id></mixed-citation>
</ref>
<ref id="B131">
<label>131.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skuja</surname><given-names>S</given-names></name><name><surname>Zieda</surname><given-names>A</given-names></name><name><surname>Ravina</surname><given-names>K</given-names></name><name><surname>Chapenko</surname><given-names>S</given-names></name><name><surname>Roga</surname><given-names>S</given-names></name><name><surname>Teteris</surname><given-names>O</given-names></name><etal></etal></person-group>. <article-title>Structural and Ultrastructural Alterations in Human Olfactory Pathways and Possible Associations with Herpesvirus 6 Infection</article-title>. <source/>PLoS ONE (<year>2017</year>) <volume>12</volume>:<fpage>e0170071</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0170071</pub-id><pub-id pub-id-type="pmid">28072884</pub-id></mixed-citation>
</ref>
<ref id="B132">
<label>132.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flamand</surname><given-names>L</given-names></name><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Boutolleau</surname><given-names>D</given-names></name><name><surname>Alvarez-Lafuente</surname><given-names>R</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name><name><surname>Malnati</surname><given-names>MS</given-names></name><etal></etal></person-group>. <article-title>Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum</article-title>. <source/>J Clin Microbiol. (<year>2008</year>) <volume>46</volume>:<fpage>2700</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.00370-08</pub-id><pub-id pub-id-type="pmid">18550745</pub-id></mixed-citation>
</ref>
<ref id="B133">
<label>133.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peri</surname><given-names>P</given-names></name><name><surname>Mattila</surname><given-names>RK</given-names></name><name><surname>Kantola</surname><given-names>H</given-names></name><name><surname>Broberg</surname><given-names>E</given-names></name><name><surname>Karttunen</surname><given-names>HS</given-names></name><name><surname>Waris</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells</article-title>. <source/>Virol J. (<year>2008</year>) <volume>5</volume>:<fpage>140</fpage>. <pub-id pub-id-type="doi">10.1186/1743-422X-5-140</pub-id><pub-id pub-id-type="pmid">19025601</pub-id></mixed-citation>
</ref>
<ref id="B134">
<label>134.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sultanova</surname><given-names>A</given-names></name><name><surname>Chistjakovs</surname><given-names>M</given-names></name><name><surname>Chapenko</surname><given-names>S</given-names></name><name><surname>Donina</surname><given-names>S</given-names></name><name><surname>Murovska</surname><given-names>M</given-names></name></person-group>. <article-title>Possible interference of human beta-herpesviruses-6 and−7 in gastrointestinal cancer development</article-title>. <source/>Exp Oncol. (<year>2013</year>) <volume>35</volume>:<fpage>93</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="pmid">23828382</pub-id></mixed-citation>
</ref>
<ref id="B135">
<label>135.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falasca</surname><given-names>F</given-names></name><name><surname>Maida</surname><given-names>P</given-names></name><name><surname>Gaeta</surname><given-names>A</given-names></name><name><surname>Verzaro</surname><given-names>S</given-names></name><name><surname>Mezzaroma</surname><given-names>I</given-names></name><name><surname>Fantauzzi</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Detection and quantification of EBV, HHV-6 and CMV DNA in the gastrointestinal tract of HIV-positive patients</article-title>. <source/>Infection (<year>2014</year>) <volume>42</volume>:<fpage>1033</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s15010-014-0690-5</pub-id><pub-id pub-id-type="pmid">25326253</pub-id></mixed-citation>
</ref>
<ref id="B136">
<label>136.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halme</surname><given-names>L</given-names></name><name><surname>Arola</surname><given-names>J</given-names></name><name><surname>Höckerstedt</surname><given-names>KH</given-names></name><name><surname>Lautenschlager</surname><given-names>I</given-names></name></person-group>. <article-title>Human Herpesvirus 6 Infection of the Gastroduodenal Mucosa</article-title>. <source/>Clin Infect Dis. (<year>2008</year>) <volume>46</volume>:<fpage>434</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/525264</pub-id><pub-id pub-id-type="pmid">18181741</pub-id></mixed-citation>
</ref>
<ref id="B137">
<label>137.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Revest</surname><given-names>M</given-names></name><name><surname>Minjolle</surname><given-names>S</given-names></name><name><surname>Veyer</surname><given-names>D</given-names></name><name><surname>Lagathu</surname><given-names>GL</given-names></name><name><surname>Michelet</surname><given-names>C</given-names></name><name><surname>Colimon</surname><given-names>R</given-names></name></person-group>. <article-title>Detection of HHV-6 in over a thousand samples: New types of infection revealed by an analysis of positive results</article-title>. <source/>J Clin Virol. (<year>2011</year>) <volume>51</volume>:<fpage>20</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2011.02.001</pub-id><pub-id pub-id-type="pmid">21376662</pub-id></mixed-citation>
</ref>
<ref id="B138">
<label>138.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasui</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Yatsuya</surname><given-names>H</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Clinical course of human herpesvirus 6 infection in pediatric living donor liver transplantation</article-title>. <source/>Pediatr Transplant. (<year>2018</year>) <volume>22</volume>:<fpage>e13239</fpage>. <pub-id pub-id-type="doi">10.1111/petr.13239</pub-id><pub-id pub-id-type="pmid">29862613</pub-id></mixed-citation>
</ref>
<ref id="B139">
<label>139.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niller</surname><given-names>HH</given-names></name><name><surname>Wolf</surname><given-names>H</given-names></name><name><surname>Minarovits</surname><given-names>J</given-names></name></person-group>. <article-title>Viral hit and run-oncogenesis: genetic and epigenetic scenarios</article-title>. <source/>Cancer Lett. (<year>2011</year>) <volume>305</volume>:<fpage>200</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2010.08.007</pub-id><pub-id pub-id-type="pmid">20813452</pub-id></mixed-citation>
</ref>
<ref id="B140">
<label>140.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>JL</given-names></name><name><surname>Stolf</surname><given-names>HO</given-names></name><name><surname>Reis</surname><given-names>NA</given-names></name><name><surname>Ward</surname><given-names>LS</given-names></name></person-group>. <article-title>Human herpesvirus type 6 and type 1 infection increases susceptibility to nonmelanoma skin tumors</article-title>. <source/>Cancer Lett. (<year>2005</year>) <volume>224</volume>:<fpage>213</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2004.11.010</pub-id><pub-id pub-id-type="pmid">15914272</pub-id></mixed-citation>
</ref>
<ref id="B141">
<label>141.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Dubuc</surname><given-names>I</given-names></name><name><surname>Brooks-Wilson</surname><given-names>A</given-names></name><name><surname>Aronson</surname><given-names>KJ</given-names></name><name><surname>Simard</surname><given-names>J</given-names></name><name><surname>Velasquez-Garcia</surname><given-names>HA</given-names></name><etal></etal></person-group>. <article-title>Inherited chromosomally integrated human herpesvirus 6 and breast cancer</article-title>. <source/>Cancer Epidemiol Biomarkers Prev. (<year>2017</year>) <volume>26</volume>:<fpage>425</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1158/1055-9965.EPI-16-0735</pub-id><pub-id pub-id-type="pmid">27777240</pub-id></mixed-citation>
</ref>
<ref id="B142">
<label>142.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iampietro</surname><given-names>M</given-names></name><name><surname>Gravel</surname><given-names>A</given-names></name><name><surname>Flamand</surname><given-names>L</given-names></name></person-group>. <article-title>Inhibition of breast cancer cell proliferation through disturbance of the calcineurin/NFAT pathway by human herpesvirus 6B U54 tegument protein</article-title>. <source/>J Virol. (<year>2014</year>) <volume>88</volume>:<fpage>12910</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02107-14</pub-id><pub-id pub-id-type="pmid">25122795</pub-id></mixed-citation>
</ref>
<ref id="B143">
<label>143.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 activates lytic cycle replication of Kaposi's sarcoma-associated herpesvirus</article-title>. <source/>Am J Pathol. (<year>2005</year>) <volume>166</volume>:<fpage>173</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/S0002-9440(10)62242-0</pub-id><pub-id pub-id-type="pmid">15632010</pub-id></mixed-citation>
</ref>
<ref id="B144">
<label>144.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>BJ</given-names></name><name><surname>Efstathiou</surname><given-names>S</given-names></name><name><surname>Honess</surname><given-names>RW</given-names></name></person-group>. <article-title>Acquisition of the human adeno-associated virus type-2 rep gene by human herpesvirus type-6</article-title>. <source/>Nature (<year>1991</year>) <volume>351</volume>:<fpage>78</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/351078a0</pub-id><pub-id pub-id-type="pmid">1851252</pub-id></mixed-citation>
</ref>
<ref id="B145">
<label>145.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cesarman</surname><given-names>E</given-names></name><name><surname>Knowles</surname><given-names>DM</given-names></name></person-group>. <article-title>The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases</article-title>. <source/>Semin Cancer Biol. (<year>1999</year>) <volume>9</volume>:<fpage>165</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1006/scbi.1998.0118</pub-id><pub-id pub-id-type="pmid">10343068</pub-id></mixed-citation>
</ref>
<ref id="B146">
<label>146.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarid</surname><given-names>R</given-names></name><name><surname>Olsen</surname><given-names>SJ</given-names></name><name><surname>Moore</surname><given-names>PS</given-names></name></person-group>. <article-title>Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology</article-title>. <source/>Adv Virus Res. (<year>1999</year>) <volume>52</volume>:<fpage>139</fpage>–<lpage>232</lpage>. <pub-id pub-id-type="pmid">10384236</pub-id></mixed-citation>
</ref>
<ref id="B147">
<label>147.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassig</surname><given-names>BA</given-names></name><name><surname>Willhauck-Fleckenstein</surname><given-names>M</given-names></name><name><surname>Shu</surname><given-names>XO</given-names></name><name><surname>Koh</surname><given-names>WP</given-names></name><name><surname>Gao</surname><given-names>YT</given-names></name><name><surname>Purdue</surname><given-names>MP</given-names></name><etal></etal></person-group>. <article-title>Serologic markers of viral infection and risk of non-Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore</article-title>. <source/>Int J Cancer (<year>2018</year>). <pub-id pub-id-type="doi">10.1002/ijc.31385</pub-id><pub-id pub-id-type="pmid">29574937</pub-id></mixed-citation>
</ref>
<ref id="B148">
<label>148.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomez-Roman</surname><given-names>JJ</given-names></name><name><surname>Martinez</surname><given-names>MN</given-names></name><name><surname>Fernandez</surname><given-names>SL</given-names></name><name><surname>Val-Bernal</surname><given-names>JF</given-names></name></person-group>. <article-title>Epstein-Barr virus-associated adenocarcinomas and squamous-cell lung carcinomas</article-title>. <source/>Mod Pathol. (<year>2009</year>) <volume>22</volume>:<fpage>530</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2009.7</pub-id><pub-id pub-id-type="pmid">19252476</pub-id></mixed-citation>
</ref>
<ref id="B149">
<label>149.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Popescu</surname><given-names>N</given-names></name><name><surname>Woodworth</surname><given-names>C</given-names></name><name><surname>Berneman</surname><given-names>Z</given-names></name><name><surname>Corbellino</surname><given-names>M</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 infects cervical epithelial cells and transactivates human papillomavirus gene expression</article-title>. <source/>J Virol. (<year>1994</year>) <volume>68</volume>:<fpage>1173</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">8289346</pub-id></mixed-citation>
</ref>
<ref id="B150">
<label>150.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garzino-Demo</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name><name><surname>Berneman</surname><given-names>Z</given-names></name><name><surname>DiPaolo</surname><given-names>JA</given-names></name></person-group>. <article-title>Enhancement of TAT-induced transactivation of the HIV-1 LTR by two genomic fragments of HHV-6</article-title>. <source/>J Med Virol. (<year>1996</year>) <volume>50</volume>:<fpage>20</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/(SICI)1096-9071(199609)50:1&lt;20::AID-JMV5&gt;3.0.CO;2-V</pub-id><pub-id pub-id-type="pmid">8890036</pub-id></mixed-citation>
</ref>
<ref id="B151">
<label>151.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marci</surname><given-names>R</given-names></name><name><surname>Gentili</surname><given-names>V</given-names></name><name><surname>Bortolotti</surname><given-names>D</given-names></name><name><surname>Lo Monte</surname><given-names>G</given-names></name><name><surname>Caselli</surname><given-names>E</given-names></name><name><surname>Bolzani</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Presence of HHV-6A in endometrial epithelial cells from women with primary unexplained infertility</article-title>. <source/>PLoS ONE (<year>2016</year>) <volume>11</volume>:<fpage>e0158304</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0158304</pub-id><pub-id pub-id-type="pmid">27367597</pub-id></mixed-citation>
</ref>
<ref id="B152">
<label>152.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>T</given-names></name><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Terashima</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Outcomes of infants whose mothers are positive for human herpesvirus-6 DNA within the genital tract in early gestation</article-title>. <source/>Acta Paediatr Jpn. (<year>1997</year>) <volume>39</volume>:<fpage>653</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">9447752</pub-id></mixed-citation>
</ref>
<ref id="B153">
<label>153.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neofytou</surname><given-names>E</given-names></name><name><surname>Sourvinos</surname><given-names>G</given-names></name><name><surname>Asmarianaki</surname><given-names>M</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name><name><surname>Makrigiannakis</surname><given-names>A</given-names></name></person-group>. <article-title>Prevalence of human herpes virus types 1-7 in the semen of men attending an infertility clinic and correlation with semen parameters</article-title>. <source/>Fertil Steril. (<year>2009</year>) <volume>91</volume>:<fpage>2487</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.fertnstert.2008.03.074</pub-id><pub-id pub-id-type="pmid">18565516</pub-id></mixed-citation>
</ref>
<ref id="B154">
<label>154.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escudero</surname><given-names>AL</given-names></name><name><surname>Luque</surname><given-names>RJ</given-names></name><name><surname>Quintero</surname><given-names>A</given-names></name><name><surname>Alvarez-Kindelan</surname><given-names>J</given-names></name><name><surname>Requena</surname><given-names>MJ</given-names></name><name><surname>Montironi</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Association of human herpesvirus type 6 DNA with human bladder cancer</article-title>. <source/>Cancer Lett. (<year>2005</year>) <volume>230</volume>:<fpage>20</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2004.12.014</pub-id><pub-id pub-id-type="pmid">16253757</pub-id></mixed-citation>
</ref>
<ref id="B155">
<label>155.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panagiotakis</surname><given-names>GI</given-names></name><name><surname>Papadogianni</surname><given-names>D</given-names></name><name><surname>Chatziioannou</surname><given-names>MN</given-names></name><name><surname>Lasithiotaki</surname><given-names>I</given-names></name><name><surname>Delakas</surname><given-names>D</given-names></name><name><surname>Spandidos</surname><given-names>DA</given-names></name></person-group>. <article-title>Association of human herpes, papilloma and polyoma virus families with bladder cancer</article-title>. <source/>Tumour Biol. (<year>2013</year>) <volume>34</volume>:<fpage>71</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-012-0512-2</pub-id><pub-id pub-id-type="pmid">22972505</pub-id></mixed-citation>
</ref>
<ref id="B156">
<label>156.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>EM</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Easton</surname><given-names>J</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Pounds</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Genomic landscape of paediatric adrenocortical tumours</article-title>. <source/>Nat Commun. (<year>2015</year>) <volume>6</volume>:<fpage>6302</fpage>. <pub-id pub-id-type="doi">10.1038/ncomms7302</pub-id><pub-id pub-id-type="pmid">25743702</pub-id></mixed-citation>
</ref>
<ref id="B157">
<label>157.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letouze</surname><given-names>E</given-names></name><name><surname>Rosati</surname><given-names>R</given-names></name><name><surname>Komechen</surname><given-names>H</given-names></name><name><surname>Doghman</surname><given-names>M</given-names></name><name><surname>Marisa</surname><given-names>L</given-names></name><name><surname>Fluck</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>SNP array profiling of childhood adrenocortical tumors reveals distinct pathways of tumorigenesis and highlights candidate driver genes</article-title>. <source/>J Clin Endocrinol Metab. (<year>2012</year>) <volume>97</volume>:<fpage>E1284</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2012-1184</pub-id><pub-id pub-id-type="pmid">22539591</pub-id></mixed-citation>
</ref>
<ref id="B158">
<label>158.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovannoni</surname><given-names>I</given-names></name><name><surname>Boldrini</surname><given-names>R</given-names></name><name><surname>Benedetti</surname><given-names>MC</given-names></name><name><surname>Inserra</surname><given-names>A</given-names></name><name><surname>De Pasquale</surname><given-names>MD</given-names></name><name><surname>Francalanci</surname><given-names>P</given-names></name></person-group>. <article-title>Pediatric adrenocortical neoplasms: immunohistochemical expression of p57 identifies loss of heterozygosity and abnormal imprinting of the 11p15</article-title>.5. <source/>Pediatr Res. (<year>2017</year>) <volume>81</volume>:<fpage>468</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1038/pr.2016.239</pub-id><pub-id pub-id-type="pmid">27842055</pub-id></mixed-citation>
</ref>
<ref id="B159">
<label>159.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tweedy</surname><given-names>J</given-names></name><name><surname>Spyrou</surname><given-names>MA</given-names></name><name><surname>Pearson</surname><given-names>M</given-names></name><name><surname>Lassner</surname><given-names>D</given-names></name><name><surname>Kuhl</surname><given-names>U</given-names></name><name><surname>Gompels</surname><given-names>UA</given-names></name></person-group>. <article-title>Complete genome sequence of germline chromosomally integrated human herpesvirus 6A and analyses integration sites define a new human endogenous virus with potential to reactivate as an emerging infection</article-title>. <source/>Viruses (<year>2016</year>) <volume>8</volume>:<fpage>E19</fpage>. <pub-id pub-id-type="doi">10.3390/v8010019</pub-id><pub-id pub-id-type="pmid">26784220</pub-id></mixed-citation>
</ref>
<ref id="B160">
<label>160.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engdahl</surname><given-names>E</given-names></name><name><surname>Dunn</surname><given-names>N</given-names></name><name><surname>Niehusmann</surname><given-names>P</given-names></name><name><surname>Wideman</surname><given-names>S</given-names></name><name><surname>Wipfler</surname><given-names>P</given-names></name><name><surname>Becker</surname><given-names>AJ</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6B induces hypomethylation on chromosome 17p13</article-title>.3, correlating with increased gene expression and virus integration. <source/>J Virol. (<year>2017</year>) <volume>91</volume>:<fpage>e02105-16</fpage>. <pub-id pub-id-type="doi">10.1128/JVI.02105-16</pub-id><pub-id pub-id-type="pmid">28298607</pub-id></mixed-citation>
</ref>
<ref id="B161">
<label>161.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Razzaque</surname><given-names>A</given-names></name></person-group>. <article-title>Oncogenic potential of human herpesvirus-6 DNA</article-title>. <source/>Oncogene (<year>1990</year>) <volume>5</volume>:<fpage>1365</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="pmid">2170897</pub-id></mixed-citation>
</ref>
<ref id="B162">
<label>162.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemoto</surname><given-names>M</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Yonemoto</surname><given-names>S</given-names></name><name><surname>Sasamoto</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus 6 open reading frame U14 protein and cellular p53 interact with each other and are contained in the virion</article-title>. <source/>J Virol (<year>2005</year>) <volume>79</volume>:<fpage>13037</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.20.13037-13046.2005</pub-id><pub-id pub-id-type="pmid">16189006</pub-id></mixed-citation>
</ref>
<ref id="B163">
<label>163.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemoto</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Kondo</surname><given-names>K</given-names></name><name><surname>Yamanishi</surname><given-names>K</given-names></name></person-group>. <article-title>Productive human herpesvirus 6 infection causes aberrant accumulation of p53 and prevents apoptosis</article-title>. <source/>J Gen Virol. (<year>2004</year>) <volume>85</volume>(<issue>Pt 4</issue>), <fpage>869</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1099/vir.0.19626-0</pub-id><pub-id pub-id-type="pmid">15039530</pub-id></mixed-citation>
</ref>
<ref id="B164">
<label>164.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>WR</given-names></name><name><surname>Creagh</surname><given-names>AL</given-names></name><name><surname>Haynes</surname><given-names>CA</given-names></name><name><surname>Straus</surname><given-names>SK</given-names></name></person-group>. <article-title>U24 from Roseolovirus interacts strongly with Nedd4 WW domains</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>39776</fpage>. <pub-id pub-id-type="doi">10.1038/srep39776</pub-id><pub-id pub-id-type="pmid">28051106</pub-id></mixed-citation>
</ref>
<ref id="B165">
<label>165.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name></person-group>. <article-title>Down-regulation of Nedd4L is associated with the aggressive progression and worse prognosis of malignant glioma</article-title>. <source/>Jpn J Clin Oncol. (<year>2012</year>) <volume>42</volume>:<fpage>196</fpage>–<lpage>201</lpage>. <pub-id pub-id-type="doi">10.1093/jjco/hyr195</pub-id><pub-id pub-id-type="pmid">22217575</pub-id></mixed-citation>
</ref>
<ref id="B166">
<label>166.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Nie</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>NEDD4-1 regulates migration and invasion of glioma cells through CNrasGEF ubiquitination <italic>in vitro</italic></article-title>. <source/>PLoS ONE (<year>2013</year>) <volume>8</volume>:<fpage>e82789</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0082789</pub-id><pub-id pub-id-type="pmid">24340059</pub-id></mixed-citation>
</ref>
<ref id="B167">
<label>167.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>B</given-names></name><name><surname>Pieper</surname><given-names>RO</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Wei</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Woo</surname><given-names>SY</given-names></name><etal></etal></person-group>. <article-title>FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes</article-title>. <source/>Cancer Res. (<year>2010</year>) <volume>70</volume>:<fpage>2951</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-3909</pub-id><pub-id pub-id-type="pmid">20332230</pub-id></mixed-citation>
</ref>
<ref id="B168">
<label>168.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>WM</given-names></name><name><surname>Isegawa</surname><given-names>Y</given-names></name><name><surname>Chow</surname><given-names>VT</given-names></name></person-group>. <article-title>The U95 protein of human herpesvirus 6B interacts with human GRIM-19: silencing of U95 expression reduces viral load and abrogates loss of mitochondrial membrane potential</article-title>. <source/>J Virol. (<year>2008</year>) <volume>82</volume>:<fpage>1011</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01156-07</pub-id><pub-id pub-id-type="pmid">17928352</pub-id></mixed-citation>
</ref>
<ref id="B169">
<label>169.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalvakolanu</surname><given-names>DV</given-names></name><name><surname>Nallar</surname><given-names>SC</given-names></name><name><surname>Kalakonda</surname><given-names>S</given-names></name></person-group>. <article-title><italic>Cytokine</italic>-induced tumor suppressors: a GRIM story</article-title>. <source/>Cytokine (<year>2010</year>) <volume>52</volume>:<fpage>128</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2010.03.009</pub-id><pub-id pub-id-type="pmid">20382543</pub-id></mixed-citation>
</ref>
<ref id="B170">
<label>170.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takemoto</surname><given-names>M</given-names></name><name><surname>Shimamoto</surname><given-names>T</given-names></name><name><surname>Isegawa</surname><given-names>Y</given-names></name><name><surname>Yamanishi</surname><given-names>K</given-names></name></person-group>. <article-title>The R3 region, one of three major repetitive regions of human herpesvirus 6, is a strong enhancer of immediate-early gene U95</article-title>. <source/>J Virol. (<year>2001</year>) <volume>75</volume>:<fpage>10149</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.75.21.10149-10160.2001</pub-id><pub-id pub-id-type="pmid">11581383</pub-id></mixed-citation>
</ref>
<ref id="B171">
<label>171.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ojima</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Ohyashiki</surname><given-names>JH</given-names></name><name><surname>Shirakata</surname><given-names>M</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name></person-group>. <article-title>IL-2-regulated persistent human herpesvirus-6B infection facilitates growth of adult T cell leukemia cells</article-title>. <source/>J Med Dent Sci. (<year>2005</year>) <volume>52</volume>:<fpage>135</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.11480/jmds.520206</pub-id><pub-id pub-id-type="pmid">16187619</pub-id></mixed-citation>
</ref>
<ref id="B172">
<label>172.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusso</surname><given-names>P</given-names></name></person-group>. <article-title>HHV-6 and the immune system: mechanisms of immunomodulation and viral escape</article-title>. <source/>J Clin Virol. (<year>2006</year>) <volume>37</volume>(<issue>Suppl. 1</issue>):<fpage>S4</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/S1386-6532(06)70004-X</pub-id><pub-id pub-id-type="pmid">17276368</pub-id></mixed-citation>
</ref>
<ref id="B173">
<label>173.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caccuri</surname><given-names>F</given-names></name><name><surname>Ronca</surname><given-names>R</given-names></name><name><surname>Laimbacher</surname><given-names>AS</given-names></name><name><surname>Berenzi</surname><given-names>A</given-names></name><name><surname>Steimberg</surname><given-names>N</given-names></name><name><surname>Campilongo</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis</article-title>. <source/>Oncotarget (<year>2017</year>) <volume>8</volume>:<fpage>44533</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.17817</pub-id><pub-id pub-id-type="pmid">28562350</pub-id></mixed-citation>
</ref>
<ref id="B174">
<label>174.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caruso</surname><given-names>A</given-names></name><name><surname>Caselli</surname><given-names>E</given-names></name><name><surname>Fiorentini</surname><given-names>S</given-names></name><name><surname>Rotola</surname><given-names>A</given-names></name><name><surname>Prandini</surname><given-names>A</given-names></name><name><surname>Garrafa</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>U94 of human herpesvirus 6 inhibits <italic>in vitro</italic> angiogenesis and lymphangiogenesis</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2009</year>) <volume>106</volume>:<fpage>20446</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0905535106</pub-id><pub-id pub-id-type="pmid">19918067</pub-id></mixed-citation>
</ref>
<ref id="B175">
<label>175.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>A</given-names></name><name><surname>Hogestyn</surname><given-names>JM</given-names></name><name><surname>Folts</surname><given-names>CJ</given-names></name><name><surname>Lopez</surname><given-names>B</given-names></name><name><surname>Proschel</surname><given-names>C</given-names></name><name><surname>Mock</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Expression of the human herpesvirus 6A latency-associated transcript U94A disrupts human oligodendrocyte progenitor migration</article-title>. <source/>Sci Rep. (<year>2017</year>) <volume>7</volume>:<fpage>3978</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-04432-y</pub-id><pub-id pub-id-type="pmid">28638124</pub-id></mixed-citation>
</ref>
<ref id="B176">
<label>176.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoro</surname><given-names>F</given-names></name><name><surname>Kennedy</surname><given-names>PE</given-names></name><name><surname>Locatelli</surname><given-names>G</given-names></name><name><surname>Malnati</surname><given-names>MS</given-names></name><name><surname>Berger</surname><given-names>EA</given-names></name><name><surname>Lusso</surname><given-names>P</given-names></name></person-group>. <article-title>CD46 is a cellular receptor for human herpesvirus 6</article-title>. <source/>Cell (<year>1999</year>) <volume>99</volume>:<fpage>817</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="pmid">10619434</pub-id></mixed-citation>
</ref>
<ref id="B177">
<label>177.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutzen</surname><given-names>B</given-names></name><name><surname>Bid</surname><given-names>HK</given-names></name><name><surname>Houghton</surname><given-names>PJ</given-names></name><name><surname>Pierson</surname><given-names>CR</given-names></name><name><surname>Powell</surname><given-names>K</given-names></name><name><surname>Bratasz</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin</article-title>. <source/>BMC Cancer (<year>2014</year>) <volume>14</volume>:<fpage>206</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2407-14-206</pub-id><pub-id pub-id-type="pmid">24646176</pub-id></mixed-citation>
</ref>
<ref id="B178">
<label>178.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Serada</surname><given-names>S</given-names></name><name><surname>Kawabata</surname><given-names>A</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Hayash</surname><given-names>E</given-names></name><name><surname>Naka</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>CD134 is a cellular receptor specific for human herpesvirus-6B entry</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2013</year>) <volume>110</volume>:<fpage>9096</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1305187110</pub-id><pub-id pub-id-type="pmid">23674671</pub-id></mixed-citation>
</ref>
<ref id="B179">
<label>179.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>AS</given-names></name><name><surname>Bundgaard</surname><given-names>BB</given-names></name><name><surname>Biltoft</surname><given-names>M</given-names></name><name><surname>Rossen</surname><given-names>LS</given-names></name><name><surname>Hollsberg</surname><given-names>P</given-names></name></person-group>. <article-title>Divergent tropism of HHV-6AGS and HHV-6BPL1 in T cells expressing different CD46 isoform patterns</article-title>. <source/>Virology (<year>2017</year>) <volume>502</volume>:<fpage>160</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2016.12.027</pub-id><pub-id pub-id-type="pmid">28056415</pub-id></mixed-citation>
</ref>
<ref id="B180">
<label>180.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>S</given-names></name><name><surname>Toellner</surname><given-names>KM</given-names></name><name><surname>Raykundalia</surname><given-names>C</given-names></name><name><surname>Goodall</surname><given-names>M</given-names></name><name><surname>Lane</surname><given-names>P</given-names></name></person-group>. <article-title>CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1</article-title>. <source/>J Exp Med. (<year>1998</year>) <volume>188</volume>:<fpage>297</fpage>–<lpage>304</lpage>. <pub-id pub-id-type="pmid">9670042</pub-id></mixed-citation>
</ref>
<ref id="B181">
<label>181.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>T</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Sugie</surname><given-names>K</given-names></name><name><surname>Altman</surname><given-names>A</given-names></name><name><surname>Croft</surname><given-names>M</given-names></name></person-group>. <article-title>Signals from OX40 regulate nuclear factor of activated T cells c1 and T cell helper 2 lineage commitment</article-title>. <source/>Proc Natl Acad Sci USA. (<year>2006</year>) <volume>103</volume>:<fpage>3740</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0600205103</pub-id><pub-id pub-id-type="pmid">16501042</pub-id></mixed-citation>
</ref>
<ref id="B182">
<label>182.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piedade</surname><given-names>D</given-names></name><name><surname>Azevedo-Pereira</surname><given-names>JM</given-names></name></person-group>. <article-title>The role of microRNAs in the pathogenesis of herpesvirus infection</article-title>. <source/>Viruses (<year>2016</year>) <volume>8</volume>:<fpage>E156</fpage>. <pub-id pub-id-type="doi">10.3390/v8060156</pub-id><pub-id pub-id-type="pmid">27271654</pub-id></mixed-citation>
</ref>
<ref id="B183">
<label>183.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nukui</surname><given-names>M</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Murphy</surname><given-names>EA</given-names></name></person-group>. <article-title>A human herpesvirus 6A-encoded microRNA: role in viral lytic replication</article-title>. <source/>J Virol. (<year>2015</year>) <volume>89</volume>:<fpage>2615</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02007-14</pub-id><pub-id pub-id-type="pmid">25520507</pub-id></mixed-citation>
</ref>
<ref id="B184">
<label>184.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caselli</surname><given-names>E</given-names></name><name><surname>D'Accolti</surname><given-names>M</given-names></name><name><surname>Soffritti</surname><given-names>I</given-names></name><name><surname>Zatelli</surname><given-names>MC</given-names></name><name><surname>Rossi</surname><given-names>R</given-names></name><name><surname>Degli Uberti</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>HHV-6A <italic>in vitro</italic> infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis</article-title>. <source/>Virol J. (<year>2017</year>) <volume>14</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-016-0672-6</pub-id><pub-id pub-id-type="pmid">28081700</pub-id></mixed-citation>
</ref>
<ref id="B185">
<label>185.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butz</surname><given-names>H</given-names></name><name><surname>Liko</surname><given-names>I</given-names></name><name><surname>Czirjak</surname><given-names>S</given-names></name><name><surname>Igaz</surname><given-names>P</given-names></name><name><surname>Korbonits</surname><given-names>M</given-names></name><name><surname>Racz</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>MicroRNA profile indicates downregulation of the TGFbeta pathway in sporadic non-functioning pituitary adenomas</article-title>. <source/>Pituitary (<year>2011</year>) <volume>14</volume>:<fpage>112</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/s11102-010-0268-x</pub-id><pub-id pub-id-type="pmid">21063788</pub-id></mixed-citation>
</ref>
<ref id="B186">
<label>186.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuddenham</surname><given-names>L</given-names></name><name><surname>Jung</surname><given-names>JS</given-names></name><name><surname>Chane-Woon-Ming</surname><given-names>B</given-names></name><name><surname>Dolken</surname><given-names>L</given-names></name><name><surname>Pfeffer</surname><given-names>S</given-names></name></person-group>. <article-title>Small RNA deep sequencing identifies microRNAs and other small noncoding RNAs from human herpesvirus 6B</article-title>. <source/>J Virol. (<year>2012</year>) <volume>86</volume>:<fpage>1638</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.05911-11</pub-id><pub-id pub-id-type="pmid">22114334</pub-id></mixed-citation>
</ref>
<ref id="B187">
<label>187.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Serada</surname><given-names>S</given-names></name><name><surname>Naka</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name></person-group>. <article-title>MHC class I molecules are incorporated into human herpesvirus-6 viral particles and released into the extracellular environment</article-title>. <source/>Microbiol Immunol. (<year>2014</year>) <volume>58</volume>:<fpage>119</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12121</pub-id><pub-id pub-id-type="pmid">24330265</pub-id></mixed-citation>
</ref>
<ref id="B188">
<label>188.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bubeník</surname><given-names>J</given-names></name></person-group>. <article-title>MHC class I down-regulation: tumour escape from immune surveillance?</article-title>. <source/>Int J Oncol. (<year>2004</year>) <volume>25</volume>:<fpage>487</fpage>–<lpage>491</lpage>. <pub-id pub-id-type="doi">10.3892/ijo.25.2.487</pub-id><pub-id pub-id-type="pmid">15254748</pub-id></mixed-citation>
</ref>
<ref id="B189">
<label>189.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Moriishi</surname><given-names>E</given-names></name><name><surname>Kawabata</surname><given-names>A</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Oyaizu</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Human herpesvirus-6 induces MVB formation, and virus egress occurs by an exosomal release pathway</article-title>. <source/>Traffic (<year>2008</year>) <volume>9</volume>:<fpage>1728</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2008.00796.x</pub-id><pub-id pub-id-type="pmid">18637904</pub-id></mixed-citation>
</ref>
<ref id="B190">
<label>190.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maas</surname><given-names>SLN</given-names></name><name><surname>Breakefield</surname><given-names>XO</given-names></name><name><surname>Weaver</surname><given-names>AM</given-names></name></person-group>. <article-title>Extracellular vesicles: unique intercellular delivery vehicles</article-title>. <source/>Trends Cell Biol. (<year>2017</year>) <volume>27</volume>:<fpage>172</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2016.11.003</pub-id><pub-id pub-id-type="pmid">27979573</pub-id></mixed-citation>
</ref>
<ref id="B191">
<label>191.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>MR</given-names></name><name><surname>Kashanchi</surname><given-names>F</given-names></name><name><surname>Jacobson</surname><given-names>S</given-names></name></person-group>. <article-title>Exosomes in viral disease</article-title>. <source/>Neurotherapeutics (<year>2016</year>) <volume>13</volume>:<fpage>535</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1007/s13311-016-0450-6</pub-id><pub-id pub-id-type="pmid">27324390</pub-id></mixed-citation>
</ref>
<ref id="B192">
<label>192.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathupala</surname><given-names>SP</given-names></name><name><surname>Rempel</surname><given-names>A</given-names></name><name><surname>Pedersen</surname><given-names>PL</given-names></name></person-group>. <article-title>Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase</article-title>. <source/>J Bioenerg Biomembr. (<year>1997</year>) <volume>29</volume>:<fpage>339</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="pmid">9387094</pub-id></mixed-citation>
</ref>
<ref id="B193">
<label>193.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumari</surname><given-names>N</given-names></name><name><surname>Dwarakanath</surname><given-names>BS</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Bhatt</surname><given-names>AN</given-names></name></person-group>. <article-title>Role of interleukin-6 in cancer progression and therapeutic resistance</article-title>. <source/>Tumour Biol. (<year>2016</year>) <volume>37</volume>:<fpage>11553</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-016-5098-7</pub-id><pub-id pub-id-type="pmid">27260630</pub-id></mixed-citation>
</ref>
<ref id="B194">
<label>194.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inazawa</surname><given-names>N</given-names></name><name><surname>Hori</surname><given-names>T</given-names></name><name><surname>Hatakeyama</surname><given-names>N</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Yoto</surname><given-names>Y</given-names></name><name><surname>Nojima</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Large-scale multiplex polymerase chain reaction assay for diagnosis of viral reactivations after allogeneic hematopoietic stem cell transplantation</article-title>. <source/>J Med Virol. (<year>2015</year>) <volume>87</volume>:<fpage>1427</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.24161</pub-id><pub-id pub-id-type="pmid">25946433</pub-id></mixed-citation>
</ref>
<ref id="B195">
<label>195.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Koning</surname><given-names>C</given-names></name><name><surname>Admiraal</surname><given-names>R</given-names></name><name><surname>Nierkens</surname><given-names>S</given-names></name><name><surname>Boelens</surname><given-names>JJ</given-names></name></person-group>. <article-title>Human herpesvirus 6 viremia affects T-cell reconstitution after allogeneic hematopoietic stem cell transplantation</article-title>. <source/>Blood Adv. (<year>2018</year>) <volume>2</volume>:<fpage>428</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1182/bloodadvances.2017012724</pub-id><pub-id pub-id-type="pmid">29487057</pub-id></mixed-citation>
</ref>
<ref id="B196">
<label>196.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TL</given-names></name><name><surname>Carlin</surname><given-names>K</given-names></name><name><surname>Ljungman</surname><given-names>P</given-names></name><name><surname>Politikos</surname><given-names>I</given-names></name><name><surname>Boussiotis</surname><given-names>V</given-names></name><name><surname>Boeckh</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Human herpesvirus-6B (HHV-6B) reactivation is a risk factor for grade 2-4 acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation (HCT): a systematic review and meta-analysis</article-title>. <source/>Biol Blood Marrow Transplant. (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.bbmt.2018.04.021</pub-id>. [Epub ahead of print].</mixed-citation>
</ref>
<ref id="B197">
<label>197.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phan</surname><given-names>TL</given-names></name><name><surname>Pritchett</surname><given-names>JC</given-names></name><name><surname>Leifer</surname><given-names>C</given-names></name><name><surname>Zerr</surname><given-names>DM</given-names></name><name><surname>Koelle</surname><given-names>DM</given-names></name><name><surname>Di Luca</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>HHV-6B infection, T-cell reconstitution, and graft-vs-host disease after hematopoietic stem cell transplantation</article-title>. <source/>Bone Marrow Transplant. (<year>2018</year>). <pub-id pub-id-type="doi">10.1038/s41409-018-0225-2</pub-id><pub-id pub-id-type="pmid">29795424</pub-id></mixed-citation>
</ref>
<ref id="B198">
<label>198.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Josephs</surname><given-names>SF</given-names></name></person-group>. <article-title>Diagnosis and differential diagnosis of progressive lymphoproliferation and malignant lymphoma in persistent active herpesvirus infection</article-title>. <source/>J Virol Methods (<year>1988</year>) <volume>21</volume>:<fpage>255</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="pmid">2846616</pub-id></mixed-citation>
</ref>
<ref id="B199">
<label>199.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Manak</surname><given-names>M</given-names></name><name><surname>Bourgeois</surname><given-names>N</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Josephs</surname><given-names>SS</given-names></name><etal></etal></person-group>. <article-title>Persistent active herpes virus infection associated with atypical polyclonal lymphoproliferation (APL) and malignant lymphoma</article-title>. <source/>Anticancer Res. (<year>1989</year>) <volume>9</volume>:<fpage>1457</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="pmid">2560617</pub-id></mixed-citation>
</ref>
<ref id="B200">
<label>200.</label>
<mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Brandt</surname><given-names>ME</given-names></name><name><surname>Krueger</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name></person-group> (Eds.). <source/>A Biodynamical Model of Human T-Cell Development and Pathology: Design, Testing and Validation. <publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name> (<year>2008</year>).</mixed-citation>
</ref>
<ref id="B201">
<label>201.</label>
<mixed-citation publication-type="book"><person-group person-group-type="editor"><name><surname>Krueger</surname><given-names>GRF</given-names></name><name><surname>Buja</surname><given-names>L</given-names></name></person-group> (Eds.). <source/>Abnormal Variation of the Immune Response as Related to Cancer. <publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name> (<year>2008</year>).</mixed-citation>
</ref>
<ref id="B202">
<label>202.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flamand</surname><given-names>L</given-names></name><name><surname>Menezes</surname><given-names>J</given-names></name></person-group>. <article-title>Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6</article-title>. <source/>J Virol. (<year>1996</year>) <volume>70</volume>:<fpage>1784</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="pmid">8627701</pub-id></mixed-citation>
</ref>
<ref id="B203">
<label>203.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuomo</surname><given-names>L</given-names></name><name><surname>Angeloni</surname><given-names>A</given-names></name><name><surname>Zompetta</surname><given-names>C</given-names></name><name><surname>Cirone</surname><given-names>M</given-names></name><name><surname>Calogero</surname><given-names>A</given-names></name><name><surname>Frati</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Human herpesvirus 6 variant A, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism</article-title>. <source/>AIDS Res Hum Retroviruses (<year>1995</year>) <volume>11</volume>:<fpage>1241</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1089/aid.1995.11.1241</pub-id><pub-id pub-id-type="pmid">8573381</pub-id></mixed-citation>
</ref>
<ref id="B204">
<label>204.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuomo</surname><given-names>L</given-names></name><name><surname>Trivedi</surname><given-names>P</given-names></name><name><surname>de Grazia</surname><given-names>U</given-names></name><name><surname>Calogero</surname><given-names>A</given-names></name><name><surname>D'Onofrio</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Upregulation of Epstein-Barr virus-encoded latent membrane protein by human herpesvirus 6 superinfection of EBV-carrying Burkitt lymphoma cells</article-title>. <source/>J Med Virol. (<year>1998</year>) <volume>55</volume>:<fpage>219</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="pmid">9624610</pub-id></mixed-citation>
</ref>
<ref id="B205">
<label>205.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusso</surname><given-names>P</given-names></name><name><surname>Ensoli</surname><given-names>B</given-names></name><name><surname>Markham</surname><given-names>PD</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name><name><surname>Salahuddin</surname><given-names>SZ</given-names></name><name><surname>Tschachler</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Productive dual infection of human CD4<sup>+</sup> T lymphocytes by HIV-1 and HHV-6</article-title>. <source/>Nature (<year>1989</year>) <volume>337</volume>:<fpage>370</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/337370a0</pub-id><pub-id pub-id-type="pmid">2463490</pub-id></mixed-citation>
</ref>
<ref id="B206">
<label>206.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ongradi</surname><given-names>J</given-names></name><name><surname>Kovesdi</surname><given-names>V</given-names></name><name><surname>Nagy</surname><given-names>K</given-names></name><name><surname>Matteoli</surname><given-names>B</given-names></name><name><surname>Ceccherini-Nelli</surname><given-names>L</given-names></name><name><surname>Ablashi</surname><given-names>DV</given-names></name></person-group>
<source/>In vitro and in vivo Transactivation of HIV by HHV-6.
<publisher-loc>Vienna</publisher-loc>: <publisher-name>InTech</publisher-name> (<year>2011</year>).</mixed-citation>
</ref>
<ref id="B207">
<label>207.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ongradi</surname><given-names>J</given-names></name><name><surname>Ceccherini-Nelli</surname><given-names>L</given-names></name><name><surname>Soldaini</surname><given-names>E</given-names></name><name><surname>Bendinelli</surname><given-names>M</given-names></name></person-group>
<source/>Endotoxin Suppresses Indirect Activation of HIV-1 by Human Herpesvirus 6.
<publisher-loc>Amsterdam</publisher-loc>: <publisher-name>Elsevier Science Publishers, B.V.</publisher-name> (<year>1990</year>).</mixed-citation>
</ref>
<ref id="B208">
<label>208.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>AK</given-names></name><name><surname>Luka</surname><given-names>J</given-names></name><name><surname>Ablashi</surname><given-names>D</given-names></name><name><surname>Huber</surname><given-names>BT</given-names></name></person-group>. <article-title>HHV-6A infection induces expression of HERV-K18-encoded superantigen</article-title>. <source/>J Clin Virol. (<year>2009</year>) <volume>46</volume>:<fpage>47</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2009.05.019</pub-id><pub-id pub-id-type="pmid">19505843</pub-id></mixed-citation>
</ref>
<ref id="B209">
<label>209.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turcanova</surname><given-names>VL</given-names></name><name><surname>Bundgaard</surname><given-names>B</given-names></name><name><surname>Hollsberg</surname><given-names>P</given-names></name></person-group>. <article-title>Human herpesvirus-6B induces expression of the human endogenous retrovirus K18-encoded superantigen</article-title>. <source/>J Clin Virol. (<year>2009</year>) <volume>46</volume>:<fpage>15</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2009.05.015</pub-id><pub-id pub-id-type="pmid">19505847</pub-id></mixed-citation>
</ref>
<ref id="B210">
<label>210.</label>
<mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>RK</given-names></name><name><surname>T</surname><given-names>J</given-names></name></person-group>
<source/>The Evolution of Diversity Within Tumors and Metastases.
<publisher-loc>Dordrecht</publisher-loc>: <publisher-name>Springer Netherlands</publisher-name> (<year>2008</year>).</mixed-citation>
</ref>
<ref id="B211">
<label>211.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krueger</surname><given-names>GR</given-names></name><name><surname>Huetter</surname><given-names>ML</given-names></name><name><surname>Rojo</surname><given-names>J</given-names></name><name><surname>Romero</surname><given-names>M</given-names></name><name><surname>Cruz-Ortiz</surname><given-names>H</given-names></name></person-group>. <article-title>Human herpesviruses HHV-4 (EBV) and HHV-6 in Hodgkin's and Kikuchi's diseases and their relation to proliferation and apoptosis</article-title>. <source/>Anticancer Res. (<year>2001</year>) <volume>21</volume>:<fpage>2155</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="pmid">11501840</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>